{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "min_rank = 1\n",
    "max_rnk = 100\n",
    "total = 1000\n",
    "responses = []\n",
    "\n",
    "# url = f\"https://clinicaltrials.gov/api/query/full_studies?expr=COVID-19+AND+SEARCH%5BLocation%5D%28AREA%5BLocationCountry%5D+United+States%29&min_rnk={min_rank}&max_rnk={max_rnk}&fmt=json\"\n",
    "# response = requests.get(url)\n",
    "# json = response.json()\n",
    "\n",
    "try:\n",
    "    while max_rnk < total:\n",
    "        url = f\"https://clinicaltrials.gov/api/query/full_studies?expr=COVID-19+AND+SEARCH%5BLocation%5D%28AREA%5BLocationCountry%5D+United+States%29&min_rnk={min_rank}&max_rnk={max_rnk}&fmt=json\"\n",
    "        response = requests.get(url)\n",
    "        json = response.json()\n",
    "        for rank in json['FullStudiesResponse']['FullStudies']:\n",
    "            responses.append(rank)\n",
    "        min_rank += 100\n",
    "        max_rnk += 100\n",
    "except:\n",
    "    pass\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "138"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(responses)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Rank': 1,\n",
       " 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04349202',\n",
       "    'OrgStudyIdInfo': {'OrgStudyId': '2020-134'},\n",
       "    'Organization': {'OrgFullName': 'William Beaumont Hospitals',\n",
       "     'OrgClass': 'OTHER'},\n",
       "    'BriefTitle': 'Beaumont Health Large-scale Automated Serologic Testing for COVID-19',\n",
       "    'OfficialTitle': 'Beaumont Health Large-scale Automated Serologic Testing for COVID-19',\n",
       "    'Acronym': 'BLAST COVID-19'},\n",
       "   'StatusModule': {'StatusVerifiedDate': 'April 2020',\n",
       "    'OverallStatus': 'Recruiting',\n",
       "    'ExpandedAccessInfo': {'HasExpandedAccess': 'No'},\n",
       "    'StartDateStruct': {'StartDate': 'April 2020',\n",
       "     'StartDateType': 'Anticipated'},\n",
       "    'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2021',\n",
       "     'PrimaryCompletionDateType': 'Anticipated'},\n",
       "    'CompletionDateStruct': {'CompletionDate': 'June 2021',\n",
       "     'CompletionDateType': 'Anticipated'},\n",
       "    'StudyFirstSubmitDate': 'April 13, 2020',\n",
       "    'StudyFirstSubmitQCDate': 'April 13, 2020',\n",
       "    'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 16, 2020',\n",
       "     'StudyFirstPostDateType': 'Actual'},\n",
       "    'LastUpdateSubmitDate': 'April 13, 2020',\n",
       "    'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 16, 2020',\n",
       "     'LastUpdatePostDateType': 'Actual'}},\n",
       "   'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator',\n",
       "     'ResponsiblePartyInvestigatorFullName': 'Matthew Sims, MD, PhD',\n",
       "     'ResponsiblePartyInvestigatorTitle': 'Director Infectious Disease Research, Beaumont Health; Professor of Internal Medicine and Foundational Medical Studies, OUWB School of Medicine',\n",
       "     'ResponsiblePartyInvestigatorAffiliation': 'William Beaumont Hospitals'},\n",
       "    'LeadSponsor': {'LeadSponsorName': 'William Beaumont Hospitals',\n",
       "     'LeadSponsorClass': 'OTHER'}},\n",
       "   'OversightModule': {'OversightHasDMC': 'No',\n",
       "    'IsFDARegulatedDrug': 'No',\n",
       "    'IsFDARegulatedDevice': 'Yes',\n",
       "    'IsUSExport': 'No'},\n",
       "   'DescriptionModule': {'BriefSummary': \"The purpose of this study is to determine how peoples' bodies respond to exposure to COVID-19. Employees of Beaumont Health in Michigan who are older than 18 years may be eligible to participate. Participants will have blood drawn two or more times for serology testing. This serology test will determine if participants have detectable levels of the antibodies that our bodies develop to fight COVID-19 infection. Participants will fill out a questionnaire each time they provide a blood sample. The questionnaires include questions about participants' personal traits; their health; general questions about their risk to exposure; job and risk of exposure; symptoms, diagnosis, treatment of COVID-19 since last blood draw. Researchers will monitor participants' medical records in a confidential manner for one year after the last blood draw to help determine if people who develop antibodies to COVID-19 are protected against developing a COVID-19 infection in the future.There may be no direct benefits for participants; however, information from this study may benefit other people by increasing our understanding of COVID-19, how it spreads from person to person, and how people respond to fight off the infection.The results of the serology test are used for research only and will not affect clinical decisions regarding participants' treatment or quarantine\",\n",
       "    'DetailedDescription': \"Beaumont Health is an eight-hospital regional health care system with a total of 3,337 beds, 38,000 employees and 5,000 physicians in Southeast Michigan. In the first 3 weeks of the COVID-19 pandemic within Michigan over 3300 patients tested positive through our system and over 1000 have been admitted for inpatient care. COVID-19 has a wide range of presentations from asymptomatic to multisystem organ failure and death. Spread from asymptomatic individuals has been described in the literature but the extent of this transmission is unclear. Large scale serologic testing can help address this question by detecting antibodies generated after an individual is infected with COVID-19. Healthcare workers have developed COVID-19 but the true infection rate among those who care for COVID-19 patients and whether the infection occurs at work is unknown.\\n\\nEvery day, thousands of Beaumont physicians, nurses, technicians and other caregivers are working under extraordinary stress, doing their very best to care for patients with this highly contagious and potentially deadly virus. They are trying to protect themselves from infection while dealing with personal protective equipment requirements and limited knowledge of who in the hospital environment may be carrying the infection and potentially spreading it among the staff. Caregivers are at greater risk of infection than the public, and when they become sick, it reduces the number of trained personnel available to care for hospitalized patients. Serological testing would give Beaumont's front-line staff and patients peace of mind by determining infection rates in our care units. Knowing the infection rates will demonstrate how effective the use of personal protective equipment has been for staff, whether any flaws exist in the system, and how many clinical staff currently have potentially protective antibodies.\\n\\nBeaumont Health has 2 EURO Lab Workstations capable of running the SARS-CoV-2 IgG and IgA EUROIMMUN serology assay (referred to as the EUROIMMUN assay hereafter). Each EUROIMMUN assay consists of 2 separate tests; one of which measures IgG (the memory antibody which should give long acting resistance to people who mount an immune response) and the second of which measures IgA (the secretory antibody that should protect against infection through mucous membranes). Researchers can run 5,000 samples a day with each sample being tested for IgA and IgG.\\n\\nPotential participants (employees and affiliated non-employed physicians and advanced practice providers) will provide informed consent. Researchers will analyze all participants over 2 blood draws between 2 and 4 weeks apart to see if they developed antibodies to COVID-19. Participants at medium risk for exposure in their job function at Beaumont will have 3 draws 2-4 weeks apart and people considered the highest risk, those who provide the direct patient care to COVID-19 patients, will be tested 2-4 weeks apart until the pandemic in Michigan is under control (estimated to be 8 blood draws). If the participants agree, researchers will bank 0.5 ml of serum for future testing related to COVID-19. An initial questionnaire and subsequent questionnaires with each blood draw will be completed by participants. Biostatistics will analyze the data from the questionnaires and the serology test to determine any links between level of risk associated with the participants job, medical history, and exposure history to development of COVID-19 antibodies. Participants medical records will be monitored for one year to see if they are diagnosed with COVID-19 and if they have a positive PCR test for COVID-19 since they were tested for the presence of antibodies. All employees identified as developing COVID-19 after their antibody levels were tested will be analyzed and a correlation between antibody level and development of COVID-19 will be generated. This will allow an estimation of the protective effect of antibodies relative to people who have no detectable antibodies. Researchers will perform an epidemiologic analysis to identify contacts between staff and patients based on records in the EMR and can cross reference to determine if nosocomial transmission is likely occurring from staff to patients and vice versa. Researchers will also determine if there was any likely exposure to patients with COVID-19 on the same floor or if prior patients in the room had COVID-19. This will also allow researchers to model the rate of spread of the virus within the hospital from unknown sources.\"},\n",
       "   'ConditionsModule': {'ConditionList': {'Condition': ['COVID-19',\n",
       "      'Coronavirus Infection',\n",
       "      'Severe Acute Respiratory Syndrome Coronavirus 2']},\n",
       "    'KeywordList': {'Keyword': ['Exposure, Occupational',\n",
       "      'COVID-19 virus infection',\n",
       "      'COVID-19 pandemic',\n",
       "      'COVID-19 virus testing']}},\n",
       "   'DesignModule': {'StudyType': 'Observational',\n",
       "    'PatientRegistry': 'No',\n",
       "    'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']},\n",
       "     'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}},\n",
       "    'BioSpec': {'BioSpecRetention': 'Samples With DNA',\n",
       "     'BioSpecDescription': 'Whole blood and serum'},\n",
       "    'EnrollmentInfo': {'EnrollmentCount': '50000',\n",
       "     'EnrollmentType': 'Anticipated'}},\n",
       "   'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Beaumont employees',\n",
       "       'ArmGroupDescription': 'Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies',\n",
       "       'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: EUROIMMUN assay']}}]},\n",
       "    'InterventionList': {'Intervention': [{'InterventionType': 'Diagnostic Test',\n",
       "       'InterventionName': 'EUROIMMUN assay',\n",
       "       'InterventionDescription': 'Serology testing to detect SARS-CoV-2 antibodies',\n",
       "       'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Beaumont employees']}}]}},\n",
       "   'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Prevalence COVID antibodies in employees of Beaumont Health',\n",
       "       'PrimaryOutcomeDescription': 'Serology testing of Beaumont Health employees will allow an estimation of asymptomatic carriage and help determine level of nosocomial spread of COVID-19 within our institution among its employees. All participants will provide over 2 blood draws between 2 and 4 weeks apart to determine if they developed antibodies to COVID-19. Participants at medium risk for exposure in their job function at Beaumont will have 3 draws 2-4 weeks apart and people considered the highest risk, those who provide the direct patient care to COVID-19 patients, will be tested 2-4 weeks apart until the pandemic in Michigan is under control (estimated to be 8 blood draws).',\n",
       "       'PrimaryOutcomeTimeFrame': '1 year'}]}},\n",
       "   'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge â‰¥ 18 years\\nBeaumont Health employees and affiliated non-employed physicians and advanced practice providers\\n\\nExclusion Criteria:\\n\\nDecisionally impaired',\n",
       "    'HealthyVolunteers': 'Accepts Healthy Volunteers',\n",
       "    'Gender': 'All',\n",
       "    'MinimumAge': '18 Years',\n",
       "    'StdAgeList': {'StdAge': ['Adult', 'Older Adult']},\n",
       "    'StudyPopulation': 'Beaumont Health Employees and affiliated non-employed physicians and advanced practice providers',\n",
       "    'SamplingMethod': 'Non-Probability Sample'},\n",
       "   'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Maureen Cooney, RN, BSN',\n",
       "       'CentralContactRole': 'Contact',\n",
       "       'CentralContactPhone': '248-551-0099',\n",
       "       'CentralContactEMail': 'Maureen.Cooney@beaumont.org'},\n",
       "      {'CentralContactName': 'Matthew Sims, MD, PhD',\n",
       "       'CentralContactRole': 'Contact',\n",
       "       'CentralContactPhone': '248-551-0027',\n",
       "       'CentralContactEMail': 'Matthew.Sims@beaumont.edu'}]},\n",
       "    'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Matthew Sims, MD, PhD',\n",
       "       'OverallOfficialAffiliation': 'William Beaumont Hospitals',\n",
       "       'OverallOfficialRole': 'Principal Investigator'}]},\n",
       "    'LocationList': {'Location': [{'LocationFacility': 'Beaumont Health System',\n",
       "       'LocationStatus': 'Recruiting',\n",
       "       'LocationCity': 'Royal Oak',\n",
       "       'LocationState': 'Michigan',\n",
       "       'LocationZip': '48073',\n",
       "       'LocationCountry': 'United States'},\n",
       "      {'LocationFacility': 'Beaumont Health',\n",
       "       'LocationStatus': 'Not yet recruiting',\n",
       "       'LocationCity': 'Royal Oak',\n",
       "       'LocationState': 'Michigan',\n",
       "       'LocationZip': '48073',\n",
       "       'LocationCountry': 'United States',\n",
       "       'LocationContactList': {'LocationContact': [{'LocationContactName': 'Maureen Cooney, RN, BSN',\n",
       "          'LocationContactRole': 'Contact',\n",
       "          'LocationContactPhone': '248-551-0099',\n",
       "          'LocationContactEMail': 'Maureen.Cooney@beaumont.org'}]}}]}},\n",
       "   'IPDSharingStatementModule': {'IPDSharing': 'No'}},\n",
       "  'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'April 17, 2020'},\n",
       "   'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000018352',\n",
       "       'ConditionMeshTerm': 'Coronavirus Infections'},\n",
       "      {'ConditionMeshId': 'D000045169',\n",
       "       'ConditionMeshTerm': 'Severe Acute Respiratory Syndrome'}]},\n",
       "    'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000003333',\n",
       "       'ConditionAncestorTerm': 'Coronaviridae Infections'},\n",
       "      {'ConditionAncestorId': 'D000030341',\n",
       "       'ConditionAncestorTerm': 'Nidovirales Infections'},\n",
       "      {'ConditionAncestorId': 'D000012327',\n",
       "       'ConditionAncestorTerm': 'RNA Virus Infections'},\n",
       "      {'ConditionAncestorId': 'D000014777',\n",
       "       'ConditionAncestorTerm': 'Virus Diseases'},\n",
       "      {'ConditionAncestorId': 'D000012141',\n",
       "       'ConditionAncestorTerm': 'Respiratory Tract Infections'},\n",
       "      {'ConditionAncestorId': 'D000012140',\n",
       "       'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]},\n",
       "    'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M14938',\n",
       "       'ConditionBrowseLeafName': 'Syndrome',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M19074',\n",
       "       'ConditionBrowseLeafName': 'Coronavirus Infections',\n",
       "       'ConditionBrowseLeafAsFound': 'Coronavirus',\n",
       "       'ConditionBrowseLeafRelevance': 'high'},\n",
       "      {'ConditionBrowseLeafId': 'M24032',\n",
       "       'ConditionBrowseLeafName': 'Severe Acute Respiratory Syndrome',\n",
       "       'ConditionBrowseLeafAsFound': 'Severe Acute Respiratory Syndrome',\n",
       "       'ConditionBrowseLeafRelevance': 'high'},\n",
       "      {'ConditionBrowseLeafId': 'M16105',\n",
       "       'ConditionBrowseLeafName': 'Virus Diseases',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M8866',\n",
       "       'ConditionBrowseLeafName': 'Infection',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M4951',\n",
       "       'ConditionBrowseLeafName': 'Communicable Diseases',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M13732',\n",
       "       'ConditionBrowseLeafName': 'RNA Virus Infections',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M13561',\n",
       "       'ConditionBrowseLeafName': 'Respiratory Tract Infections',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'M13560',\n",
       "       'ConditionBrowseLeafName': 'Respiratory Tract Diseases',\n",
       "       'ConditionBrowseLeafRelevance': 'low'},\n",
       "      {'ConditionBrowseLeafId': 'T5212',\n",
       "       'ConditionBrowseLeafName': 'Severe Acute Respiratory Syndrome',\n",
       "       'ConditionBrowseLeafAsFound': 'Severe Acute Respiratory Syndrome',\n",
       "       'ConditionBrowseLeafRelevance': 'high'}]},\n",
       "    'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23',\n",
       "       'ConditionBrowseBranchName': 'Symptoms and General Pathology'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'All',\n",
       "       'ConditionBrowseBranchName': 'All Conditions'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'BC02',\n",
       "       'ConditionBrowseBranchName': 'Viral Diseases'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'BC08',\n",
       "       'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'BC01',\n",
       "       'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'},\n",
       "      {'ConditionBrowseBranchAbbrev': 'Rare',\n",
       "       'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "responses[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "n = 0\n",
    "list = []\n",
    "\n",
    "for rank in responses:\n",
    "    try:\n",
    "        nctid = responses[n][\"Study\"][\"ProtocolSection\"][\"IdentificationModule\"][\"NCTId\"]\n",
    "        brieftitle = responses[n][\"Study\"][\"ProtocolSection\"][\"IdentificationModule\"][\"BriefTitle\"]\n",
    "        start_date = responses[n][\"Study\"][\"ProtocolSection\"][\"StatusModule\"][\"StartDateStruct\"][\"StartDate\"]\n",
    "        completiondate = responses[n][\"Study\"][\"ProtocolSection\"][\"StatusModule\"][\"CompletionDateStruct\"][\"CompletionDate\"]\n",
    "        overallstatus = responses[n][\"Study\"][\"ProtocolSection\"][\"StatusModule\"][\"OverallStatus\"]\n",
    "        leadsponsor = responses[n][\"Study\"][\"ProtocolSection\"][\"SponsorCollaboratorsModule\"][\"LeadSponsor\"][\"LeadSponsorName\"]\n",
    "        contactname = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"CentralContactList\"][\"CentralContact\"][0][\"CentralContactName\"]\n",
    "        contactphone = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"CentralContactList\"][\"CentralContact\"][0][\"CentralContactPhone\"]\n",
    "        contactemail = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"CentralContactList\"][\"CentralContact\"][0][\"CentralContactEMail\"]\n",
    "        interventiondesc = responses[n][\"Study\"][\"ProtocolSection\"][\"ArmsInterventionsModule\"][\"InterventionList\"][\"Intervention\"][0][\"InterventionDescription\"]\n",
    "        briefsummary = responses[n][\"Study\"][\"ProtocolSection\"][\"DescriptionModule\"][\"BriefSummary\"]\n",
    "        enrollmentcount = responses[n][\"Study\"][\"ProtocolSection\"][\"DesignModule\"][\"EnrollmentInfo\"][\"EnrollmentCount\"]\n",
    "        primaryoutcomedesc = responses[n][\"Study\"][\"ProtocolSection\"][\"OutcomesModule\"][\"PrimaryOutcomeList\"][\"PrimaryOutcome\"][0][\"PrimaryOutcomeMeasure\"]\n",
    "        facility = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"LocationList\"][\"Location\"][0][\"LocationFacility\"]\n",
    "        locationcity = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"LocationList\"][\"Location\"][0][\"LocationCity\"]\n",
    "        locationstate = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"LocationList\"][\"Location\"][0][\"LocationState\"]\n",
    "        locationzip = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"LocationList\"][\"Location\"][0][\"LocationZip\"]\n",
    "        locationcountry = responses[n][\"Study\"][\"ProtocolSection\"][\"ContactsLocationsModule\"][\"LocationList\"][\"Location\"][0][\"LocationCountry\"]\n",
    "        dict = {\"nctid\":nctid,\n",
    "               \"brieftitle\":brieftitle,\n",
    "               \"start_date\":start_date,\n",
    "               \"completiondate\":completiondate,\n",
    "               \"overallstatus\":overallstatus,\n",
    "               \"leadsponsor\":leadsponsor,\n",
    "               \"contactname\":contactname,\n",
    "               \"contactphone\": contactphone,\n",
    "               \"contactemail\":contactemail,\n",
    "               \"interventiondesc\":interventiondesc,\n",
    "               \"briefsummary\":briefsummary,\n",
    "               \"enrollmentcount\":enrollmentcount,\n",
    "               \"primaryoutcomedesc\":primaryoutcomedesc,\n",
    "               \"facility\":facility,\n",
    "               \"locationcity\":locationcity,\n",
    "               \"locationstate\":locationstate,\n",
    "               \"locationzip\":locationzip,\n",
    "               \"locationcountry\":locationcountry}\n",
    "        list.append(dict)\n",
    "        n+=1\n",
    "    except:\n",
    "        n+=1\n",
    "        pass\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "101"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "covid_df = pd.DataFrame(list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>briefsummary</th>\n",
       "      <th>brieftitle</th>\n",
       "      <th>completiondate</th>\n",
       "      <th>contactemail</th>\n",
       "      <th>contactname</th>\n",
       "      <th>contactphone</th>\n",
       "      <th>enrollmentcount</th>\n",
       "      <th>facility</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>locationcity</th>\n",
       "      <th>locationcountry</th>\n",
       "      <th>locationstate</th>\n",
       "      <th>locationzip</th>\n",
       "      <th>nctid</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>primaryoutcomedesc</th>\n",
       "      <th>start_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The purpose of this study is to determine how ...</td>\n",
       "      <td>Beaumont Health Large-scale Automated Serologi...</td>\n",
       "      <td>June 2021</td>\n",
       "      <td>Maureen.Cooney@beaumont.org</td>\n",
       "      <td>Maureen Cooney, RN, BSN</td>\n",
       "      <td>248-551-0099</td>\n",
       "      <td>50000</td>\n",
       "      <td>Beaumont Health System</td>\n",
       "      <td>Serology testing to detect SARS-CoV-2 antibodies</td>\n",
       "      <td>William Beaumont Hospitals</td>\n",
       "      <td>Royal Oak</td>\n",
       "      <td>United States</td>\n",
       "      <td>Michigan</td>\n",
       "      <td>48073</td>\n",
       "      <td>NCT04349202</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Prevalence COVID antibodies in employees of Be...</td>\n",
       "      <td>April 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>This study will compare two drugs (hydroxychlo...</td>\n",
       "      <td>Hydroxychloroquine vs. Azithromycin for Hospit...</td>\n",
       "      <td>December 31, 2021</td>\n",
       "      <td>Valerie.Aston@imail.org</td>\n",
       "      <td>Valerie T Aston, MBA</td>\n",
       "      <td>8015074606</td>\n",
       "      <td>300</td>\n",
       "      <td>Intermountain Medical Center</td>\n",
       "      <td>Patients in the hydroxychloroquine arm will re...</td>\n",
       "      <td>Intermountain Health Care, Inc.</td>\n",
       "      <td>Murray</td>\n",
       "      <td>United States</td>\n",
       "      <td>Utah</td>\n",
       "      <td>84107</td>\n",
       "      <td>NCT04329832</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>COVID Ordinal Outcomes Scale at 14 days</td>\n",
       "      <td>March 30, 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study will compare two drugs (hydroxychlo...</td>\n",
       "      <td>Hydroxychloroquine vs. Azithromycin for Outpat...</td>\n",
       "      <td>December 31, 2021</td>\n",
       "      <td>Valerie.Aston@imail.org</td>\n",
       "      <td>Valerie T Aston, MBA</td>\n",
       "      <td>8015074606</td>\n",
       "      <td>1550</td>\n",
       "      <td>Intermountain Medical Center</td>\n",
       "      <td>Patients in the hydroxychloroquine arm will re...</td>\n",
       "      <td>Intermountain Health Care, Inc.</td>\n",
       "      <td>Murray</td>\n",
       "      <td>United States</td>\n",
       "      <td>Utah</td>\n",
       "      <td>84107</td>\n",
       "      <td>NCT04334382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Hospitalization within 14 days of enrollment</td>\n",
       "      <td>April 2, 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The objective of this study is to determine th...</td>\n",
       "      <td>Bidirectional Oxygenation Valve in the Managem...</td>\n",
       "      <td>May 2020</td>\n",
       "      <td>jeffrey.miller@emory.edu</td>\n",
       "      <td>Jeffrey Miller, MD</td>\n",
       "      <td>404-778-7200</td>\n",
       "      <td>5</td>\n",
       "      <td>Emory University Hospital</td>\n",
       "      <td>The GO2 PEEP MOUTHPIECE has a bidirectional va...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>Atlanta</td>\n",
       "      <td>United States</td>\n",
       "      <td>Georgia</td>\n",
       "      <td>30322</td>\n",
       "      <td>NCT04331366</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change in Oxygen Saturation by Pulse Oximetry</td>\n",
       "      <td>April 8, 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Specific Aims:\\n\\nThe investigators will prosp...</td>\n",
       "      <td>Assessment of Exam Findings in Coronavirus Dis...</td>\n",
       "      <td>October 2020</td>\n",
       "      <td>yocum007@umn.edu</td>\n",
       "      <td>Matthew Yocum, MD</td>\n",
       "      <td>612-626-8015</td>\n",
       "      <td>500</td>\n",
       "      <td>University of Minnesota Medical Center (UMMC)</td>\n",
       "      <td>The POCUS exam of the heart will capture 2 sta...</td>\n",
       "      <td>University of Minnesota</td>\n",
       "      <td>Minneapolis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>55455</td>\n",
       "      <td>NCT04339998</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>POCUS Score - Lungs</td>\n",
       "      <td>April 15, 2020</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        briefsummary  \\\n",
       "0  The purpose of this study is to determine how ...   \n",
       "1  This study will compare two drugs (hydroxychlo...   \n",
       "2  This study will compare two drugs (hydroxychlo...   \n",
       "3  The objective of this study is to determine th...   \n",
       "4  Specific Aims:\\n\\nThe investigators will prosp...   \n",
       "\n",
       "                                          brieftitle     completiondate  \\\n",
       "0  Beaumont Health Large-scale Automated Serologi...          June 2021   \n",
       "1  Hydroxychloroquine vs. Azithromycin for Hospit...  December 31, 2021   \n",
       "2  Hydroxychloroquine vs. Azithromycin for Outpat...  December 31, 2021   \n",
       "3  Bidirectional Oxygenation Valve in the Managem...           May 2020   \n",
       "4  Assessment of Exam Findings in Coronavirus Dis...       October 2020   \n",
       "\n",
       "                  contactemail              contactname  contactphone  \\\n",
       "0  Maureen.Cooney@beaumont.org  Maureen Cooney, RN, BSN  248-551-0099   \n",
       "1      Valerie.Aston@imail.org     Valerie T Aston, MBA    8015074606   \n",
       "2      Valerie.Aston@imail.org     Valerie T Aston, MBA    8015074606   \n",
       "3     jeffrey.miller@emory.edu       Jeffrey Miller, MD  404-778-7200   \n",
       "4             yocum007@umn.edu        Matthew Yocum, MD  612-626-8015   \n",
       "\n",
       "  enrollmentcount                                       facility  \\\n",
       "0           50000                         Beaumont Health System   \n",
       "1             300                   Intermountain Medical Center   \n",
       "2            1550                   Intermountain Medical Center   \n",
       "3               5                      Emory University Hospital   \n",
       "4             500  University of Minnesota Medical Center (UMMC)   \n",
       "\n",
       "                                    interventiondesc  \\\n",
       "0   Serology testing to detect SARS-CoV-2 antibodies   \n",
       "1  Patients in the hydroxychloroquine arm will re...   \n",
       "2  Patients in the hydroxychloroquine arm will re...   \n",
       "3  The GO2 PEEP MOUTHPIECE has a bidirectional va...   \n",
       "4  The POCUS exam of the heart will capture 2 sta...   \n",
       "\n",
       "                       leadsponsor locationcity locationcountry locationstate  \\\n",
       "0       William Beaumont Hospitals    Royal Oak   United States      Michigan   \n",
       "1  Intermountain Health Care, Inc.       Murray   United States          Utah   \n",
       "2  Intermountain Health Care, Inc.       Murray   United States          Utah   \n",
       "3                 Emory University      Atlanta   United States       Georgia   \n",
       "4          University of Minnesota  Minneapolis   United States     Minnesota   \n",
       "\n",
       "  locationzip        nctid       overallstatus  \\\n",
       "0       48073  NCT04349202          Recruiting   \n",
       "1       84107  NCT04329832          Recruiting   \n",
       "2       84107  NCT04334382          Recruiting   \n",
       "3       30322  NCT04331366          Recruiting   \n",
       "4       55455  NCT04339998  Not yet recruiting   \n",
       "\n",
       "                                  primaryoutcomedesc      start_date  \n",
       "0  Prevalence COVID antibodies in employees of Be...      April 2020  \n",
       "1            COVID Ordinal Outcomes Scale at 14 days  March 30, 2020  \n",
       "2       Hospitalization within 14 days of enrollment   April 2, 2020  \n",
       "3      Change in Oxygen Saturation by Pulse Oximetry   April 8, 2020  \n",
       "4                                POCUS Score - Lungs  April 15, 2020  "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "covid_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>briefsummary</th>\n",
       "      <th>brieftitle</th>\n",
       "      <th>completiondate</th>\n",
       "      <th>contactemail</th>\n",
       "      <th>contactname</th>\n",
       "      <th>contactphone</th>\n",
       "      <th>enrollmentcount</th>\n",
       "      <th>facility</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>locationcity</th>\n",
       "      <th>locationcountry</th>\n",
       "      <th>locationstate</th>\n",
       "      <th>locationzip</th>\n",
       "      <th>nctid</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>primaryoutcomedesc</th>\n",
       "      <th>start_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>unique</th>\n",
       "      <td>101</td>\n",
       "      <td>101</td>\n",
       "      <td>61</td>\n",
       "      <td>93</td>\n",
       "      <td>95</td>\n",
       "      <td>94</td>\n",
       "      <td>62</td>\n",
       "      <td>85</td>\n",
       "      <td>100</td>\n",
       "      <td>69</td>\n",
       "      <td>50</td>\n",
       "      <td>1</td>\n",
       "      <td>27</td>\n",
       "      <td>68</td>\n",
       "      <td>101</td>\n",
       "      <td>2</td>\n",
       "      <td>98</td>\n",
       "      <td>42</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>top</th>\n",
       "      <td>The primary objective of this study is to eval...</td>\n",
       "      <td>Colchicine Coronavirus SARS-CoV2 Trial (COLCOR...</td>\n",
       "      <td>December 31, 2021</td>\n",
       "      <td>estice@ori.org</td>\n",
       "      <td>Christopher Tignanelli, MD</td>\n",
       "      <td>2059079743</td>\n",
       "      <td>200</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>Administered as an intravenous infusion</td>\n",
       "      <td>University of Minnesota</td>\n",
       "      <td>New York</td>\n",
       "      <td>United States</td>\n",
       "      <td>New York</td>\n",
       "      <td>60637</td>\n",
       "      <td>NCT04292730</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Mortality</td>\n",
       "      <td>April 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>freq</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>6</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>5</td>\n",
       "      <td>4</td>\n",
       "      <td>2</td>\n",
       "      <td>5</td>\n",
       "      <td>10</td>\n",
       "      <td>101</td>\n",
       "      <td>16</td>\n",
       "      <td>4</td>\n",
       "      <td>1</td>\n",
       "      <td>66</td>\n",
       "      <td>3</td>\n",
       "      <td>21</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             briefsummary  \\\n",
       "count                                                 101   \n",
       "unique                                                101   \n",
       "top     The primary objective of this study is to eval...   \n",
       "freq                                                    1   \n",
       "\n",
       "                                               brieftitle     completiondate  \\\n",
       "count                                                 101                101   \n",
       "unique                                                101                 61   \n",
       "top     Colchicine Coronavirus SARS-CoV2 Trial (COLCOR...  December 31, 2021   \n",
       "freq                                                    1                  6   \n",
       "\n",
       "          contactemail                 contactname contactphone  \\\n",
       "count              101                         101          101   \n",
       "unique              93                          95           94   \n",
       "top     estice@ori.org  Christopher Tignanelli, MD   2059079743   \n",
       "freq                 2                           2            2   \n",
       "\n",
       "       enrollmentcount                        facility  \\\n",
       "count              101                             101   \n",
       "unique              62                              85   \n",
       "top                200  Massachusetts General Hospital   \n",
       "freq                 5                               4   \n",
       "\n",
       "                               interventiondesc              leadsponsor  \\\n",
       "count                                       101                      101   \n",
       "unique                                      100                       69   \n",
       "top     Administered as an intravenous infusion  University of Minnesota   \n",
       "freq                                          2                        5   \n",
       "\n",
       "       locationcity locationcountry locationstate locationzip        nctid  \\\n",
       "count           101             101           101         101          101   \n",
       "unique           50               1            27          68          101   \n",
       "top        New York   United States      New York       60637  NCT04292730   \n",
       "freq             10             101            16           4            1   \n",
       "\n",
       "       overallstatus primaryoutcomedesc  start_date  \n",
       "count            101                101         101  \n",
       "unique             2                 98          42  \n",
       "top       Recruiting          Mortality  April 2020  \n",
       "freq              66                  3          21  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "covid_df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#check if there are Null cells in covid_df\n",
    "covid_df.isnull().values.any()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# look at datatypes\n",
    "# covid_df.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>briefsummary</th>\n",
       "      <th>brieftitle</th>\n",
       "      <th>contactemail</th>\n",
       "      <th>contactname</th>\n",
       "      <th>contactphone</th>\n",
       "      <th>enrollmentcount</th>\n",
       "      <th>facility</th>\n",
       "      <th>interventiondesc</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>locationcity</th>\n",
       "      <th>locationcountry</th>\n",
       "      <th>locationstate</th>\n",
       "      <th>locationzip</th>\n",
       "      <th>nctid</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>primaryoutcomedesc</th>\n",
       "      <th>starting_date</th>\n",
       "      <th>completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The purpose of this study is to determine how ...</td>\n",
       "      <td>Beaumont Health Large-scale Automated Serologi...</td>\n",
       "      <td>Maureen.Cooney@beaumont.org</td>\n",
       "      <td>Maureen Cooney, RN, BSN</td>\n",
       "      <td>248-551-0099</td>\n",
       "      <td>50000</td>\n",
       "      <td>Beaumont Health System</td>\n",
       "      <td>Serology testing to detect SARS-CoV-2 antibodies</td>\n",
       "      <td>William Beaumont Hospitals</td>\n",
       "      <td>Royal Oak</td>\n",
       "      <td>United States</td>\n",
       "      <td>Michigan</td>\n",
       "      <td>48073</td>\n",
       "      <td>NCT04349202</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Prevalence COVID antibodies in employees of Be...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>June 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>This study will compare two drugs (hydroxychlo...</td>\n",
       "      <td>Hydroxychloroquine vs. Azithromycin for Hospit...</td>\n",
       "      <td>Valerie.Aston@imail.org</td>\n",
       "      <td>Valerie T Aston, MBA</td>\n",
       "      <td>8015074606</td>\n",
       "      <td>300</td>\n",
       "      <td>Intermountain Medical Center</td>\n",
       "      <td>Patients in the hydroxychloroquine arm will re...</td>\n",
       "      <td>Intermountain Health Care, Inc.</td>\n",
       "      <td>Murray</td>\n",
       "      <td>United States</td>\n",
       "      <td>Utah</td>\n",
       "      <td>84107</td>\n",
       "      <td>NCT04329832</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>COVID Ordinal Outcomes Scale at 14 days</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study will compare two drugs (hydroxychlo...</td>\n",
       "      <td>Hydroxychloroquine vs. Azithromycin for Outpat...</td>\n",
       "      <td>Valerie.Aston@imail.org</td>\n",
       "      <td>Valerie T Aston, MBA</td>\n",
       "      <td>8015074606</td>\n",
       "      <td>1550</td>\n",
       "      <td>Intermountain Medical Center</td>\n",
       "      <td>Patients in the hydroxychloroquine arm will re...</td>\n",
       "      <td>Intermountain Health Care, Inc.</td>\n",
       "      <td>Murray</td>\n",
       "      <td>United States</td>\n",
       "      <td>Utah</td>\n",
       "      <td>84107</td>\n",
       "      <td>NCT04334382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Hospitalization within 14 days of enrollment</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The objective of this study is to determine th...</td>\n",
       "      <td>Bidirectional Oxygenation Valve in the Managem...</td>\n",
       "      <td>jeffrey.miller@emory.edu</td>\n",
       "      <td>Jeffrey Miller, MD</td>\n",
       "      <td>404-778-7200</td>\n",
       "      <td>5</td>\n",
       "      <td>Emory University Hospital</td>\n",
       "      <td>The GO2 PEEP MOUTHPIECE has a bidirectional va...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>Atlanta</td>\n",
       "      <td>United States</td>\n",
       "      <td>Georgia</td>\n",
       "      <td>30322</td>\n",
       "      <td>NCT04331366</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change in Oxygen Saturation by Pulse Oximetry</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>May 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Specific Aims:\\n\\nThe investigators will prosp...</td>\n",
       "      <td>Assessment of Exam Findings in Coronavirus Dis...</td>\n",
       "      <td>yocum007@umn.edu</td>\n",
       "      <td>Matthew Yocum, MD</td>\n",
       "      <td>612-626-8015</td>\n",
       "      <td>500</td>\n",
       "      <td>University of Minnesota Medical Center (UMMC)</td>\n",
       "      <td>The POCUS exam of the heart will capture 2 sta...</td>\n",
       "      <td>University of Minnesota</td>\n",
       "      <td>Minneapolis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>55455</td>\n",
       "      <td>NCT04339998</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>POCUS Score - Lungs</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>October 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The purpose of this research study is to deter...</td>\n",
       "      <td>A Double-blind, Placebo-controlled Clinical Tr...</td>\n",
       "      <td>stevens.a@wustl.edu</td>\n",
       "      <td>Angela Stevens</td>\n",
       "      <td>(314)362-6291</td>\n",
       "      <td>152</td>\n",
       "      <td>BJC</td>\n",
       "      <td>Randomized to either fluvoxamine or placebo fo...</td>\n",
       "      <td>Washington University School of Medicine</td>\n",
       "      <td>Belleville</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>62220</td>\n",
       "      <td>NCT04342663</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Time to clinical worsening</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>July 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>This current proposal evaluates the Longitudin...</td>\n",
       "      <td>Longitudinal Energy Expenditure and Metabolic ...</td>\n",
       "      <td>paul.wischmeyer@duke.edu</td>\n",
       "      <td>Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM</td>\n",
       "      <td>919-681-6437</td>\n",
       "      <td>120</td>\n",
       "      <td>Duke University Medial Center</td>\n",
       "      <td>COVID-19 ICU patients will be measured using t...</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>Durham</td>\n",
       "      <td>United States</td>\n",
       "      <td>North Carolina</td>\n",
       "      <td>27710</td>\n",
       "      <td>NCT04350073</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Metabolic and Nutritional Needs of COVID-19 Pa...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Currently there are no US Food and Drug Admini...</td>\n",
       "      <td>Evaluate the Efficacy and Safety of Oral Hydro...</td>\n",
       "      <td>nhank@prcresearcheducation.com</td>\n",
       "      <td>Nicole C Hank, PhD,MCR,MHSM</td>\n",
       "      <td>4804716132</td>\n",
       "      <td>80</td>\n",
       "      <td>Perseverance Research Center</td>\n",
       "      <td>200 mg PO BID 5 days</td>\n",
       "      <td>Perseverance Research Center, LLC</td>\n",
       "      <td>Scottsdale</td>\n",
       "      <td>United States</td>\n",
       "      <td>Arizona</td>\n",
       "      <td>85254</td>\n",
       "      <td>NCT04344457</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Improvement of clinical status</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>September 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>This is a single arm phase IIa study of conval...</td>\n",
       "      <td>Convalescent Plasma as Treatment for Hospitali...</td>\n",
       "      <td>Mariefel.Vendivil@HackensackMeridian.org</td>\n",
       "      <td>Mariefel Vendivil</td>\n",
       "      <td>551-996-5828</td>\n",
       "      <td>55</td>\n",
       "      <td>Hackensack University Medical Center</td>\n",
       "      <td>Fresh plasma will be infused one time to hospi...</td>\n",
       "      <td>Hackensack Meridian Health</td>\n",
       "      <td>Hackensack</td>\n",
       "      <td>United States</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>07601</td>\n",
       "      <td>NCT04343755</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>For patients hospitalized for COVID-19 but not...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This study is a randomized, open label clinica...</td>\n",
       "      <td>A Randomized Controlled Clinical Trial: Hydrox...</td>\n",
       "      <td>tseto@queens.org</td>\n",
       "      <td>Todd Seto, MD</td>\n",
       "      <td>808 354-3533</td>\n",
       "      <td>350</td>\n",
       "      <td>Queen's Medical Center</td>\n",
       "      <td>oral tablet administered by hospital staff or ...</td>\n",
       "      <td>Queen's Medical Centre</td>\n",
       "      <td>Honolulu</td>\n",
       "      <td>United States</td>\n",
       "      <td>Hawaii</td>\n",
       "      <td>96813</td>\n",
       "      <td>NCT04345692</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>i. Clinical status</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Background: During the current COVID-19 pandem...</td>\n",
       "      <td>Behavior, Environment And Treatments for Covid-19</td>\n",
       "      <td>info@beat19.org</td>\n",
       "      <td>BEAT19.org</td>\n",
       "      <td>(415) 754-9290</td>\n",
       "      <td>100000</td>\n",
       "      <td>BEAT19.org</td>\n",
       "      <td>Participants will receive daily diary surveys ...</td>\n",
       "      <td>xCures</td>\n",
       "      <td>San Francisco</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>94022</td>\n",
       "      <td>NCT04321811</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Define Natural Symptom Course</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>March 2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>This is a Phase II interventional study testin...</td>\n",
       "      <td>A Study of Hydroxychloroquine, Vitamin C, Vita...</td>\n",
       "      <td>sabinehazan@aim.com</td>\n",
       "      <td>Sabine Hazan, MD</td>\n",
       "      <td>805-200-7426</td>\n",
       "      <td>600</td>\n",
       "      <td>ProgenaBiome</td>\n",
       "      <td>Prophylaxis treatment for COVID-19</td>\n",
       "      <td>ProgenaBiome</td>\n",
       "      <td>Ventura</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>93003</td>\n",
       "      <td>NCT04335084</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Prevention of COVID-19 measured by negative te...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>July 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Patients who are severely ill with COVID-19 ma...</td>\n",
       "      <td>COVID-19 Plasma Collection</td>\n",
       "      <td>CovidPlasma@jefferson.edu</td>\n",
       "      <td>Julie Karp, MD</td>\n",
       "      <td>215-503-4838</td>\n",
       "      <td>2000</td>\n",
       "      <td>Thomas Jefferson University Hospital</td>\n",
       "      <td>Previously infected COVID-19 patients will be ...</td>\n",
       "      <td>Thomas Jefferson University</td>\n",
       "      <td>Philadelphia</td>\n",
       "      <td>United States</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19107</td>\n",
       "      <td>NCT04344015</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Number of patients who screen eligible for don...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Coronavirus disease 2019 (COVID-19) is an emer...</td>\n",
       "      <td>Early PP With HFNC Versus HFNC in COVID-19 Ind...</td>\n",
       "      <td>Jie_Li@rush.edu</td>\n",
       "      <td>Jie Li, PhD</td>\n",
       "      <td>312-947-0065</td>\n",
       "      <td>346</td>\n",
       "      <td>Rush University Medical Center</td>\n",
       "      <td>HFNC will be initiated at 50 L/min (AIRVO2 or ...</td>\n",
       "      <td>Rush University Medical Center</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60612</td>\n",
       "      <td>NCT04325906</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Treatment failure</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>June 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>The purpose of this study is 1) to understand ...</td>\n",
       "      <td>COPING With COVID-19( CWC-19)</td>\n",
       "      <td>erika.ratcliffe@duke.edu</td>\n",
       "      <td>Erika Ratcliffe</td>\n",
       "      <td>919-681-5006</td>\n",
       "      <td>100</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>Crisis management coaching will be offered to ...</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>Durham</td>\n",
       "      <td>United States</td>\n",
       "      <td>North Carolina</td>\n",
       "      <td>27710</td>\n",
       "      <td>NCT04343690</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Change in stress level as measured by survey</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>June 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>This is an open label, phase 1 clinical trial ...</td>\n",
       "      <td>Study of Open Label Losartan in COVID-19</td>\n",
       "      <td>msalathe@kumc.edu</td>\n",
       "      <td>Matthias Salathe, MD</td>\n",
       "      <td>9135886000</td>\n",
       "      <td>50</td>\n",
       "      <td>University of Kansas Medical Center</td>\n",
       "      <td>25 mg QD from day 0 to day 3. Dose escalation ...</td>\n",
       "      <td>University of Kansas Medical Center</td>\n",
       "      <td>Kansas City</td>\n",
       "      <td>United States</td>\n",
       "      <td>Kansas</td>\n",
       "      <td>66160</td>\n",
       "      <td>NCT04335123</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Number of participants with treatment-related ...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>October 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>The purpose of this study is to assess the fea...</td>\n",
       "      <td>COVID-19 Convalescent Plasma</td>\n",
       "      <td>mlmadariaga@bsd.uchicago.edu</td>\n",
       "      <td>Maria Lucia Madariaga, MD</td>\n",
       "      <td>773-270-2004</td>\n",
       "      <td>10</td>\n",
       "      <td>University of Chicago Medicine</td>\n",
       "      <td>Infusion of one unit of anti-SARS-CoV-2 conval...</td>\n",
       "      <td>University of Chicago</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60637</td>\n",
       "      <td>NCT04340050</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Feasibility of performing study pathway consis...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>The goal of the research is to assess candidat...</td>\n",
       "      <td>COVID-19 Antibody Self-testing Using Virtual P...</td>\n",
       "      <td>drdon@neuroganicslabs.com</td>\n",
       "      <td>Donald Cooper, Ph.D.</td>\n",
       "      <td>7204313495</td>\n",
       "      <td>100</td>\n",
       "      <td>Neuroganics</td>\n",
       "      <td>An immunodiagnostic rapid (10-20 minute) test ...</td>\n",
       "      <td>Neuroganics LLC</td>\n",
       "      <td>Northglenn</td>\n",
       "      <td>United States</td>\n",
       "      <td>Colorado</td>\n",
       "      <td>80260</td>\n",
       "      <td>NCT04348864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical accuracy of the antibody-based rapid ...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>There is significant interest throughout the U...</td>\n",
       "      <td>Military COVID-19 Hydroxychloroquine Pre-expos...</td>\n",
       "      <td>usaf.pentagon.11-mdg.mbx.flight-med-clinic@mai...</td>\n",
       "      <td>Scott A Wallace, MD</td>\n",
       "      <td>703-697-3255</td>\n",
       "      <td>1450</td>\n",
       "      <td>Pentagon</td>\n",
       "      <td>Daily dosing of hydroxychloroquine as PrEP or PEP</td>\n",
       "      <td>United States Department of Defense</td>\n",
       "      <td>Arlington</td>\n",
       "      <td>United States</td>\n",
       "      <td>Virginia</td>\n",
       "      <td>20301</td>\n",
       "      <td>NCT04343677</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Incidence</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>August 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>This study plans to learn more about the effec...</td>\n",
       "      <td>Safety and Efficacy of Baricitinib for COVID-19</td>\n",
       "      <td>bari-covid19@cuanschutz.edu</td>\n",
       "      <td>Angela Rachubinski, PhD</td>\n",
       "      <td>(720) 507-9107</td>\n",
       "      <td>80</td>\n",
       "      <td>University of Colorado, Denver</td>\n",
       "      <td>Subjects will receive a 2 mg oral dose of bari...</td>\n",
       "      <td>University of Colorado, Denver</td>\n",
       "      <td>Aurora</td>\n",
       "      <td>United States</td>\n",
       "      <td>Colorado</td>\n",
       "      <td>80045</td>\n",
       "      <td>NCT04340232</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Phase 2: Cumulative incidence of Grade 3 and 4...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>October 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>The purpose of this study is to test the hypot...</td>\n",
       "      <td>Hydroxychloroquine Post Exposure Prophylaxis f...</td>\n",
       "      <td>eco7@cumc.columbia.edu</td>\n",
       "      <td>Elizabeth Oelsner, MD, MPH</td>\n",
       "      <td>212-305-9056</td>\n",
       "      <td>1600</td>\n",
       "      <td>Columbia University Irving Medical Center</td>\n",
       "      <td>Two tablets (400mg) twice daily on day 1; for ...</td>\n",
       "      <td>Columbia University</td>\n",
       "      <td>New York</td>\n",
       "      <td>United States</td>\n",
       "      <td>New York</td>\n",
       "      <td>10032</td>\n",
       "      <td>NCT04318444</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Number of participants with symptomatic, lab-c...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>March 2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Coronavirus disease-2019 (COVID-19) has a quot...</td>\n",
       "      <td>Tocilizumab to Prevent Clinical Decompensation...</td>\n",
       "      <td>pankti.reid@uchospitals.edu</td>\n",
       "      <td>Pankti Reid, MD, MPH</td>\n",
       "      <td>7737021220</td>\n",
       "      <td>50</td>\n",
       "      <td>University of Chicago Medicine</td>\n",
       "      <td>Group A: Tocilizumab (beginning dose 200mg) Si...</td>\n",
       "      <td>University of Chicago</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60637</td>\n",
       "      <td>NCT04331795</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical response</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The study aims to determine the safety and eff...</td>\n",
       "      <td>PVP-I Nasal Sprays and SARS-CoV-2 Nasopharynge...</td>\n",
       "      <td>hwangph@stanford.edu</td>\n",
       "      <td>Peter H Hwang, MD</td>\n",
       "      <td>650-725-6500</td>\n",
       "      <td>45</td>\n",
       "      <td>Stanford Health Care</td>\n",
       "      <td>Two sprays to each nare of PVP-I 2% via nasal ...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>94305</td>\n",
       "      <td>NCT04347954</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Mean change in viral titers of SARS-CoV-2</td>\n",
       "      <td>May 2020</td>\n",
       "      <td>August 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>The PATCH trial (Prevention And Treatment of C...</td>\n",
       "      <td>The PATCH Trial (Prevention And Treatment of C...</td>\n",
       "      <td>amelia.anderson@pennmedicine.upenn.edu</td>\n",
       "      <td>Amelia Anderson</td>\n",
       "      <td>215-509-5690</td>\n",
       "      <td>400</td>\n",
       "      <td>University of Pennsylvania</td>\n",
       "      <td>Antimalarial compound</td>\n",
       "      <td>Ravi Amaravadi, MD</td>\n",
       "      <td>Philadelphia</td>\n",
       "      <td>United States</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19104</td>\n",
       "      <td>NCT04329923</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Median release from quarantine time</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>The objective of the study is to assess the im...</td>\n",
       "      <td>COVID-19 Remote Monitoring</td>\n",
       "      <td>sam.cammack@mountsinai.org</td>\n",
       "      <td>Sam Cammack</td>\n",
       "      <td>212-824-8931</td>\n",
       "      <td>1000</td>\n",
       "      <td>Icahn School of Medicine at Mount Sinai</td>\n",
       "      <td>This patch provides continuous real-time monit...</td>\n",
       "      <td>Vivek Reddy</td>\n",
       "      <td>New York</td>\n",
       "      <td>United States</td>\n",
       "      <td>New York</td>\n",
       "      <td>10029</td>\n",
       "      <td>NCT04350476</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Number of different arrhythmias</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>This study aims to examine the tolerability of...</td>\n",
       "      <td>High-dose Hydroxychloroquine for the Treatment...</td>\n",
       "      <td>rjan@medicine.bsd.uchicago.edu</td>\n",
       "      <td>Reem Jan, MBBS BSc</td>\n",
       "      <td>734-972-7953</td>\n",
       "      <td>20</td>\n",
       "      <td>University of Chicago</td>\n",
       "      <td>Tolerability study of HCQ 1200 mg administered...</td>\n",
       "      <td>University of Chicago</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60637</td>\n",
       "      <td>NCT04351620</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Tolerability of high dose HCQ as measured by H...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>June 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>This is an international, multicenter, paralle...</td>\n",
       "      <td>Dapagliflozin in Respiratory Failure in Patien...</td>\n",
       "      <td>swindsor@saint-lukes.org</td>\n",
       "      <td>Sheryl Windsor</td>\n",
       "      <td>816-932-9858</td>\n",
       "      <td>900</td>\n",
       "      <td>Saint Luke's Mid America Heart Institute</td>\n",
       "      <td>Active Comparator: Dapagliflozin 10mg</td>\n",
       "      <td>Saint Luke's Health System</td>\n",
       "      <td>Kansas City</td>\n",
       "      <td>United States</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>64111</td>\n",
       "      <td>NCT04350593</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Time to first occurrence of either death from ...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>This is a Phase II interventional study will t...</td>\n",
       "      <td>A Study of Quintuple Therapy to Treat COVID-19...</td>\n",
       "      <td>sabinehazan@aim.com</td>\n",
       "      <td>Sabine Hazan, MD</td>\n",
       "      <td>805-200-7436</td>\n",
       "      <td>600</td>\n",
       "      <td>ProgenaBiome</td>\n",
       "      <td>treatment with hydroxychloroquine</td>\n",
       "      <td>ProgenaBiome</td>\n",
       "      <td>Ventura</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>93003</td>\n",
       "      <td>NCT04334512</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Successful treatment as determined by Negative...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>July 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>The study is designed as a randomized, placebo...</td>\n",
       "      <td>CD24Fc as a Non-antiviral Immunomodulator in C...</td>\n",
       "      <td>pzheng@oncoimmune.com</td>\n",
       "      <td>Pan Zheng, MD, PhD</td>\n",
       "      <td>(202) 7516823</td>\n",
       "      <td>230</td>\n",
       "      <td>Institute of Human Virology, University of Mar...</td>\n",
       "      <td>CD24Fc is given on Day 1.</td>\n",
       "      <td>OncoImmune, Inc.</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>United States</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>21201</td>\n",
       "      <td>NCT04317040</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Improvement of COVID-19 disease status</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>May 2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>PRIORITY (Pregnancy CoRonavIrus Outcomes RegIs...</td>\n",
       "      <td>COVID-19 PRIORITY (Pregnancy CoRonavIrus Outco...</td>\n",
       "      <td>PRIORITYCOVID19@ucsf.edu</td>\n",
       "      <td>Ruth Gebrezghi</td>\n",
       "      <td>(415) 754-3749</td>\n",
       "      <td>1000</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>This is an observational study with no interve...</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>San Francisco</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>94143</td>\n",
       "      <td>NCT04323839</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical presentation</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>March 2024</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>The viral Covid-19 outbreak is now considered ...</td>\n",
       "      <td>COVID-19 Symptom Tracker</td>\n",
       "      <td>victoria.vazquez@kcl.ac.uk</td>\n",
       "      <td>Victoria Vazquez</td>\n",
       "      <td>02071886765</td>\n",
       "      <td>10000000</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>No Intervention</td>\n",
       "      <td>King's College London</td>\n",
       "      <td>Boston</td>\n",
       "      <td>United States</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>02114</td>\n",
       "      <td>NCT04331509</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Physical health symptoms</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>March 2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>The purpose of the study is to develop a clini...</td>\n",
       "      <td>Breath Analysis Based Disease Biomarkers of CO...</td>\n",
       "      <td>brannock.robert@mayo.edu</td>\n",
       "      <td>Robert Brannock</td>\n",
       "      <td>904-953-2000</td>\n",
       "      <td>120</td>\n",
       "      <td>Mayo Clinic Florida</td>\n",
       "      <td>Analysis of volatile organic compounds in breath</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>Jacksonville</td>\n",
       "      <td>United States</td>\n",
       "      <td>Florida</td>\n",
       "      <td>32224</td>\n",
       "      <td>NCT04341012</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breath volatile organic compound profiles</td>\n",
       "      <td>September 2019</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>Severe acute respiratory syndrome (SARS-CoV2) ...</td>\n",
       "      <td>Nitric Oxide Gas Inhalation in Severe Acute Re...</td>\n",
       "      <td>lberra@mgh.harvard.edu</td>\n",
       "      <td>Lorenzo Berra, MD</td>\n",
       "      <td>+16176437733</td>\n",
       "      <td>200</td>\n",
       "      <td>University of Alabama</td>\n",
       "      <td>80 ppm of inhaled nitric oxide for 48 hours, f...</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>Birmingham</td>\n",
       "      <td>United States</td>\n",
       "      <td>Alabama</td>\n",
       "      <td>35294</td>\n",
       "      <td>NCT04306393</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change of arterial oxygenation at 48 hours fro...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>March 2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>This is a phase I, open-label, dose ranging cl...</td>\n",
       "      <td>Safety and Immunogenicity Study of 2019-nCoV V...</td>\n",
       "      <td>KPWA.vaccine@kp.org</td>\n",
       "      <td>20-0003 Central Contact</td>\n",
       "      <td>12062872061</td>\n",
       "      <td>45</td>\n",
       "      <td>Emory Vaccine Center - The Hope Clinic</td>\n",
       "      <td>Lipid nanoparticle (LNP) dispersion containing...</td>\n",
       "      <td>National Institute of Allergy and Infectious D...</td>\n",
       "      <td>Decatur</td>\n",
       "      <td>United States</td>\n",
       "      <td>Georgia</td>\n",
       "      <td>30030-1705</td>\n",
       "      <td>NCT04283461</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Frequency of solicited local reactogenicity ad...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>June 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>Primary Objective:\\n\\nTo assess the effect of ...</td>\n",
       "      <td>Hydroxychloroquine in Outpatient Adults With C...</td>\n",
       "      <td>Contact-US@sanofi.com</td>\n",
       "      <td>Trial Transparency email recommended (Toll fre...</td>\n",
       "      <td>800-633-1610</td>\n",
       "      <td>210</td>\n",
       "      <td>Investigational Site Number 8400001</td>\n",
       "      <td>Pharmaceutical form:Tablet Route of administra...</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>Boston</td>\n",
       "      <td>United States</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>02115</td>\n",
       "      <td>NCT04333654</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change from baseline to Day 3 in nasopharyngea...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>May 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>The primary objective of this study is to dete...</td>\n",
       "      <td>Will Hydroxychloroquine Impede or Prevent COVI...</td>\n",
       "      <td>whipcovid19@hfhs.org</td>\n",
       "      <td>Dee Dee Wang, MD</td>\n",
       "      <td>313-574-2651</td>\n",
       "      <td>3000</td>\n",
       "      <td>Henry Ford Hospital</td>\n",
       "      <td>The daily hydroxychloroquine treatment arm wil...</td>\n",
       "      <td>Henry Ford Health System</td>\n",
       "      <td>Detroit</td>\n",
       "      <td>United States</td>\n",
       "      <td>Michigan</td>\n",
       "      <td>48202</td>\n",
       "      <td>NCT04341441</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Reduction in the number of COVID-19 infections...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>This Phase III trial four treatment strategies...</td>\n",
       "      <td>Hydroxychloroquine,Hydroxychloroquine,Azithrom...</td>\n",
       "      <td>mklebert@wustl.edu</td>\n",
       "      <td>Michael Klebert, RN PhD</td>\n",
       "      <td>314 747 1098</td>\n",
       "      <td>500</td>\n",
       "      <td>Washington University School of Medicine Infec...</td>\n",
       "      <td>anti-rheumatic drug (DMARD)</td>\n",
       "      <td>Washington University School of Medicine</td>\n",
       "      <td>Saint Louis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63110</td>\n",
       "      <td>NCT04341727</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Hours to recovery</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>August 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>This is a randomized, double-blind, placebo-co...</td>\n",
       "      <td>Study of TJ003234 (Anti-GM-CSF Monoclonal Anti...</td>\n",
       "      <td>US.Info@I-MabBiopharma.com</td>\n",
       "      <td>US Site Head</td>\n",
       "      <td>240-767-6981</td>\n",
       "      <td>144</td>\n",
       "      <td>OSF Healthcare Saint Francis Medical Center</td>\n",
       "      <td>patients receive a single infusion</td>\n",
       "      <td>I-Mab Biopharma Co. Ltd.</td>\n",
       "      <td>Peoria</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61637</td>\n",
       "      <td>NCT04341116</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Proportion (%) of subjects experiencing deteri...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>September 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>This is a multi-center, double-blinded study o...</td>\n",
       "      <td>Losartan for Patients With COVID-19 Not Requir...</td>\n",
       "      <td>Covid19trial@umn.edu</td>\n",
       "      <td>Christopher Tignanelli, MD</td>\n",
       "      <td>612-624-4373</td>\n",
       "      <td>580</td>\n",
       "      <td>Hennepin County Medical Center</td>\n",
       "      <td>Losartan; 25 mg daily; oral administration</td>\n",
       "      <td>University of Minnesota</td>\n",
       "      <td>Minneapolis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>55415</td>\n",
       "      <td>NCT04311177</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Hospital Admission</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>This is a pragmatic, randomized, open-label, i...</td>\n",
       "      <td>Pragmatic Factorial Trial of Hydroxychloroquin...</td>\n",
       "      <td>jason.stout@dm.duke.edu</td>\n",
       "      <td>Jason Stout, MD</td>\n",
       "      <td>919-668-0826</td>\n",
       "      <td>500</td>\n",
       "      <td>Duke Regional Hospital</td>\n",
       "      <td>Standard of care</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>Durham</td>\n",
       "      <td>United States</td>\n",
       "      <td>North Carolina</td>\n",
       "      <td>27704</td>\n",
       "      <td>NCT04335552</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>World Health Organization (WHO) ordinal scale ...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>August 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>Novel Corona Virus (COVID-19) is known to caus...</td>\n",
       "      <td>Intravenous Aviptadil for COVID-19 Associated ...</td>\n",
       "      <td>rbesthof@neurorxpharma.com</td>\n",
       "      <td>Robert E Besthof, MIM</td>\n",
       "      <td>+14842546134</td>\n",
       "      <td>120</td>\n",
       "      <td>Miller School of Medicine / University of Miam...</td>\n",
       "      <td>Aviptadil by intravenous infusion + maximal in...</td>\n",
       "      <td>NeuroRx, Inc.</td>\n",
       "      <td>Miami</td>\n",
       "      <td>United States</td>\n",
       "      <td>Florida</td>\n",
       "      <td>33136</td>\n",
       "      <td>NCT04311697</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Mortality</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>September 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>The purpose of this research is to identify wh...</td>\n",
       "      <td>Do Angiotensin Receptor Blockers Mitigate Prog...</td>\n",
       "      <td>kathryn.miller@sharp.com</td>\n",
       "      <td>Katie Miller</td>\n",
       "      <td>(858) 939-7162</td>\n",
       "      <td>200</td>\n",
       "      <td>Sharp Grossmont Hospital</td>\n",
       "      <td>Standard of care plus the starting dose of los...</td>\n",
       "      <td>Sharp HealthCare</td>\n",
       "      <td>La Mesa</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>91942</td>\n",
       "      <td>NCT04340557</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Mechanical ventilation</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>December 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>A questionnaire containing some critical quest...</td>\n",
       "      <td>COVID-19 Endoscopy Survey</td>\n",
       "      <td>alboraie@azhar.edu.eg</td>\n",
       "      <td>Mohamed Alboraie, MD, MRCP(UK)</td>\n",
       "      <td>00201155019700</td>\n",
       "      <td>40</td>\n",
       "      <td>Kings County Hospital Center, Brooklyn, NY, USA</td>\n",
       "      <td>Physicians will report details of their endosc...</td>\n",
       "      <td>Al-Azhar University</td>\n",
       "      <td>Albertson</td>\n",
       "      <td>United States</td>\n",
       "      <td>New York</td>\n",
       "      <td>11507</td>\n",
       "      <td>NCT04342637</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Effect of GI societies recommendations on prev...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>December 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>SARS-CoV-2 spreads rapidly throughout the worl...</td>\n",
       "      <td>BCG Vaccine for Health Care Workers as Defense...</td>\n",
       "      <td>Andrew.Dinardo@Bcm.Edu</td>\n",
       "      <td>Andrew DiNardo, MD</td>\n",
       "      <td>832-822-1038</td>\n",
       "      <td>700</td>\n",
       "      <td>Harvard T.H. Chan School of Public Health</td>\n",
       "      <td>BCG vaccine will be administered by research n...</td>\n",
       "      <td>Andrew Dinardo</td>\n",
       "      <td>Boston</td>\n",
       "      <td>United States</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>02115</td>\n",
       "      <td>NCT04348370</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>incidence (measured by confirmed positive test...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>November 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Study KIN-1901-2001 is a multi-center, adaptiv...</td>\n",
       "      <td>A Study to Assess the Efficacy and Safety of G...</td>\n",
       "      <td>arnaud.bastien@roivant.com</td>\n",
       "      <td>Arnaud Bastien, MD</td>\n",
       "      <td>(609)-410-2691</td>\n",
       "      <td>270</td>\n",
       "      <td>Mount Sinai</td>\n",
       "      <td>Gimsilumab is a fully human monoclonal antibod...</td>\n",
       "      <td>Kinevant Sciences GmbH</td>\n",
       "      <td>New York</td>\n",
       "      <td>United States</td>\n",
       "      <td>New York</td>\n",
       "      <td>10029</td>\n",
       "      <td>NCT04351243</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Primary endpoint</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>October 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>The objective of the study is to evaluate the ...</td>\n",
       "      <td>Early Extubation for Patients With Acute Hypox...</td>\n",
       "      <td>bpatel@medicine.bsd.uchicago.edu</td>\n",
       "      <td>Bhakti Patel, MD</td>\n",
       "      <td>773-702-6800</td>\n",
       "      <td>108</td>\n",
       "      <td>University of Chicago Medical Center</td>\n",
       "      <td>After application of the helmet, arterial bloo...</td>\n",
       "      <td>University of Chicago</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60637</td>\n",
       "      <td>NCT04349332</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>ventilator days</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>June 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Study Objective:\\n\\nTo test if post-exposure p...</td>\n",
       "      <td>Post-exposure Prophylaxis / Preemptive Therapy...</td>\n",
       "      <td>covid19@umn.edu</td>\n",
       "      <td>David Boulware (Please email), MD, MPH</td>\n",
       "      <td>6126249996</td>\n",
       "      <td>3000</td>\n",
       "      <td>Nationwide Enrollment via Internet, please ema...</td>\n",
       "      <td>200mg tablet; 800 mg orally once, followed in ...</td>\n",
       "      <td>University of Minnesota</td>\n",
       "      <td>Minneapolis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>55455</td>\n",
       "      <td>NCT04308668</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Incidence of COVID19 Disease among those who a...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>May 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>Phase 2:\\n\\nThe primary objective of the study...</td>\n",
       "      <td>Evaluation of the Efficacy and Safety of Saril...</td>\n",
       "      <td>clinicaltrials@regeneron.com</td>\n",
       "      <td>Clinical Trials Administrator</td>\n",
       "      <td>844-734-6643</td>\n",
       "      <td>400</td>\n",
       "      <td>Regeneron Study Site</td>\n",
       "      <td>Single intravenous (IV) dose of sarilumab</td>\n",
       "      <td>Regeneron Pharmaceuticals</td>\n",
       "      <td>Los Angeles</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>90095</td>\n",
       "      <td>NCT04315298</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Percent change in C-reactive protein (CRP) levels</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>April 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>The primary objective of this study is to eval...</td>\n",
       "      <td>Study to Evaluate the Safety and Antiviral Act...</td>\n",
       "      <td>GileadClinicalTrials@gilead.com</td>\n",
       "      <td>Gilead Clinical Study Information Center</td>\n",
       "      <td>1-833-445-3230 (GILEAD-0)</td>\n",
       "      <td>6000</td>\n",
       "      <td>Kaiser Permanente Los Angeles Medical Center, ...</td>\n",
       "      <td>Administered as an intravenous infusion</td>\n",
       "      <td>Gilead Sciences</td>\n",
       "      <td>Anaheim</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>92806</td>\n",
       "      <td>NCT04292899</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>The Odds of Ratio for Improvement on a 7-point...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>May 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>The primary objective of this study is to eval...</td>\n",
       "      <td>Study to Evaluate the Safety and Antiviral Act...</td>\n",
       "      <td>GileadClinicalTrials@gilead.com</td>\n",
       "      <td>Gilead Clinical Study Information Center</td>\n",
       "      <td>1-833-445-3230 (GILEAD-0)</td>\n",
       "      <td>1600</td>\n",
       "      <td>Kaiser Permanente Los Angeles Medical Center, ...</td>\n",
       "      <td>Administered as an intravenous infusion</td>\n",
       "      <td>Gilead Sciences</td>\n",
       "      <td>Anaheim</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>92806</td>\n",
       "      <td>NCT04292730</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>The Odds of Ratio for Improvement on a 7-point...</td>\n",
       "      <td>March 2020</td>\n",
       "      <td>May 2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>This study will evaluate the efficacy, safety,...</td>\n",
       "      <td>A Study to Evaluate the Safety and Efficacy of...</td>\n",
       "      <td>global-roche-genentech-trials@gene.com</td>\n",
       "      <td>Reference Study ID Number: WA42380 www.roche.c...</td>\n",
       "      <td>888-662-6728</td>\n",
       "      <td>330</td>\n",
       "      <td>University of California San Diego</td>\n",
       "      <td>Participants will receive 1 dose of IV TCZ. 1 ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>La Jolla</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>92093</td>\n",
       "      <td>NCT04320615</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical Status Assessed Using a 7-Category Or...</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>September 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>ORCHID is a multicenter, blinded, placebo-cont...</td>\n",
       "      <td>Outcomes Related to COVID-19 Treated With Hydr...</td>\n",
       "      <td>coldmixon@mgh.harvard.edu</td>\n",
       "      <td>Katie Oldmixon, RN</td>\n",
       "      <td>617 726-4777</td>\n",
       "      <td>510</td>\n",
       "      <td>University of Arizona</td>\n",
       "      <td>Hydroxychloroquine is available in 200 mg oral...</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>Tucson</td>\n",
       "      <td>United States</td>\n",
       "      <td>Arizona</td>\n",
       "      <td>85721</td>\n",
       "      <td>NCT04332991</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>COVID Ordinal Outcomes Scale on Day 15</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>July 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>This study will seek to enroll immunocompromis...</td>\n",
       "      <td>Phase III DAS181 Lower Tract PIV Infection in ...</td>\n",
       "      <td>jho@ansunbiopharma.com</td>\n",
       "      <td>Jennifer Ho, M.D</td>\n",
       "      <td>858-452-2631</td>\n",
       "      <td>250</td>\n",
       "      <td>City of Hope cancer Center</td>\n",
       "      <td>DAS181 4.5mg nebulized qd x 7 OR 10 days</td>\n",
       "      <td>Ansun Biopharma, Inc.</td>\n",
       "      <td>Duarte</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>91010</td>\n",
       "      <td>NCT03808922</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Percent of subjects who Return to Room Air (RT...</td>\n",
       "      <td>May 2019</td>\n",
       "      <td>December 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>This study is an adaptive, randomized, double-...</td>\n",
       "      <td>Adaptive COVID-19 Treatment Trial (ACTT)</td>\n",
       "      <td>DMIDClinicalTrials@niaid.nih.gov</td>\n",
       "      <td>20-0006 Central Contact</td>\n",
       "      <td>13017617948</td>\n",
       "      <td>440</td>\n",
       "      <td>University of Alabama at Birmingham School of ...</td>\n",
       "      <td>The supplied matching placebo lyophilized form...</td>\n",
       "      <td>National Institute of Allergy and Infectious D...</td>\n",
       "      <td>Birmingham</td>\n",
       "      <td>United States</td>\n",
       "      <td>Alabama</td>\n",
       "      <td>35233</td>\n",
       "      <td>NCT04280705</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Percentage of subjects reporting each severity...</td>\n",
       "      <td>February 2020</td>\n",
       "      <td>April 2023</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>The specific objective is to rapidly establish...</td>\n",
       "      <td>Rutgers COVID-19 Cohort Study</td>\n",
       "      <td>jeffrey.carson@rutgers.edu</td>\n",
       "      <td>Jeffrey L Carson, MD</td>\n",
       "      <td>732-235-7122</td>\n",
       "      <td>750</td>\n",
       "      <td>Clinical Research Center Rutgers-Robert Wood J...</td>\n",
       "      <td>This non-interventional study poses no additio...</td>\n",
       "      <td>Rutgers, The State University of New Jersey</td>\n",
       "      <td>New Brunswick</td>\n",
       "      <td>United States</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>08901</td>\n",
       "      <td>NCT04336215</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Prevalence</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>October 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>This project seeks to improve the effectivenes...</td>\n",
       "      <td>Project Health: Enhancing Effectiveness of a D...</td>\n",
       "      <td>estice@ori.org</td>\n",
       "      <td>Eric M Stice, Ph.D.</td>\n",
       "      <td>541-484-2123</td>\n",
       "      <td>450</td>\n",
       "      <td>Oregon Research Institute</td>\n",
       "      <td>A brief dissonance-based obesity prevention pr...</td>\n",
       "      <td>Oregon Research Institute</td>\n",
       "      <td>Eugene</td>\n",
       "      <td>United States</td>\n",
       "      <td>Oregon</td>\n",
       "      <td>97403</td>\n",
       "      <td>NCT03710746</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Body Fat</td>\n",
       "      <td>October 2018</td>\n",
       "      <td>July 2023</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>This is a randomized intervention study to tes...</td>\n",
       "      <td>Advocating for Supports to Improve Service Tra...</td>\n",
       "      <td>julie.l.taylor@vumc.org</td>\n",
       "      <td>Julie Lounds Taylor, PhD</td>\n",
       "      <td>615-343-5659</td>\n",
       "      <td>180</td>\n",
       "      <td>University of Illinois at Urbana-Champaign</td>\n",
       "      <td>The ASSIST program is a 12-week advocacy train...</td>\n",
       "      <td>Vanderbilt University Medical Center</td>\n",
       "      <td>Chicago</td>\n",
       "      <td>United States</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>60007</td>\n",
       "      <td>NCT04173663</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change in Parental Knowledge about adult servi...</td>\n",
       "      <td>December 2019</td>\n",
       "      <td>May 2024</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>Healthcare workers are at the frontline of the...</td>\n",
       "      <td>CROWN CORONATION: Chloroquine RepurpOsing to h...</td>\n",
       "      <td>lindayun@wustl.edu</td>\n",
       "      <td>Linda Yun, BS</td>\n",
       "      <td>314-273-2240</td>\n",
       "      <td>55000</td>\n",
       "      <td>Washington University School of Medicine</td>\n",
       "      <td>chloroquine base 300mg (equivalent to 500 mg c...</td>\n",
       "      <td>Washington University School of Medicine</td>\n",
       "      <td>Saint Louis</td>\n",
       "      <td>United States</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63110</td>\n",
       "      <td>NCT04333732</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Symptomatic COVID-19</td>\n",
       "      <td>April 2020</td>\n",
       "      <td>February 2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>This research will help us to learn if the med...</td>\n",
       "      <td>Investigation of Metformin in Pre-Diabetes on ...</td>\n",
       "      <td>Gregory.Schwartz@va.gov</td>\n",
       "      <td>Gregory G Schwartz, PhD MD</td>\n",
       "      <td>(720) 723-6070</td>\n",
       "      <td>7868</td>\n",
       "      <td>Phoenix VA Health Care System, Phoenix, AZ</td>\n",
       "      <td>For patients &lt; 80 years of age at the time of ...</td>\n",
       "      <td>VA Office of Research and Development</td>\n",
       "      <td>Phoenix</td>\n",
       "      <td>United States</td>\n",
       "      <td>Arizona</td>\n",
       "      <td>85012</td>\n",
       "      <td>NCT02915198</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Time in days to death, non-fatal myocardial in...</td>\n",
       "      <td>February 2019</td>\n",
       "      <td>August 2024</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>Most people with an eating disorder (ED) do no...</td>\n",
       "      <td>Target Engagement of a Novel Dissonance-Based ...</td>\n",
       "      <td>estice@ori.org</td>\n",
       "      <td>Eric Stice, PhD</td>\n",
       "      <td>541-484-2123</td>\n",
       "      <td>180</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>8 weekly 60 minute sessions of dissonance-base...</td>\n",
       "      <td>Oregon Research Institute</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>United States</td>\n",
       "      <td>California</td>\n",
       "      <td>94305</td>\n",
       "      <td>NCT03261050</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Change in occurrences of binge eating episodes...</td>\n",
       "      <td>July 2017</td>\n",
       "      <td>June 2022</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>101 rows Ã— 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          briefsummary  \\\n",
       "0    The purpose of this study is to determine how ...   \n",
       "1    This study will compare two drugs (hydroxychlo...   \n",
       "2    This study will compare two drugs (hydroxychlo...   \n",
       "3    The objective of this study is to determine th...   \n",
       "4    Specific Aims:\\n\\nThe investigators will prosp...   \n",
       "5    The purpose of this research study is to deter...   \n",
       "6    This current proposal evaluates the Longitudin...   \n",
       "7    Currently there are no US Food and Drug Admini...   \n",
       "8    This is a single arm phase IIa study of conval...   \n",
       "9    This study is a randomized, open label clinica...   \n",
       "10   Background: During the current COVID-19 pandem...   \n",
       "11   This is a Phase II interventional study testin...   \n",
       "12   Patients who are severely ill with COVID-19 ma...   \n",
       "13   Coronavirus disease 2019 (COVID-19) is an emer...   \n",
       "14   The purpose of this study is 1) to understand ...   \n",
       "15   This is an open label, phase 1 clinical trial ...   \n",
       "16   The purpose of this study is to assess the fea...   \n",
       "17   The goal of the research is to assess candidat...   \n",
       "18   There is significant interest throughout the U...   \n",
       "19   This study plans to learn more about the effec...   \n",
       "20   The purpose of this study is to test the hypot...   \n",
       "21   Coronavirus disease-2019 (COVID-19) has a quot...   \n",
       "22   The study aims to determine the safety and eff...   \n",
       "23   The PATCH trial (Prevention And Treatment of C...   \n",
       "24   The objective of the study is to assess the im...   \n",
       "25   This study aims to examine the tolerability of...   \n",
       "26   This is an international, multicenter, paralle...   \n",
       "27   This is a Phase II interventional study will t...   \n",
       "28   The study is designed as a randomized, placebo...   \n",
       "29   PRIORITY (Pregnancy CoRonavIrus Outcomes RegIs...   \n",
       "..                                                 ...   \n",
       "71   The viral Covid-19 outbreak is now considered ...   \n",
       "72   The purpose of the study is to develop a clini...   \n",
       "73   Severe acute respiratory syndrome (SARS-CoV2) ...   \n",
       "74   This is a phase I, open-label, dose ranging cl...   \n",
       "75   Primary Objective:\\n\\nTo assess the effect of ...   \n",
       "76   The primary objective of this study is to dete...   \n",
       "77   This Phase III trial four treatment strategies...   \n",
       "78   This is a randomized, double-blind, placebo-co...   \n",
       "79   This is a multi-center, double-blinded study o...   \n",
       "80   This is a pragmatic, randomized, open-label, i...   \n",
       "81   Novel Corona Virus (COVID-19) is known to caus...   \n",
       "82   The purpose of this research is to identify wh...   \n",
       "83   A questionnaire containing some critical quest...   \n",
       "84   SARS-CoV-2 spreads rapidly throughout the worl...   \n",
       "85   Study KIN-1901-2001 is a multi-center, adaptiv...   \n",
       "86   The objective of the study is to evaluate the ...   \n",
       "87   Study Objective:\\n\\nTo test if post-exposure p...   \n",
       "88   Phase 2:\\n\\nThe primary objective of the study...   \n",
       "89   The primary objective of this study is to eval...   \n",
       "90   The primary objective of this study is to eval...   \n",
       "91   This study will evaluate the efficacy, safety,...   \n",
       "92   ORCHID is a multicenter, blinded, placebo-cont...   \n",
       "93   This study will seek to enroll immunocompromis...   \n",
       "94   This study is an adaptive, randomized, double-...   \n",
       "95   The specific objective is to rapidly establish...   \n",
       "96   This project seeks to improve the effectivenes...   \n",
       "97   This is a randomized intervention study to tes...   \n",
       "98   Healthcare workers are at the frontline of the...   \n",
       "99   This research will help us to learn if the med...   \n",
       "100  Most people with an eating disorder (ED) do no...   \n",
       "\n",
       "                                            brieftitle  \\\n",
       "0    Beaumont Health Large-scale Automated Serologi...   \n",
       "1    Hydroxychloroquine vs. Azithromycin for Hospit...   \n",
       "2    Hydroxychloroquine vs. Azithromycin for Outpat...   \n",
       "3    Bidirectional Oxygenation Valve in the Managem...   \n",
       "4    Assessment of Exam Findings in Coronavirus Dis...   \n",
       "5    A Double-blind, Placebo-controlled Clinical Tr...   \n",
       "6    Longitudinal Energy Expenditure and Metabolic ...   \n",
       "7    Evaluate the Efficacy and Safety of Oral Hydro...   \n",
       "8    Convalescent Plasma as Treatment for Hospitali...   \n",
       "9    A Randomized Controlled Clinical Trial: Hydrox...   \n",
       "10   Behavior, Environment And Treatments for Covid-19   \n",
       "11   A Study of Hydroxychloroquine, Vitamin C, Vita...   \n",
       "12                          COVID-19 Plasma Collection   \n",
       "13   Early PP With HFNC Versus HFNC in COVID-19 Ind...   \n",
       "14                       COPING With COVID-19( CWC-19)   \n",
       "15            Study of Open Label Losartan in COVID-19   \n",
       "16                        COVID-19 Convalescent Plasma   \n",
       "17   COVID-19 Antibody Self-testing Using Virtual P...   \n",
       "18   Military COVID-19 Hydroxychloroquine Pre-expos...   \n",
       "19     Safety and Efficacy of Baricitinib for COVID-19   \n",
       "20   Hydroxychloroquine Post Exposure Prophylaxis f...   \n",
       "21   Tocilizumab to Prevent Clinical Decompensation...   \n",
       "22   PVP-I Nasal Sprays and SARS-CoV-2 Nasopharynge...   \n",
       "23   The PATCH Trial (Prevention And Treatment of C...   \n",
       "24                          COVID-19 Remote Monitoring   \n",
       "25   High-dose Hydroxychloroquine for the Treatment...   \n",
       "26   Dapagliflozin in Respiratory Failure in Patien...   \n",
       "27   A Study of Quintuple Therapy to Treat COVID-19...   \n",
       "28   CD24Fc as a Non-antiviral Immunomodulator in C...   \n",
       "29   COVID-19 PRIORITY (Pregnancy CoRonavIrus Outco...   \n",
       "..                                                 ...   \n",
       "71                            COVID-19 Symptom Tracker   \n",
       "72   Breath Analysis Based Disease Biomarkers of CO...   \n",
       "73   Nitric Oxide Gas Inhalation in Severe Acute Re...   \n",
       "74   Safety and Immunogenicity Study of 2019-nCoV V...   \n",
       "75   Hydroxychloroquine in Outpatient Adults With C...   \n",
       "76   Will Hydroxychloroquine Impede or Prevent COVI...   \n",
       "77   Hydroxychloroquine,Hydroxychloroquine,Azithrom...   \n",
       "78   Study of TJ003234 (Anti-GM-CSF Monoclonal Anti...   \n",
       "79   Losartan for Patients With COVID-19 Not Requir...   \n",
       "80   Pragmatic Factorial Trial of Hydroxychloroquin...   \n",
       "81   Intravenous Aviptadil for COVID-19 Associated ...   \n",
       "82   Do Angiotensin Receptor Blockers Mitigate Prog...   \n",
       "83                           COVID-19 Endoscopy Survey   \n",
       "84   BCG Vaccine for Health Care Workers as Defense...   \n",
       "85   A Study to Assess the Efficacy and Safety of G...   \n",
       "86   Early Extubation for Patients With Acute Hypox...   \n",
       "87   Post-exposure Prophylaxis / Preemptive Therapy...   \n",
       "88   Evaluation of the Efficacy and Safety of Saril...   \n",
       "89   Study to Evaluate the Safety and Antiviral Act...   \n",
       "90   Study to Evaluate the Safety and Antiviral Act...   \n",
       "91   A Study to Evaluate the Safety and Efficacy of...   \n",
       "92   Outcomes Related to COVID-19 Treated With Hydr...   \n",
       "93   Phase III DAS181 Lower Tract PIV Infection in ...   \n",
       "94            Adaptive COVID-19 Treatment Trial (ACTT)   \n",
       "95                       Rutgers COVID-19 Cohort Study   \n",
       "96   Project Health: Enhancing Effectiveness of a D...   \n",
       "97   Advocating for Supports to Improve Service Tra...   \n",
       "98   CROWN CORONATION: Chloroquine RepurpOsing to h...   \n",
       "99   Investigation of Metformin in Pre-Diabetes on ...   \n",
       "100  Target Engagement of a Novel Dissonance-Based ...   \n",
       "\n",
       "                                          contactemail  \\\n",
       "0                          Maureen.Cooney@beaumont.org   \n",
       "1                              Valerie.Aston@imail.org   \n",
       "2                              Valerie.Aston@imail.org   \n",
       "3                             jeffrey.miller@emory.edu   \n",
       "4                                     yocum007@umn.edu   \n",
       "5                                  stevens.a@wustl.edu   \n",
       "6                             paul.wischmeyer@duke.edu   \n",
       "7                       nhank@prcresearcheducation.com   \n",
       "8             Mariefel.Vendivil@HackensackMeridian.org   \n",
       "9                                     tseto@queens.org   \n",
       "10                                     info@beat19.org   \n",
       "11                                 sabinehazan@aim.com   \n",
       "12                           CovidPlasma@jefferson.edu   \n",
       "13                                     Jie_Li@rush.edu   \n",
       "14                            erika.ratcliffe@duke.edu   \n",
       "15                                   msalathe@kumc.edu   \n",
       "16                        mlmadariaga@bsd.uchicago.edu   \n",
       "17                           drdon@neuroganicslabs.com   \n",
       "18   usaf.pentagon.11-mdg.mbx.flight-med-clinic@mai...   \n",
       "19                         bari-covid19@cuanschutz.edu   \n",
       "20                              eco7@cumc.columbia.edu   \n",
       "21                         pankti.reid@uchospitals.edu   \n",
       "22                                hwangph@stanford.edu   \n",
       "23              amelia.anderson@pennmedicine.upenn.edu   \n",
       "24                          sam.cammack@mountsinai.org   \n",
       "25                      rjan@medicine.bsd.uchicago.edu   \n",
       "26                            swindsor@saint-lukes.org   \n",
       "27                                 sabinehazan@aim.com   \n",
       "28                               pzheng@oncoimmune.com   \n",
       "29                            PRIORITYCOVID19@ucsf.edu   \n",
       "..                                                 ...   \n",
       "71                          victoria.vazquez@kcl.ac.uk   \n",
       "72                            brannock.robert@mayo.edu   \n",
       "73                              lberra@mgh.harvard.edu   \n",
       "74                                 KPWA.vaccine@kp.org   \n",
       "75                               Contact-US@sanofi.com   \n",
       "76                                whipcovid19@hfhs.org   \n",
       "77                                  mklebert@wustl.edu   \n",
       "78                          US.Info@I-MabBiopharma.com   \n",
       "79                                Covid19trial@umn.edu   \n",
       "80                             jason.stout@dm.duke.edu   \n",
       "81                          rbesthof@neurorxpharma.com   \n",
       "82                            kathryn.miller@sharp.com   \n",
       "83                               alboraie@azhar.edu.eg   \n",
       "84                              Andrew.Dinardo@Bcm.Edu   \n",
       "85                          arnaud.bastien@roivant.com   \n",
       "86                    bpatel@medicine.bsd.uchicago.edu   \n",
       "87                                     covid19@umn.edu   \n",
       "88                        clinicaltrials@regeneron.com   \n",
       "89                     GileadClinicalTrials@gilead.com   \n",
       "90                     GileadClinicalTrials@gilead.com   \n",
       "91              global-roche-genentech-trials@gene.com   \n",
       "92                           coldmixon@mgh.harvard.edu   \n",
       "93                              jho@ansunbiopharma.com   \n",
       "94                    DMIDClinicalTrials@niaid.nih.gov   \n",
       "95                          jeffrey.carson@rutgers.edu   \n",
       "96                                      estice@ori.org   \n",
       "97                             julie.l.taylor@vumc.org   \n",
       "98                                  lindayun@wustl.edu   \n",
       "99                             Gregory.Schwartz@va.gov   \n",
       "100                                     estice@ori.org   \n",
       "\n",
       "                                           contactname  \\\n",
       "0                              Maureen Cooney, RN, BSN   \n",
       "1                                 Valerie T Aston, MBA   \n",
       "2                                 Valerie T Aston, MBA   \n",
       "3                                   Jeffrey Miller, MD   \n",
       "4                                    Matthew Yocum, MD   \n",
       "5                                       Angela Stevens   \n",
       "6            Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM   \n",
       "7                          Nicole C Hank, PhD,MCR,MHSM   \n",
       "8                                    Mariefel Vendivil   \n",
       "9                                        Todd Seto, MD   \n",
       "10                                          BEAT19.org   \n",
       "11                                    Sabine Hazan, MD   \n",
       "12                                      Julie Karp, MD   \n",
       "13                                         Jie Li, PhD   \n",
       "14                                     Erika Ratcliffe   \n",
       "15                                Matthias Salathe, MD   \n",
       "16                           Maria Lucia Madariaga, MD   \n",
       "17                                Donald Cooper, Ph.D.   \n",
       "18                                 Scott A Wallace, MD   \n",
       "19                             Angela Rachubinski, PhD   \n",
       "20                          Elizabeth Oelsner, MD, MPH   \n",
       "21                                Pankti Reid, MD, MPH   \n",
       "22                                   Peter H Hwang, MD   \n",
       "23                                     Amelia Anderson   \n",
       "24                                         Sam Cammack   \n",
       "25                                  Reem Jan, MBBS BSc   \n",
       "26                                      Sheryl Windsor   \n",
       "27                                    Sabine Hazan, MD   \n",
       "28                                  Pan Zheng, MD, PhD   \n",
       "29                                      Ruth Gebrezghi   \n",
       "..                                                 ...   \n",
       "71                                    Victoria Vazquez   \n",
       "72                                     Robert Brannock   \n",
       "73                                   Lorenzo Berra, MD   \n",
       "74                             20-0003 Central Contact   \n",
       "75   Trial Transparency email recommended (Toll fre...   \n",
       "76                                    Dee Dee Wang, MD   \n",
       "77                             Michael Klebert, RN PhD   \n",
       "78                                        US Site Head   \n",
       "79                          Christopher Tignanelli, MD   \n",
       "80                                     Jason Stout, MD   \n",
       "81                               Robert E Besthof, MIM   \n",
       "82                                        Katie Miller   \n",
       "83                      Mohamed Alboraie, MD, MRCP(UK)   \n",
       "84                                  Andrew DiNardo, MD   \n",
       "85                                  Arnaud Bastien, MD   \n",
       "86                                    Bhakti Patel, MD   \n",
       "87              David Boulware (Please email), MD, MPH   \n",
       "88                       Clinical Trials Administrator   \n",
       "89            Gilead Clinical Study Information Center   \n",
       "90            Gilead Clinical Study Information Center   \n",
       "91   Reference Study ID Number: WA42380 www.roche.c...   \n",
       "92                                  Katie Oldmixon, RN   \n",
       "93                                    Jennifer Ho, M.D   \n",
       "94                             20-0006 Central Contact   \n",
       "95                                Jeffrey L Carson, MD   \n",
       "96                                 Eric M Stice, Ph.D.   \n",
       "97                            Julie Lounds Taylor, PhD   \n",
       "98                                       Linda Yun, BS   \n",
       "99                          Gregory G Schwartz, PhD MD   \n",
       "100                                    Eric Stice, PhD   \n",
       "\n",
       "                  contactphone enrollmentcount  \\\n",
       "0                 248-551-0099           50000   \n",
       "1                   8015074606             300   \n",
       "2                   8015074606            1550   \n",
       "3                 404-778-7200               5   \n",
       "4                 612-626-8015             500   \n",
       "5                (314)362-6291             152   \n",
       "6                 919-681-6437             120   \n",
       "7                   4804716132              80   \n",
       "8                 551-996-5828              55   \n",
       "9                 808 354-3533             350   \n",
       "10              (415) 754-9290          100000   \n",
       "11                805-200-7426             600   \n",
       "12                215-503-4838            2000   \n",
       "13                312-947-0065             346   \n",
       "14                919-681-5006             100   \n",
       "15                  9135886000              50   \n",
       "16                773-270-2004              10   \n",
       "17                  7204313495             100   \n",
       "18                703-697-3255            1450   \n",
       "19              (720) 507-9107              80   \n",
       "20                212-305-9056            1600   \n",
       "21                  7737021220              50   \n",
       "22                650-725-6500              45   \n",
       "23                215-509-5690             400   \n",
       "24                212-824-8931            1000   \n",
       "25                734-972-7953              20   \n",
       "26                816-932-9858             900   \n",
       "27                805-200-7436             600   \n",
       "28               (202) 7516823             230   \n",
       "29              (415) 754-3749            1000   \n",
       "..                         ...             ...   \n",
       "71                 02071886765        10000000   \n",
       "72                904-953-2000             120   \n",
       "73                +16176437733             200   \n",
       "74                 12062872061              45   \n",
       "75                800-633-1610             210   \n",
       "76                313-574-2651            3000   \n",
       "77                314 747 1098             500   \n",
       "78                240-767-6981             144   \n",
       "79                612-624-4373             580   \n",
       "80                919-668-0826             500   \n",
       "81                +14842546134             120   \n",
       "82              (858) 939-7162             200   \n",
       "83              00201155019700              40   \n",
       "84                832-822-1038             700   \n",
       "85              (609)-410-2691             270   \n",
       "86                773-702-6800             108   \n",
       "87                  6126249996            3000   \n",
       "88                844-734-6643             400   \n",
       "89   1-833-445-3230 (GILEAD-0)            6000   \n",
       "90   1-833-445-3230 (GILEAD-0)            1600   \n",
       "91                888-662-6728             330   \n",
       "92                617 726-4777             510   \n",
       "93                858-452-2631             250   \n",
       "94                 13017617948             440   \n",
       "95                732-235-7122             750   \n",
       "96                541-484-2123             450   \n",
       "97                615-343-5659             180   \n",
       "98                314-273-2240           55000   \n",
       "99              (720) 723-6070            7868   \n",
       "100               541-484-2123             180   \n",
       "\n",
       "                                              facility  \\\n",
       "0                               Beaumont Health System   \n",
       "1                         Intermountain Medical Center   \n",
       "2                         Intermountain Medical Center   \n",
       "3                            Emory University Hospital   \n",
       "4        University of Minnesota Medical Center (UMMC)   \n",
       "5                                                  BJC   \n",
       "6                        Duke University Medial Center   \n",
       "7                         Perseverance Research Center   \n",
       "8                 Hackensack University Medical Center   \n",
       "9                               Queen's Medical Center   \n",
       "10                                          BEAT19.org   \n",
       "11                                        ProgenaBiome   \n",
       "12                Thomas Jefferson University Hospital   \n",
       "13                      Rush University Medical Center   \n",
       "14                                     Duke University   \n",
       "15                 University of Kansas Medical Center   \n",
       "16                      University of Chicago Medicine   \n",
       "17                                         Neuroganics   \n",
       "18                                            Pentagon   \n",
       "19                      University of Colorado, Denver   \n",
       "20           Columbia University Irving Medical Center   \n",
       "21                      University of Chicago Medicine   \n",
       "22                                Stanford Health Care   \n",
       "23                          University of Pennsylvania   \n",
       "24             Icahn School of Medicine at Mount Sinai   \n",
       "25                               University of Chicago   \n",
       "26            Saint Luke's Mid America Heart Institute   \n",
       "27                                        ProgenaBiome   \n",
       "28   Institute of Human Virology, University of Mar...   \n",
       "29             University of California, San Francisco   \n",
       "..                                                 ...   \n",
       "71                      Massachusetts General Hospital   \n",
       "72                                 Mayo Clinic Florida   \n",
       "73                               University of Alabama   \n",
       "74              Emory Vaccine Center - The Hope Clinic   \n",
       "75                 Investigational Site Number 8400001   \n",
       "76                                 Henry Ford Hospital   \n",
       "77   Washington University School of Medicine Infec...   \n",
       "78         OSF Healthcare Saint Francis Medical Center   \n",
       "79                      Hennepin County Medical Center   \n",
       "80                              Duke Regional Hospital   \n",
       "81   Miller School of Medicine / University of Miam...   \n",
       "82                            Sharp Grossmont Hospital   \n",
       "83     Kings County Hospital Center, Brooklyn, NY, USA   \n",
       "84           Harvard T.H. Chan School of Public Health   \n",
       "85                                         Mount Sinai   \n",
       "86                University of Chicago Medical Center   \n",
       "87   Nationwide Enrollment via Internet, please ema...   \n",
       "88                                Regeneron Study Site   \n",
       "89   Kaiser Permanente Los Angeles Medical Center, ...   \n",
       "90   Kaiser Permanente Los Angeles Medical Center, ...   \n",
       "91                  University of California San Diego   \n",
       "92                               University of Arizona   \n",
       "93                          City of Hope cancer Center   \n",
       "94   University of Alabama at Birmingham School of ...   \n",
       "95   Clinical Research Center Rutgers-Robert Wood J...   \n",
       "96                           Oregon Research Institute   \n",
       "97          University of Illinois at Urbana-Champaign   \n",
       "98            Washington University School of Medicine   \n",
       "99          Phoenix VA Health Care System, Phoenix, AZ   \n",
       "100                                Stanford University   \n",
       "\n",
       "                                      interventiondesc  \\\n",
       "0     Serology testing to detect SARS-CoV-2 antibodies   \n",
       "1    Patients in the hydroxychloroquine arm will re...   \n",
       "2    Patients in the hydroxychloroquine arm will re...   \n",
       "3    The GO2 PEEP MOUTHPIECE has a bidirectional va...   \n",
       "4    The POCUS exam of the heart will capture 2 sta...   \n",
       "5    Randomized to either fluvoxamine or placebo fo...   \n",
       "6    COVID-19 ICU patients will be measured using t...   \n",
       "7                                 200 mg PO BID 5 days   \n",
       "8    Fresh plasma will be infused one time to hospi...   \n",
       "9    oral tablet administered by hospital staff or ...   \n",
       "10   Participants will receive daily diary surveys ...   \n",
       "11                  Prophylaxis treatment for COVID-19   \n",
       "12   Previously infected COVID-19 patients will be ...   \n",
       "13   HFNC will be initiated at 50 L/min (AIRVO2 or ...   \n",
       "14   Crisis management coaching will be offered to ...   \n",
       "15   25 mg QD from day 0 to day 3. Dose escalation ...   \n",
       "16   Infusion of one unit of anti-SARS-CoV-2 conval...   \n",
       "17   An immunodiagnostic rapid (10-20 minute) test ...   \n",
       "18   Daily dosing of hydroxychloroquine as PrEP or PEP   \n",
       "19   Subjects will receive a 2 mg oral dose of bari...   \n",
       "20   Two tablets (400mg) twice daily on day 1; for ...   \n",
       "21   Group A: Tocilizumab (beginning dose 200mg) Si...   \n",
       "22   Two sprays to each nare of PVP-I 2% via nasal ...   \n",
       "23                               Antimalarial compound   \n",
       "24   This patch provides continuous real-time monit...   \n",
       "25   Tolerability study of HCQ 1200 mg administered...   \n",
       "26               Active Comparator: Dapagliflozin 10mg   \n",
       "27                   treatment with hydroxychloroquine   \n",
       "28                           CD24Fc is given on Day 1.   \n",
       "29   This is an observational study with no interve...   \n",
       "..                                                 ...   \n",
       "71                                     No Intervention   \n",
       "72    Analysis of volatile organic compounds in breath   \n",
       "73   80 ppm of inhaled nitric oxide for 48 hours, f...   \n",
       "74   Lipid nanoparticle (LNP) dispersion containing...   \n",
       "75   Pharmaceutical form:Tablet Route of administra...   \n",
       "76   The daily hydroxychloroquine treatment arm wil...   \n",
       "77                         anti-rheumatic drug (DMARD)   \n",
       "78                  patients receive a single infusion   \n",
       "79          Losartan; 25 mg daily; oral administration   \n",
       "80                                    Standard of care   \n",
       "81   Aviptadil by intravenous infusion + maximal in...   \n",
       "82   Standard of care plus the starting dose of los...   \n",
       "83   Physicians will report details of their endosc...   \n",
       "84   BCG vaccine will be administered by research n...   \n",
       "85   Gimsilumab is a fully human monoclonal antibod...   \n",
       "86   After application of the helmet, arterial bloo...   \n",
       "87   200mg tablet; 800 mg orally once, followed in ...   \n",
       "88           Single intravenous (IV) dose of sarilumab   \n",
       "89             Administered as an intravenous infusion   \n",
       "90             Administered as an intravenous infusion   \n",
       "91   Participants will receive 1 dose of IV TCZ. 1 ...   \n",
       "92   Hydroxychloroquine is available in 200 mg oral...   \n",
       "93            DAS181 4.5mg nebulized qd x 7 OR 10 days   \n",
       "94   The supplied matching placebo lyophilized form...   \n",
       "95   This non-interventional study poses no additio...   \n",
       "96   A brief dissonance-based obesity prevention pr...   \n",
       "97   The ASSIST program is a 12-week advocacy train...   \n",
       "98   chloroquine base 300mg (equivalent to 500 mg c...   \n",
       "99   For patients < 80 years of age at the time of ...   \n",
       "100  8 weekly 60 minute sessions of dissonance-base...   \n",
       "\n",
       "                                           leadsponsor   locationcity  \\\n",
       "0                           William Beaumont Hospitals      Royal Oak   \n",
       "1                      Intermountain Health Care, Inc.         Murray   \n",
       "2                      Intermountain Health Care, Inc.         Murray   \n",
       "3                                     Emory University        Atlanta   \n",
       "4                              University of Minnesota    Minneapolis   \n",
       "5             Washington University School of Medicine     Belleville   \n",
       "6                                      Duke University         Durham   \n",
       "7                    Perseverance Research Center, LLC     Scottsdale   \n",
       "8                           Hackensack Meridian Health     Hackensack   \n",
       "9                               Queen's Medical Centre       Honolulu   \n",
       "10                                              xCures  San Francisco   \n",
       "11                                        ProgenaBiome        Ventura   \n",
       "12                         Thomas Jefferson University   Philadelphia   \n",
       "13                      Rush University Medical Center        Chicago   \n",
       "14                                     Duke University         Durham   \n",
       "15                 University of Kansas Medical Center    Kansas City   \n",
       "16                               University of Chicago        Chicago   \n",
       "17                                     Neuroganics LLC     Northglenn   \n",
       "18                 United States Department of Defense      Arlington   \n",
       "19                      University of Colorado, Denver         Aurora   \n",
       "20                                 Columbia University       New York   \n",
       "21                               University of Chicago        Chicago   \n",
       "22                                 Stanford University       Stanford   \n",
       "23                                  Ravi Amaravadi, MD   Philadelphia   \n",
       "24                                         Vivek Reddy       New York   \n",
       "25                               University of Chicago        Chicago   \n",
       "26                          Saint Luke's Health System    Kansas City   \n",
       "27                                        ProgenaBiome        Ventura   \n",
       "28                                    OncoImmune, Inc.      Baltimore   \n",
       "29             University of California, San Francisco  San Francisco   \n",
       "..                                                 ...            ...   \n",
       "71                               King's College London         Boston   \n",
       "72                                         Mayo Clinic   Jacksonville   \n",
       "73                      Massachusetts General Hospital     Birmingham   \n",
       "74   National Institute of Allergy and Infectious D...        Decatur   \n",
       "75                                              Sanofi         Boston   \n",
       "76                            Henry Ford Health System        Detroit   \n",
       "77            Washington University School of Medicine    Saint Louis   \n",
       "78                            I-Mab Biopharma Co. Ltd.         Peoria   \n",
       "79                             University of Minnesota    Minneapolis   \n",
       "80                                     Duke University         Durham   \n",
       "81                                       NeuroRx, Inc.          Miami   \n",
       "82                                    Sharp HealthCare        La Mesa   \n",
       "83                                 Al-Azhar University      Albertson   \n",
       "84                                      Andrew Dinardo         Boston   \n",
       "85                              Kinevant Sciences GmbH       New York   \n",
       "86                               University of Chicago        Chicago   \n",
       "87                             University of Minnesota    Minneapolis   \n",
       "88                           Regeneron Pharmaceuticals    Los Angeles   \n",
       "89                                     Gilead Sciences        Anaheim   \n",
       "90                                     Gilead Sciences        Anaheim   \n",
       "91                                   Hoffmann-La Roche       La Jolla   \n",
       "92                      Massachusetts General Hospital         Tucson   \n",
       "93                               Ansun Biopharma, Inc.         Duarte   \n",
       "94   National Institute of Allergy and Infectious D...     Birmingham   \n",
       "95         Rutgers, The State University of New Jersey  New Brunswick   \n",
       "96                           Oregon Research Institute         Eugene   \n",
       "97                Vanderbilt University Medical Center        Chicago   \n",
       "98            Washington University School of Medicine    Saint Louis   \n",
       "99               VA Office of Research and Development        Phoenix   \n",
       "100                          Oregon Research Institute       Stanford   \n",
       "\n",
       "    locationcountry   locationstate locationzip        nctid  \\\n",
       "0     United States        Michigan       48073  NCT04349202   \n",
       "1     United States            Utah       84107  NCT04329832   \n",
       "2     United States            Utah       84107  NCT04334382   \n",
       "3     United States         Georgia       30322  NCT04331366   \n",
       "4     United States       Minnesota       55455  NCT04339998   \n",
       "5     United States        Illinois       62220  NCT04342663   \n",
       "6     United States  North Carolina       27710  NCT04350073   \n",
       "7     United States         Arizona       85254  NCT04344457   \n",
       "8     United States      New Jersey       07601  NCT04343755   \n",
       "9     United States          Hawaii       96813  NCT04345692   \n",
       "10    United States      California       94022  NCT04321811   \n",
       "11    United States      California       93003  NCT04335084   \n",
       "12    United States    Pennsylvania       19107  NCT04344015   \n",
       "13    United States        Illinois       60612  NCT04325906   \n",
       "14    United States  North Carolina       27710  NCT04343690   \n",
       "15    United States          Kansas       66160  NCT04335123   \n",
       "16    United States        Illinois       60637  NCT04340050   \n",
       "17    United States        Colorado       80260  NCT04348864   \n",
       "18    United States        Virginia       20301  NCT04343677   \n",
       "19    United States        Colorado       80045  NCT04340232   \n",
       "20    United States        New York       10032  NCT04318444   \n",
       "21    United States        Illinois       60637  NCT04331795   \n",
       "22    United States      California       94305  NCT04347954   \n",
       "23    United States    Pennsylvania       19104  NCT04329923   \n",
       "24    United States        New York       10029  NCT04350476   \n",
       "25    United States        Illinois       60637  NCT04351620   \n",
       "26    United States        Missouri       64111  NCT04350593   \n",
       "27    United States      California       93003  NCT04334512   \n",
       "28    United States        Maryland       21201  NCT04317040   \n",
       "29    United States      California       94143  NCT04323839   \n",
       "..              ...             ...         ...          ...   \n",
       "71    United States   Massachusetts       02114  NCT04331509   \n",
       "72    United States         Florida       32224  NCT04341012   \n",
       "73    United States         Alabama       35294  NCT04306393   \n",
       "74    United States         Georgia  30030-1705  NCT04283461   \n",
       "75    United States   Massachusetts       02115  NCT04333654   \n",
       "76    United States        Michigan       48202  NCT04341441   \n",
       "77    United States        Missouri       63110  NCT04341727   \n",
       "78    United States        Illinois       61637  NCT04341116   \n",
       "79    United States       Minnesota       55415  NCT04311177   \n",
       "80    United States  North Carolina       27704  NCT04335552   \n",
       "81    United States         Florida       33136  NCT04311697   \n",
       "82    United States      California       91942  NCT04340557   \n",
       "83    United States        New York       11507  NCT04342637   \n",
       "84    United States   Massachusetts       02115  NCT04348370   \n",
       "85    United States        New York       10029  NCT04351243   \n",
       "86    United States        Illinois       60637  NCT04349332   \n",
       "87    United States       Minnesota       55455  NCT04308668   \n",
       "88    United States      California       90095  NCT04315298   \n",
       "89    United States      California       92806  NCT04292899   \n",
       "90    United States      California       92806  NCT04292730   \n",
       "91    United States      California       92093  NCT04320615   \n",
       "92    United States         Arizona       85721  NCT04332991   \n",
       "93    United States      California       91010  NCT03808922   \n",
       "94    United States         Alabama       35233  NCT04280705   \n",
       "95    United States      New Jersey       08901  NCT04336215   \n",
       "96    United States          Oregon       97403  NCT03710746   \n",
       "97    United States        Illinois       60007  NCT04173663   \n",
       "98    United States        Missouri       63110  NCT04333732   \n",
       "99    United States         Arizona       85012  NCT02915198   \n",
       "100   United States      California       94305  NCT03261050   \n",
       "\n",
       "          overallstatus                                 primaryoutcomedesc  \\\n",
       "0            Recruiting  Prevalence COVID antibodies in employees of Be...   \n",
       "1            Recruiting            COVID Ordinal Outcomes Scale at 14 days   \n",
       "2            Recruiting       Hospitalization within 14 days of enrollment   \n",
       "3            Recruiting      Change in Oxygen Saturation by Pulse Oximetry   \n",
       "4    Not yet recruiting                                POCUS Score - Lungs   \n",
       "5            Recruiting                         Time to clinical worsening   \n",
       "6    Not yet recruiting  Metabolic and Nutritional Needs of COVID-19 Pa...   \n",
       "7            Recruiting                     Improvement of clinical status   \n",
       "8            Recruiting  For patients hospitalized for COVID-19 but not...   \n",
       "9            Recruiting                                 i. Clinical status   \n",
       "10           Recruiting                      Define Natural Symptom Course   \n",
       "11   Not yet recruiting  Prevention of COVID-19 measured by negative te...   \n",
       "12           Recruiting  Number of patients who screen eligible for don...   \n",
       "13   Not yet recruiting                                  Treatment failure   \n",
       "14   Not yet recruiting       Change in stress level as measured by survey   \n",
       "15           Recruiting  Number of participants with treatment-related ...   \n",
       "16           Recruiting  Feasibility of performing study pathway consis...   \n",
       "17           Recruiting  Clinical accuracy of the antibody-based rapid ...   \n",
       "18   Not yet recruiting                                          Incidence   \n",
       "19   Not yet recruiting  Phase 2: Cumulative incidence of Grade 3 and 4...   \n",
       "20   Not yet recruiting  Number of participants with symptomatic, lab-c...   \n",
       "21           Recruiting                                  Clinical response   \n",
       "22   Not yet recruiting          Mean change in viral titers of SARS-CoV-2   \n",
       "23           Recruiting                Median release from quarantine time   \n",
       "24   Not yet recruiting                    Number of different arrhythmias   \n",
       "25           Recruiting  Tolerability of high dose HCQ as measured by H...   \n",
       "26           Recruiting  Time to first occurrence of either death from ...   \n",
       "27   Not yet recruiting  Successful treatment as determined by Negative...   \n",
       "28           Recruiting             Improvement of COVID-19 disease status   \n",
       "29           Recruiting                              Clinical presentation   \n",
       "..                  ...                                                ...   \n",
       "71           Recruiting                           Physical health symptoms   \n",
       "72           Recruiting          Breath volatile organic compound profiles   \n",
       "73           Recruiting  Change of arterial oxygenation at 48 hours fro...   \n",
       "74           Recruiting  Frequency of solicited local reactogenicity ad...   \n",
       "75           Recruiting  Change from baseline to Day 3 in nasopharyngea...   \n",
       "76           Recruiting  Reduction in the number of COVID-19 infections...   \n",
       "77           Recruiting                                  Hours to recovery   \n",
       "78           Recruiting  Proportion (%) of subjects experiencing deteri...   \n",
       "79           Recruiting                                 Hospital Admission   \n",
       "80   Not yet recruiting  World Health Organization (WHO) ordinal scale ...   \n",
       "81   Not yet recruiting                                          Mortality   \n",
       "82           Recruiting                             Mechanical ventilation   \n",
       "83   Not yet recruiting  Effect of GI societies recommendations on prev...   \n",
       "84   Not yet recruiting  incidence (measured by confirmed positive test...   \n",
       "85           Recruiting                                   Primary endpoint   \n",
       "86   Not yet recruiting                                    ventilator days   \n",
       "87           Recruiting  Incidence of COVID19 Disease among those who a...   \n",
       "88           Recruiting  Percent change in C-reactive protein (CRP) levels   \n",
       "89           Recruiting  The Odds of Ratio for Improvement on a 7-point...   \n",
       "90           Recruiting  The Odds of Ratio for Improvement on a 7-point...   \n",
       "91           Recruiting  Clinical Status Assessed Using a 7-Category Or...   \n",
       "92           Recruiting             COVID Ordinal Outcomes Scale on Day 15   \n",
       "93           Recruiting  Percent of subjects who Return to Room Air (RT...   \n",
       "94           Recruiting  Percentage of subjects reporting each severity...   \n",
       "95           Recruiting                                         Prevalence   \n",
       "96           Recruiting                                           Body Fat   \n",
       "97           Recruiting  Change in Parental Knowledge about adult servi...   \n",
       "98   Not yet recruiting                               Symptomatic COVID-19   \n",
       "99           Recruiting  Time in days to death, non-fatal myocardial in...   \n",
       "100          Recruiting  Change in occurrences of binge eating episodes...   \n",
       "\n",
       "      starting_date completion_date  \n",
       "0        April 2020       June 2021  \n",
       "1        March 2020   December 2021  \n",
       "2        April 2020   December 2021  \n",
       "3        April 2020        May 2020  \n",
       "4        April 2020    October 2020  \n",
       "5        April 2020       July 2020  \n",
       "6        April 2020   December 2020  \n",
       "7        April 2020  September 2020  \n",
       "8        April 2020      April 2021  \n",
       "9        March 2020   December 2021  \n",
       "10       March 2020      March 2022  \n",
       "11       April 2020       July 2021  \n",
       "12       April 2020      April 2021  \n",
       "13       April 2020       June 2020  \n",
       "14       April 2020       June 2020  \n",
       "15       March 2020    October 2020  \n",
       "16       April 2020   December 2021  \n",
       "17       April 2020      April 2021  \n",
       "18       April 2020     August 2020  \n",
       "19       April 2020    October 2020  \n",
       "20       March 2020      March 2022  \n",
       "21       April 2020   December 2020  \n",
       "22         May 2020     August 2020  \n",
       "23       April 2020   December 2021  \n",
       "24       April 2020      April 2021  \n",
       "25       April 2020       June 2020  \n",
       "26       April 2020   December 2020  \n",
       "27       April 2020       July 2021  \n",
       "28       April 2020        May 2022  \n",
       "29       March 2020      March 2024  \n",
       "..              ...             ...  \n",
       "71       March 2020      March 2022  \n",
       "72   September 2019   December 2021  \n",
       "73       March 2020      March 2022  \n",
       "74       March 2020       June 2021  \n",
       "75       March 2020        May 2020  \n",
       "76       April 2020      April 2021  \n",
       "77       April 2020     August 2021  \n",
       "78       April 2020  September 2020  \n",
       "79       April 2020      April 2021  \n",
       "80       April 2020     August 2020  \n",
       "81       April 2020  September 2020  \n",
       "82       March 2020   December 2020  \n",
       "83       April 2020   December 2020  \n",
       "84       April 2020   November 2021  \n",
       "85       April 2020    October 2020  \n",
       "86       April 2020       June 2021  \n",
       "87       March 2020        May 2020  \n",
       "88       March 2020      April 2021  \n",
       "89       March 2020        May 2020  \n",
       "90       March 2020        May 2020  \n",
       "91       April 2020  September 2021  \n",
       "92       April 2020       July 2021  \n",
       "93         May 2019   December 2021  \n",
       "94    February 2020      April 2023  \n",
       "95       April 2020    October 2021  \n",
       "96     October 2018       July 2023  \n",
       "97    December 2019        May 2024  \n",
       "98       April 2020   February 2021  \n",
       "99    February 2019     August 2024  \n",
       "100       July 2017       June 2022  \n",
       "\n",
       "[101 rows x 18 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# remove day from start date column\n",
    "covid_df['starting_date']=covid_df['start_date'].str.split(r'\\s+').apply(lambda x: x[0:1] + x[2:] if len(x) > 2 else x).str.join(' ')\n",
    "# covid_df\n",
    "covid_df['completion_date']=covid_df['completiondate'].str.split(r'\\s+').apply(lambda x: x[0:1] + x[2:] if len(x) > 2 else x).str.join(' ')\n",
    "\n",
    "# drop initial date columns\n",
    "covid_df = covid_df.drop(['start_date','completiondate' ], axis=1)\n",
    "covid_df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sqlalchemy as db"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "ename": "OperationalError",
     "evalue": "(sqlite3.OperationalError) too many SQL variables [SQL: 'INSERT INTO \"COVID_ClinicalTrials\" (\"index\", briefsummary, brieftitle, contactemail, contactname, contactphone, enrollmentcount, facility, interventiondesc, leadsponsor, locationcity, locationcountry, locationstate, locationzip, nctid, overallstatus, primaryoutcomedesc, starting_date, completion_date) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)'] [parameters: (0, \"The purpose of this study is to determine how peoples' bodies respond to exposure to COVID-19. Employees of Beaumont Health in Michigan who are older ... (1068 characters truncated) ... on.The results of the serology test are used for research only and will not affect clinical decisions regarding participants' treatment or quarantine\", 'Beaumont Health Large-scale Automated Serologic Testing for COVID-19', 'Maureen.Cooney@beaumont.org', 'Maureen Cooney, RN, BSN', '248-551-0099', '50000', 'Beaumont Health System', 'Serology testing to detect SARS-CoV-2 antibodies', 'William Beaumont Hospitals', 'Royal Oak', 'United States', 'Michigan', '48073', 'NCT04349202', 'Recruiting', 'Prevalence COVID antibodies in employees of Beaumont Health', 'April 2020', 'June 2021', 1, 'This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.', 'Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19', 'Valerie.Aston@imail.org', 'Valerie T Aston, MBA', '8015074606', '300', 'Intermountain Medical Center', 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).', 'Intermountain Health Care, Inc.', 'Murray', 'United States', 'Utah', '84107', 'NCT04329832', 'Recruiting', 'COVID Ordinal Outcomes Scale at 14 days', 'March 2020', 'December 2021', 2, 'This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.', 'Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19', 'Valerie.Aston@imail.org', 'Valerie T Aston, MBA', '8015074606', '1550', 'Intermountain Medical Center', 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < ... (141 characters truncated) ...  in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.', 'Intermountain Health Care, Inc.', 'Murray', 'United States', 'Utah', '84107', 'NCT04334382', 'Recruiting', 'Hospitalization within 14 days of enrollment', 'April 2020', 'December 2021', 3, 'The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.', 'Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19', 'jeffrey.miller@emory.edu', 'Jeffrey Miller, MD', '404-778-7200', '5', 'Emory University Hospital', 'The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use und ... (146 characters truncated) ... and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.', 'Emory University', 'Atlanta', 'United States', 'Georgia', '30322', 'NCT04331366', 'Recruiting', 'Change in Oxygen Saturation by Pulse Oximetry', 'April 2020', 'May 2020', 4, 'Specific Aims:\\n\\nThe investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisiti ... (226 characters truncated) ... certain whether changes on ultrasound could improve care through earlier diagnosis or identification of patients at high risk of disease progression.', 'Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)', 'yocum007@umn.edu', 'Matthew Yocum, MD', '612-626-8015', '500', 'University of Minnesota Medical Center (UMMC)', 'The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS ... (578 characters truncated) ...  mm), abnormal (>10 mm)\\nLeft ventricular (LV) mass approximation by septal thickness\\nLeft Ventricular Chamber Size by internal diameter at diastole', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04339998', 'Not yet recruiting', 'POCUS Score - Lungs', 'April 2020', 'October 2020', 5, \"The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent  ... (397 characters truncated) ... -face contact; study materials including study drug will be shipped to participants' houses. Only residents of Missouri and Illinois may participate.\", 'A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection', 'stevens.a@wustl.edu', 'Angela Stevens', '(314)362-6291', '152', 'BJC', 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.', 'Washington University School of Medicine', 'Belleville', 'United States', 'Illinois', '62220', 'NCT04342663', 'Recruiting', 'Time to clinical worsening', 'April 2020', 'July 2020', 6, 'This current proposal evaluates the Longitudinal Energy Expenditure and Metabolic Effects in Patients with COVID-19 (LEEP-COVID) to understand, guide ... (326 characters truncated) ... ter with 2 of the FDA-approved devices in existence currently capable of collecting this vital data to guide the care of COVID-19 patients worldwide.', 'Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)', 'paul.wischmeyer@duke.edu', 'Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM', '919-681-6437', '120', 'Duke University Medial Center', 'COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04350073', 'Not yet recruiting', 'Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device', 'April 2020', 'December 2020', 7, 'Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, cli ... (420 characters truncated) ... atients in Arizona.\\n\\nThis study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2', 'Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19', 'nhank@prcresearcheducation.com', 'Nicole C Hank, PhD,MCR,MHSM', '4804716132', '80', 'Perseverance Research Center', '200 mg PO BID 5 days', 'Perseverance Research Center, LLC', 'Scottsdale', 'United States', 'Arizona', '85254', 'NCT04344457', 'Recruiting', 'Improvement of clinical status', 'April 2020', 'September 2020', 8, 'This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.\\nSubjects will be  ... (158 characters truncated) ... bed in the statistical section 8.\\nThe final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.', 'Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection', 'Mariefel.Vendivil@HackensackMeridian.org', 'Mariefel Vendivil', '551-996-5828', '55', 'Hackensack University Medical Center', 'Fresh plasma will be infused one time to hospitalized patients with COVID-19 infection', 'Hackensack Meridian Health', 'Hackensack', 'United States', 'New Jersey', '07601', 'NCT04343755', 'Recruiting', 'For patients hospitalized for COVID-19 but not intubated', 'April 2020', 'April 2021', 9, 'This study is a randomized, open label clinical trial to evaluate the safety and efficacy of hydroxychloroquine (HCQ) plus usual care compared to usu ... (121 characters truncated) ... ison between open label hydroxychloroquine and usual care. The course of treatment (HCQ) is five days. Participants will be followed to study day 28.', 'A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients', 'tseto@queens.org', 'Todd Seto, MD', '808 354-3533', '350', \"Queen's Medical Center\", 'oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet', \"Queen's Medical Centre\", 'Honolulu', 'United States', 'Hawaii', '96813', 'NCT04345692', 'Recruiting', 'i. Clinical status', 'March 2020', 'December 2021', 10, 'Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized  ... (1262 characters truncated) ... ollow-up, or death. As a patient-centric registry, patients themselves may propose, suggest, and/or submit evidence or ideas for relevant collection.', 'Behavior, Environment And Treatments for Covid-19', 'info@beat19.org', 'BEAT19.org', '(415) 754-9290', '100000', 'BEAT19.org', 'Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.', 'xCures', 'San Francisco', 'United States', 'California', '94022', 'NCT04321811', 'Recruiting', 'Define Natural Symptom Course', 'March 2020', 'March 2022', 11, 'This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent infection with COVID-19', 'A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection', 'sabinehazan@aim.com', 'Sabine Hazan, MD', '805-200-7426', '600', 'ProgenaBiome', 'Prophylaxis treatment for COVID-19', 'ProgenaBiome', 'Ventura', 'United States', 'California', '93003', 'NCT04335084', 'Not yet recruiting', 'Prevention of COVID-19 measured by negative testing with RT-PCR', 'April 2020', 'July 2021', 12, 'Patients who are severely ill with COVID-19 may benefit from receiving plasma infusions from donors who have recovered from the disease and are prove ... (733 characters truncated) ... ts are processed in this special population. This protocol does not involve the administration of blood products to patients with COVID-19 infection.', 'COVID-19 Plasma Collection', 'CovidPlasma@jefferson.edu', 'Julie Karp, MD', '215-503-4838', '2000', 'Thomas Jefferson University Hospital', 'Previously infected COVID-19 patients will be recruited to donate convalescent plasma.', 'Thomas Jefferson University', 'Philadelphia', 'United States', 'Pennsylvania', '19107', 'NCT04344015', 'Recruiting', 'Number of patients who screen eligible for donation', 'April 2020', 'April 2021', 13, 'Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. ... (150 characters truncated) ... sitioning combined with HFNC can avoid the need for intubation in COVID-19 induced moderate to severe ARDS patients needs to be further investigated.', 'Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS', 'Jie_Li@rush.edu', 'Jie Li, PhD', '312-947-0065', '346', 'Rush University Medical Center', \"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Na ... (67 characters truncated) ... â‰¤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.\", 'Rush University Medical Center', 'Chicago', 'United States', 'Illinois', '60612', 'NCT04325906', 'Not yet recruiting', 'Treatment failure', 'April 2020', 'June 2020', 14, 'The purpose of this study is 1) to understand effects of COVID-19 crisis on wellness of pulmonary and critical care faculty and trainees who are at f ... (75 characters truncated) ... ekly web based crisis management coaching from world renowned experts in coaching and 3) identify future areas of opportunities in physician wellness', 'COPING With COVID-19( CWC-19)', 'erika.ratcliffe@duke.edu', 'Erika Ratcliffe', '919-681-5006', '100', 'Duke University', 'Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04343690', 'Not yet recruiting', 'Change in stress level as measured by survey', 'April 2020', 'June 2020', 15, 'This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19.\\n\\nBriefly, 50 patients with ... (517 characters truncated) ... e decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group.', 'Study of Open Label Losartan in COVID-19', 'msalathe@kumc.edu', 'Matthias Salathe, MD', '9135886000', '50', 'University of Kansas Medical Center', '25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion', 'University of Kansas Medical Center', 'Kansas City', 'United States', 'Kansas', '66160', 'NCT04335123', 'Recruiting', 'Number of participants with treatment-related adverse events as assessed by protocol definition of AE', 'March 2020', 'October 2020', 16, 'The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life ... (626 characters truncated) ... easibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.', 'COVID-19 Convalescent Plasma', 'mlmadariaga@bsd.uchicago.edu', 'Maria Lucia Madariaga, MD', '773-270-2004', '10', 'University of Chicago Medicine', 'Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04340050', 'Recruiting', 'Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients', 'April 2020', 'December 2021', 17, 'The goal of the research is to assess candidate rapid (5-15 min) antibody tests in order to judge their clinical accuracy compared to Centers for Dis ... (476 characters truncated) ... the safety, ease-of-use and validity of finger-stick capillary blood self-testing assisted by mobile device imaging and telemedicine remote support..', 'COVID-19 Antibody Self-testing Using Virtual Point-of-care', 'drdon@neuroganicslabs.com', 'Donald Cooper, Ph.D.', '7204313495', '100', 'Neuroganics', 'An immunodiagnostic rapid (10-20 minute) test detects circulating antibodies (IgM and IgG) in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 in the past.', 'Neuroganics LLC', 'Northglenn', 'United States', 'Colorado', '80260', 'NCT04348864', 'Recruiting', 'Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result', 'April 2020', 'April 2021', 18, 'There is significant interest throughout the United States in performing a well-designed study to evaluate whether there is value in using Hydroxychl ... (450 characters truncated) ... 450 patients treated with 400mg Hydroxychloroquine daily\\nA post-exposure arm of 100 patients treated with 400mg Hydroxychloroquine daily for 7 days.', 'Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study', 'usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil', 'Scott A Wallace, MD', '703-697-3255', '1450', 'Pentagon', 'Daily dosing of hydroxychloroquine as PrEP or PEP', 'United States Department of Defense', 'Arlington', 'United States', 'Virginia', '20301', 'NCT04343677', 'Not yet recruiting', 'Incidence', 'April 2020', 'August 2020', 19, 'This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the m ... (387 characters truncated) ... the lungs and possibly other organs.\\n\\nThe study will recruit patients who have been diagnosed with COVID-19.\\n\\nThe goal is to recruit 80 patients.', 'Safety and Efficacy of Baricitinib for COVID-19', 'bari-covid19@cuanschutz.edu', 'Angela Rachubinski, PhD', '(720) 507-9107', '80', 'University of Colorado, Denver', 'Subjects will receive a 2 mg oral dose of baricitinib.', 'University of Colorado, Denver', 'Aurora', 'United States', 'Colorado', '80045', 'NCT04340232', 'Not yet recruiting', 'Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)', 'April 2020', 'October 2020', 20, 'The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.', 'Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)', 'eco7@cumc.columbia.edu', 'Elizabeth Oelsner, MD, MPH', '212-305-9056', '1600', 'Columbia University Irving Medical Center', 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04318444', 'Not yet recruiting', 'Number of participants with symptomatic, lab-confirmed COVID-19.', 'March 2020', 'March 2022', 21, 'Coronavirus disease-2019 (COVID-19) has a quoted inpatient mortality as high as 25%. This high mortality may be driven by hyperinflammation resemblin ... (1882 characters truncated) ... n of fever and the biochemical outcome measures of time to CRP normalization for the individual patient and the rate of patients whose CRP normalize.', 'Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis', 'pankti.reid@uchospitals.edu', 'Pankti Reid, MD, MPH', '7737021220', '50', 'University of Chicago Medicine', 'Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinica ... (8 characters truncated) ... ochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04331795', 'Recruiting', 'Clinical response', 'April 2020', 'December 2020', 22, 'The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in ... (314 characters truncated) ... an subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the \"common cold.\"', 'PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)', 'hwangph@stanford.edu', 'Peter H Hwang, MD', '650-725-6500', '45', 'Stanford Health Care', 'Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day', 'Stanford University', 'Stanford', 'United States', 'California', '94305', 'NCT04347954', 'Not yet recruiting', 'Mean change in viral titers of SARS-CoV-2', 'May 2020', 'August 2020', 23, 'The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort ... (172 characters truncated) ... of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.', 'The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)', 'amelia.anderson@pennmedicine.upenn.edu', 'Amelia Anderson', '215-509-5690', '400', 'University of Pennsylvania', 'Antimalarial compound', 'Ravi Amaravadi, MD', 'Philadelphia', 'United States', 'Pennsylvania', '19104', 'NCT04329923', 'Recruiting', 'Median release from quarantine time', 'April 2020', 'December 2021', 24, 'The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.', 'COVID-19 Remote Monitoring', 'sam.cammack@mountsinai.org', 'Sam Cammack', '212-824-8931', '1000', 'Icahn School of Medicine at Mount Sinai', 'This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring  ... (45 characters truncated) ... pplied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).', 'Vivek Reddy', 'New York', 'United States', 'New York', '10029', 'NCT04350476', 'Not yet recruiting', 'Number of different arrhythmias', 'April 2020', 'April 2021', 25, 'This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.', 'High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19', 'rjan@medicine.bsd.uchicago.edu', 'Reem Jan, MBBS BSc', '734-972-7953', '20', 'University of Chicago', 'Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04351620', 'Recruiting', 'Tolerability of high dose HCQ as measured by HCQ dose modification', 'April 2020', 'June 2020', 26, 'This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with COVID- ... (151 characters truncated) ...  daily for 30 days in addition to background local standard of care therapy, in reducing disease progression, complications, and all-cause mortality.', 'Dapagliflozin in Respiratory Failure in Patients With COVID-19', 'swindsor@saint-lukes.org', 'Sheryl Windsor', '816-932-9858', '900', \"Saint Luke's Mid America Heart Institute\", 'Active Comparator: Dapagliflozin 10mg', \"Saint Luke's Health System\", 'Kansas City', 'United States', 'Missouri', '64111', 'NCT04350593', 'Recruiting', 'Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:', 'April 2020', 'December 2020', 27, 'This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).', 'A Study of Quintuple Therapy to Treat COVID-19 Infection', 'sabinehazan@aim.com', 'Sabine Hazan, MD', '805-200-7436', '600', 'ProgenaBiome', 'treatment with hydroxychloroquine', 'ProgenaBiome', 'Ventura', 'United States', 'California', '93003', 'NCT04334512', 'Not yet recruiting', 'Successful treatment as determined by Negative Test and resolution of symptoms', 'April 2020', 'July 2021', 28, 'The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in h ... (275 characters truncated) ... andomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 15 days.', 'CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment', 'pzheng@oncoimmune.com', 'Pan Zheng, MD, PhD', '(202) 7516823', '230', 'Institute of Human Virology, University of Maryland Baltimore', 'CD24Fc is given on Day 1.', 'OncoImmune, Inc.', 'Baltimore', 'United States', 'Maryland', '21201', 'NCT04317040', 'Recruiting', 'Improvement of COVID-19 disease status', 'April 2020', 'May 2022', 29, 'PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a prospective cohort study of pregnant and recently pregnant women who are: either patients und ... (83 characters truncated) ... ill be used to evaluate the impact of COVID-19 on the clinical course and pregnancy outcomes of pregnant women and women within 6 weeks of pregnancy.', 'COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)', 'PRIORITYCOVID19@ucsf.edu', 'Ruth Gebrezghi', '(415) 754-3749', '1000', 'University of California, San Francisco', 'This is an observational study with no intervention', 'University of California, San Francisco', 'San Francisco', 'United States', 'California', '94143', 'NCT04323839', 'Recruiting', 'Clinical presentation', 'March 2020', 'March 2024', 30, 'The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in ... (274 characters truncated) ... his two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.', 'Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19', 'lberra@mgh.harvard.edu', 'Lorenzo Berra', '+16176437733', '240', 'Massachusetts General Hospital', 'Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from tim ... (177 characters truncated) ... re between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.', 'Massachusetts General Hospital', 'Boston', 'United States', 'Massachusetts', '02114-2621', 'NCT04305457', 'Recruiting', 'Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation', 'March 2020', 'April 2022', 31, 'Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper res ... (995 characters truncated) ... ral shedding/viral load and viral transmission, secondary bacterial load, nasopharyngeal inflammation in patients infected with the novel SARS-CoV-2.', 'Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19', 'kate.vonwahlde@vumc.org', 'Kate Von Wahlde, MJ, CCRP', '615-322-0333', '90', 'Vanderblt University Medical Center', 'Saline nasal irrigation BID', 'Vanderbilt University Medical Center', 'Nashville', 'United States', 'Tennessee', '37232', 'NCT04347538', 'Not yet recruiting', 'Change in SARS-CoV-2 mucosal immune response in the nasopharynx', 'May 2020', 'June 2022', 32, 'Patients who meet inclusion criteria will be randomized into treatment vs control group. Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control group.', 'Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection', 'englemd94@gmail.com', 'John F Engle, MD', '985-768-8918', '48', 'Ochsner Medical Center', 'Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.', 'Ochsner Health System', 'New Orleans', 'United States', 'Louisiana', '70121', 'NCT04343183', 'Not yet recruiting', 'Decrease incidence of intubation by 30% or greater', 'April 2020', 'June 2020', 33, 'This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.', 'Azithromycin for COVID-19 Treatment in Outpatients Nationwide', 'ACTIONTrial@ucsf.edu', 'Jessica M Brogdon, MPH', '(415) 514-1582', '2271', 'University of California San Francisco', 'Participants will be shipped a single 1 g dose of oral azithromycin', 'University of California, San Francisco', 'San Francisco', 'United States', 'California', '94143', 'NCT04332107', 'Not yet recruiting', 'Hospitalization', 'April 2020', 'July 2021', 34, 'Prospective randomized, two-stage trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs. standard of care in up to 40 subjects (20 inpatient and 20 outpatient) with COVID-19 infection.', 'Pegylated Interferon Lambda Treatment for COVID-19', 'JLGustafson@mgh.harvard.edu', 'Jenna Gustafson, MSc', '6177243836', '40', 'Massachusetts General Hospital', '180 mcg subcutaneous injection of pegylated interferon lambda', 'Raymond Chung', 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04343976', 'Not yet recruiting', 'Undetectable COVID PCR at day 7', 'May 2020', 'December 2021', 35, 'For this study, 48 patients who have been diagnosed with COVID-19 will be randomly assigned to four study groups: control, saline, chlorhexidine gluc ... (200 characters truncated) ... tion in their nose four times daily. Patients will then be tested for COVID-19 once daily in the evening for 7 days and viral loads will be measured.', 'Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19', 'scott.rickert@nyulangone.org', 'Scott Rickert, MD', '646-501-7890', '48', 'NYU Langone Health', '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.', 'NYU Langone Health', 'New York', 'United States', 'New York', '10016', 'NCT04344236', 'Recruiting', 'Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx', 'April 2020', 'May 2020', 36, 'The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.', 'Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)', 'kushd@amarexcro.com', 'Kush Dhody, MBBS, MS, CCRA', '301-956-2536', '390', 'Montefiore Medical Center', 'Placebos', 'CytoDyn, Inc.', 'Bronx', 'United States', 'New York', '10467', 'NCT04347239', 'Recruiting', 'All-cause mortality at Day 28', 'April 2020', 'April 2021', 37, 'The objective of this study is to provide remote mindfulness session(s) to help during the COVID-19 pandemic.', 'Mindfulness During COVID-19', 'rewells@wakehealth.edu', 'Rebecca E Wells, MD, MPH', '336-716-2357', '200', 'Wake Forest Health Sciences', 'The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).', 'Wake Forest University Health Sciences', 'Winston-Salem', 'United States', 'North Carolina', '27157', 'NCT04319445', 'Recruiting', 'Helpfulness of the session', 'March 2020', 'December 2020', 38, 'This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the ... (14 characters truncated) ... randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.', 'Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease', 'jeannine.ascani@lcmchealth.org', 'Jeannine Ascani, MS', '5047023141', '600', 'University Medical Center New Orleans', 'tablets provided as described in Arm B', 'LCMC Health', 'New Orleans', 'United States', 'Louisiana', '70112', 'NCT04344444', 'Recruiting', 'Most severe outcome', 'April 2020', 'December 2021', 39, 'The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. We  ... (400 characters truncated) ... nical status, concomitant medications and laboratory parameters. Study specific biomarkers will be measured at baseline and then at days 3, 7 and 14.', 'Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia', 'guptans@ucmail.uc.edu', 'Nishant Gupta, MD', '5135584831', '30', 'University of Cincinnati', 'Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.', 'University of Cincinnati', 'Cincinnati', 'United States', 'Ohio', '45267', 'NCT04341675', 'Recruiting', 'Progression to advanced respiratory support', 'April 2020', 'September 2020', 40, 'Minimal risk research study:\\n\\nComparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus;\\nQuantifying the development and trajectory of the disease through clinic visits and blood values.', 'A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research', 'ethan.berke@uhg.com', 'Ethan Berke', '603/286-0376', '120', 'Everett Clinic', 'The nostril used and order of testing will be different in each arm.', 'Dr. Deneen Vojta', 'Seattle', 'United States', 'Washington', '98133', 'NCT04327804', 'Recruiting', 'Detection of SARS-CoV-2 virus', 'March 2020', 'April 2020', 41, 'This open-label randomized controlled study will evaluate safety, efficacy, and the pharmacokinetic profile of CM4620-IE in patients with severe COVI ... (233 characters truncated) ...  receive local standard of care only. The infusion of CM4620-IE will start within 8 hours from the time the patient or LAR provides informed consent.', 'A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia', 'sudarshan@calcimedica.com', 'Sudarshan Hebbar, MD', '816-838-7105', '120', 'Henry Ford Hospital', 'CM4620-IE 2.0 mg/kg on Day 1 and then 1.6 mg/kg on Days 2 and 3. All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.', 'CalciMedica, Inc.', 'Detroit', 'United States', 'Michigan', '48202', 'NCT04345614', 'Recruiting', 'Improvement on a 7-point Ordinal Scale', 'April 2020', 'September 2020', 42, 'The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respir ... (477 characters truncated) ... atus, prevents future hospitalization, and improves the clinical course in patients diagnosed with COVID-19 specifically in the emergency department.', 'Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED', 'nsharris@mgh.harvard.edu', 'N. Stuart Harris, MD, MFA', '617-724-3290', '260', 'Massachusetts General Hospital', 'Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes', 'Massachusetts General Hospital', 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04338828', 'Not yet recruiting', 'Rates of return visits to the ED', 'April 2020', 'April 2022', 43, 'Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patient ... (203 characters truncated) ... rtion of this study, a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.', 'Hyperbaric Oxygen for COVID-19 Patients', 'Scott.Gorenstein@nyulangone.org', 'Scott Gorenstein', '516-663-8498', '40', 'NYU Winthrop Hospital', 'The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the tr ... (82 characters truncated) ... of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.', 'NYU Langone Health', 'Mineola', 'United States', 'New York', '11501', 'NCT04332081', 'Recruiting', 'Mortality', 'April 2020', 'July 2020', 44, 'In this study clazakizumab will be administered to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical pic ... (140 characters truncated) ... nts will be enrolled and randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo', 'A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection', 'bonnie.lonze@nyulangone.org', 'Bonnie Lonze, MD', '212-263-8365', '30', 'New York University School of Medicine', 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of  ... (210 characters truncated) ... If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.', 'NYU Langone Health', 'New York', 'United States', 'New York', '10016', 'NCT04343989', 'Recruiting', 'Incidence of serious adverse events associated with clazakizumab or placebo', 'March 2020', 'July 2020', 45, 'A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.', 'TXA and Corona Virus 2019 (COVID19) in Outpatients', 'tness@uabmc.edu', 'Timothy J Ness, MD PhD', '2059079743', '100', 'University of Alabama at Birmingham', 'Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos', 'University of Alabama at Birmingham', 'Birmingham', 'United States', 'Alabama', '35222', 'NCT04338074', 'Not yet recruiting', 'Hospitalization', 'April 2020', 'October 2020', 46, 'Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.', 'Pre-exposure Prophylaxis for SARS-Coronavirus-2', 'covid19prep@umn.edu', 'Radha Rajasingham (Please Email), MD', '612-626-8171', '3500', 'Nationwide Enrollment via Internet, please email: covid19@umn.edu', 'Hydroxychloroquine; 200mg tablet; oral', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04328467', 'Recruiting', 'COVID-19-free survival', 'April 2020', 'August 2020', 47, 'This study is for cancer patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutrali ... (389 characters truncated) ... l treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.', 'Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19', 'cancerclinicaltrials@cumc.columbia.edu', 'Lisa Olmos, RN', '212.342.5162', '138', 'Columbia University Irving Medical Center', 'BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).', 'Matthew Dallos', 'New York', 'United States', 'New York', '10032', 'NCT04347226', 'Not yet recruiting', 'Time to Improvement in the 7-point ordinal scale', 'April 2020', 'September 2022', 48, 'This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus  ... (210 characters truncated) ... luate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.', 'Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection', 'ssneddo2@jhmi.edu', 'Stephanie Katz, BSN', '443-997-1900', '164', 'Johns Hopkins Hospital', 'Peginterferon lambda-1a 180 micrograms by subcutaneous injection', 'Johns Hopkins University', 'Baltimore', 'United States', 'Maryland', '21287', 'NCT04344600', 'Not yet recruiting', 'Proportion of participants with no evidence of SARS-CoV-2 infection', 'April 2020', 'June 2021', 49, 'The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.', 'Convalescent Plasma in the Treatment of COVID 19', 'Latha.Dulipsingh@trinityhealthofne.org', 'Latha Dulipsingh, MD', '860-714-4402', '15', 'Trinity Health Of New England', 'treatment with 2 Units of convalescent plasma', 'Saint Francis Care', 'Hartford', 'United States', 'Connecticut', '06105', 'NCT04343261', 'Not yet recruiting', 'Mortality', 'April 2020', 'April 2021', 50, 'Although a number of therapeutics are being utilized by clinicians to treat patients with COVID-19, none have been systematically evaluated in clinic ... (574 characters truncated) ... RBs. This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo.', 'COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2', 'jennifer.victory@bassett.org', 'Jennifer Victory, RN', '6075476965', '4000', 'Bassett Medical Center', 'administered for minimum of 5 days, up to 14 days if supply available', 'Bassett Healthcare', 'Cooperstown', 'United States', 'New York', '13326', 'NCT04328012', 'Recruiting', 'National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)', 'April 2020', 'April 2021', 51, 'Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify anti ... (105 characters truncated) ... ffective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.', 'Acquiring Convalescent Specimens for COVID-19 Antibodies', 'yl4459@cumc.columbia.edu', 'Yang Luo, PhD', '2123046205', '12', 'Columbia University Irving Medical Center/NYP', 'Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04342195', 'Recruiting', 'Number of antibodies against coronaviruses isolated and identified from patient samples', 'March 2020', 'March 2021', 52, 'This study will test to see if a 72-hour intravenous vitamin C infusion protocol (100 mg/kg every 8 hours) in patients with hypoxemia and suspected COVID-19 will reduce the lung injury caused by the SARS-Cov-2.', 'Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)', 'mkashiouris@vcu.edu', 'Markos G Kashiouris, MD MPH', '804-305-7187', '200', 'Hunter Holmes McGuire VA Medical Center', '100 mg/kg intravenous vitamin C infusion every 8 hours for up to 72 hours', 'Virginia Commonwealth University', 'Richmond', 'United States', 'Virginia', '23249', 'NCT04344184', 'Not yet recruiting', 'Number of ventilator-free days', 'April 2020', 'May 2021', 53, 'This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.', 'Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19', 'kushd@amarexcro.com', 'Kush Dhody, MBBS, MS, CCRA', '301-956-2536', '75', 'Montefiore Medical Center', 'Placebo', 'CytoDyn, Inc.', 'Bronx', 'United States', 'New York', '10467', 'NCT04343651', 'Recruiting', 'Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)', 'April 2020', 'April 2021', 54, 'The current COVID-19 pandemic is providing healthcare organizations with considerable challenges and opportunities for rapid cycle improvement effort ... (1376 characters truncated) ... or these patients, while further directing the necessary protective measures for additional team members involved in the care of the injured patient.', 'The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation', 'jose.diaz-miron@childrenscolorado.org', 'Jose L Diaz-Miron, MD', '720-777-6571', '20', \"Children's Hospital Colorado\", 'FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey th ... (639 characters truncated) ... ubpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings.', 'University of Colorado, Denver', 'Aurora', 'United States', 'Colorado', '80045', 'NCT04340479', 'Not yet recruiting', 'Correlation of FAST+ pulmonary findings with active COVID infection', 'May 2020', 'May 2021', 55, 'A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals a ... (722 characters truncated) ...  trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.', 'University of Utah COVID-19 Hydrochloroquine Trial', 'christina.pacchia@hsc.utah.edu', 'Christina Pacchia, PhD', '8012138735', '400', 'University of Utah', 'HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days', 'University of Utah', 'Salt Lake City', 'United States', 'Utah', '84108', 'NCT04342169', 'Recruiting', 'Duration of viral shedding', 'April 2020', 'April 2023', 56, \"Participants scheduled for for an echocardiogram (echo) and being evaluated for, or is positive for COVID-19 will be asked if they would be willing t ... (288 characters truncated) ... being used clinically and is FDA approved. The main reason for using the updated version is that it's faster and better in terms of guiding the user.\", 'CAPTION AI to Minimize Risk of COVID Exposure', 'kristine.arges@duke.edu', 'Kristine Arges, BSN', '919-668-0927', '500', 'Duke University Medical Center', 'Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04336774', 'Not yet recruiting', 'Percent of patient echos that are not interpretable', 'April 2020', 'November 2020', 57, 'The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection', 'Effects of DPP4 Inhibition on COVID-19', 'giacobellis@med.miami.edu', 'Gianluca Iacobellis, MD PhD', '3052433636', '20', 'University of Miami', '5 mg Linagliptin administered by mouth once daily', 'University of Miami', 'Miami', 'United States', 'Florida', '33136', 'NCT04341935', 'Not yet recruiting', 'Changes in Glucose Llevels', 'April 2020', 'September 2020', 58, 'This is a study for patients who have respiratory infection caused by SARS-CoV-2 that have not gotten better. Because there is no standard treatment  ... (399 characters truncated) ...  cells, such as blood and muscle cells.\\n\\nThe purpose of this study is to see if MSCs can help to treat respiratory infections caused by SARS-CoV-2.', 'Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)', 'LaQuisa.Hill@bcm.edu', 'LaQuisa Hill, MD', '(713) 441-1450', '30', 'Houston Methodist Hospital', 'Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.', 'Baylor College of Medicine', 'Houston', 'United States', 'Texas', '77030', 'NCT04345601', 'Not yet recruiting', 'Incidence of unexpected adverse events', 'May 2020', 'February 2022', 59, 'A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.', 'Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients', 'tness@uabmc.edu', 'Timothy J Ness, MD PhD', '2059079743', '60', 'University of Alabama at Birmingham', 'previously described', 'University of Alabama at Birmingham', 'Birmingham', 'United States', 'Alabama', '35233', 'NCT04338126', 'Not yet recruiting', 'Admission to Intensive Care Unit', 'April 2020', 'December 2020', 60, 'The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory ... (340 characters truncated) ... mation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.', 'A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure', 'craig.selzman@hsc.utah.edu', 'Craig Selzman, MD', '(801) 581-5311', '10', 'University of Utah Health', 'Administration of amniotic fluid in SARS-CoV-2 positive patients', 'University of Utah', 'Salt Lake City', 'United States', 'Utah', '84132', 'NCT04319731', 'Recruiting', 'Ventilator Free Days', 'March 2020', 'March 2021', 61, 'This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic me ... (205 characters truncated) ... to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).', 'Hydroxychloroquine for COVID-19 PEP', 'meigs@uw.edu', 'Meighan Krows', '206-520-3833', '2000', 'NYU Langone Health', 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy', 'University of Washington', 'New York', 'United States', 'New York', '10016', 'NCT04328961', 'Not yet recruiting', 'Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection', 'March 2020', 'October 2020', 62, 'Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Mo ... (2 characters truncated) ... efiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness.', 'Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore', 'pnori@montefiore.org', 'Priya Nori, MD', '(718) 920-4622', '100', 'Montefiore Medical Center', '400 mg tablet', 'Montefiore Medical Center', 'Bronx', 'United States', 'New York', '10467', 'NCT04350450', 'Not yet recruiting', 'Time to resolution of symptoms', 'April 2020', 'August 2020', 63, 'The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SAR ... (283 characters truncated) ... scanning session. After the CT scan, patients are followed for 30 days by reviewing their medical records and by phone after discharge from hospital.', 'Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2', 'joanne.gondert@beaumont.org', 'Joanne Gondert, RN, BSN', '248-898-0343', '25', 'Beaumont Health', 'CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan', 'William Beaumont Hospitals', 'Royal Oak', 'United States', 'Michigan', '48073', 'NCT04320511', 'Not yet recruiting', 'Predictive association between CT-V, PBM score and disease progression', 'April 2020', 'March 2022', 64, 'Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.', 'Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19', 'deleaf@bwh.harvard.edu', 'David E Leaf, MD, MMSc', '617-525-7612', '2000', \"Brigham and Women's Hospital\", 'Observational', \"Brigham and Women's Hospital\", 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04343898', 'Recruiting', '14-Day Mortality', 'April 2020', 'June 2022', 65, 'This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromy ... (110 characters truncated) ... e control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.', 'Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19', 'hussaisa@rwjms.rutgers.edu', 'Sabiha Hussain, MD', '732-235-7840', '160', 'Robert Wood Johnson University Hopsital', 'Given PO', 'Rutgers, The State University of New Jersey', 'New Brunswick', 'United States', 'New Jersey', '08901', 'NCT04336332', 'Recruiting', 'Changes in patients viral load', 'April 2020', 'April 2021', 66, 'The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVI ... (51 characters truncated) ...  Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.', 'Saved From COVID-19', 'ada20@cumc.columbia.edu', 'Anca D. Askanase, MD, MPH', '212-305-0856', '350', 'Columbia University Irving Medical Center/NYP', 'Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months ... (12 characters truncated) ... with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04349371', 'Recruiting', 'Number of symptomatic illness in at risk healthcare workers', 'April 2020', 'April 2021', 67, 'This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRAÂ® 2000 device in healthy adult volunteers.', 'Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers', 'clinical.trials@inovio.com', 'Inovio Call Center', '(267) 440-4237', '40', 'Center for Pharmaceutical Research', 'INO-4800 will be administered ID on Day 0 and Week 4.', 'Inovio Pharmaceuticals', 'Kansas City', 'United States', 'Missouri', '64114', 'NCT04336410', 'Recruiting', 'Percentage of Participants with Adverse Events (AEs)', 'April 2020', 'November 2020', 68, 'This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.', 'Losartan for Patients With COVID-19 Requiring Hospitalization', 'Covid19trial@umn.edu', 'Christopher Tignanelli, MD', '612-624-4373', '200', 'Hennepin County Medical Center', 'Losartan; 50 mg daily; oral administration', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55415', 'NCT04312009', 'Recruiting', 'Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days', 'April 2020', 'April 2021', 69, 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first ... (1515 characters truncated) ... e treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.', 'Cardiovascular Manifestations of COVID-19', 'Efstratios.Koutroumpakis@uth.tmc.edu', 'Efstratios Koutroumpakis, MD', '4123203161', '500', 'Memorial Hermann Hospital-Texas Medical Center', 'Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.', 'Memorial Hermann Health System', 'Houston', 'United States', 'Texas', '77030', 'NCT04335630', 'Recruiting', 'Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.', 'March 2020', 'March 2022', 70, 'This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in  ... (98 characters truncated) ... imately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.', 'Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)', 'jean-claude.tardif@icm-mhi.org', 'Jean-Claude Tardif, MD', '514-376-3330', '6000', 'New York University School of Medecine', 'Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.', 'Montreal Heart Institute', 'New York', 'United States', 'New York', '10010', 'NCT04322682', 'Recruiting', 'Number of participants who die or require hospitalization due to COVID-19 infection', 'March 2020', 'September 2020', 71, \"The viral Covid-19 outbreak is now considered a pandemic according to the World Health Organisation (WHO). A free monitoring app 'COVID-19 Symptom Tr ... (409 characters truncated) ... ss of COVID-19 infection in different people, and why some go on to develop more severe or fatal disease while others have only mild symptoms do not.\", 'COVID-19 Symptom Tracker', 'victoria.vazquez@kcl.ac.uk', 'Victoria Vazquez', '02071886765', '10000000', 'Massachusetts General Hospital', 'No Intervention', \"King's College London\", 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04331509', 'Recruiting', 'Physical health symptoms', 'March 2020', 'March 2022', 72, 'The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.', 'Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases', 'brannock.robert@mayo.edu', 'Robert Brannock', '904-953-2000', '120', 'Mayo Clinic Florida', 'Analysis of volatile organic compounds in breath', 'Mayo Clinic', 'Jacksonville', 'United States', 'Florida', '32224', 'NCT04341012', 'Recruiting', 'Breath volatile organic compound profiles', 'September 2019', 'December 2021', 73, 'Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilatio ... (486 characters truncated) ... roves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter single-blinded randomized controlled trial with 1:1 individual allocation', 'Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19', 'lberra@mgh.harvard.edu', 'Lorenzo Berra, MD', '+16176437733', '200', 'University of Alabama', '80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\\n\\nWeaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.', 'Massachusetts General Hospital', 'Birmingham', 'United States', 'Alabama', '35294', 'NCT04306393', 'Recruiting', 'Change of arterial oxygenation at 48 hours from enrollment', 'March 2020', 'March 2022', 74, 'This is a phase I, open-label, dose ranging clinical trial in males and non-pregnant females, 18 to 55 years of age, inclusive, who are in good healt ... (643 characters truncated) ...  is to evaluate the safety and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart, across 3 dosages in healthy adults.', 'Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)', 'KPWA.vaccine@kp.org', '20-0003 Central Contact', '12062872061', '45', 'Emory Vaccine Center - The Hope Clinic', 'Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mR ... (25 characters truncated) ...  manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Decatur', 'United States', 'Georgia', '30030-1705', 'NCT04283461', 'Recruiting', 'Frequency of solicited local reactogenicity adverse events (AEs)', 'March 2020', 'June 2021', 75, 'Primary Objective:\\n\\nTo assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COV ... (131 characters truncated) ... ression of disease in outpatient adults with COVID-19\\nTo assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19', 'Hydroxychloroquine in Outpatient Adults With COVID-19', 'Contact-US@sanofi.com', 'Trial Transparency email recommended (Toll free number for US & Canada)', '800-633-1610', '210', 'Investigational Site Number 8400001', 'Pharmaceutical form:Tablet Route of administration: Oral', 'Sanofi', 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04333654', 'Recruiting', 'Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)', 'March 2020', 'May 2020', 76, 'The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2  ... (612 characters truncated) ... e of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.', 'Will Hydroxychloroquine Impede or Prevent COVID-19', 'whipcovid19@hfhs.org', 'Dee Dee Wang, MD', '313-574-2651', '3000', 'Henry Ford Hospital', 'The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents app ... (114 characters truncated) ... ess likely to produce side effects than standard of care.\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.', 'Henry Ford Health System', 'Detroit', 'United States', 'Michigan', '48202', 'NCT04341441', 'Recruiting', 'Reduction in the number of COVID-19 infections in healthcare workers.', 'April 2020', 'April 2021', 77, 'This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.', 'Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection', 'mklebert@wustl.edu', 'Michael Klebert, RN PhD', '314 747 1098', '500', 'Washington University School of Medicine Infectious Disease Clinical Research Unit', 'anti-rheumatic drug (DMARD)', 'Washington University School of Medicine', 'Saint Louis', 'United States', 'Missouri', '63110', 'NCT04341727', 'Recruiting', 'Hours to recovery', 'April 2020', 'August 2021', 78, 'This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.', 'Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)', 'US.Info@I-MabBiopharma.com', 'US Site Head', '240-767-6981', '144', 'OSF Healthcare Saint Francis Medical Center', 'patients receive a single infusion', 'I-Mab Biopharma Co. Ltd.', 'Peoria', 'United States', 'Illinois', '61637', 'NCT04341116', 'Recruiting', 'Proportion (%) of subjects experiencing deterioration in clinical status', 'April 2020', 'September 2020', 79, 'This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).', 'Losartan for Patients With COVID-19 Not Requiring Hospitalization', 'Covid19trial@umn.edu', 'Christopher Tignanelli, MD', '612-624-4373', '580', 'Hennepin County Medical Center', 'Losartan; 25 mg daily; oral administration', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55415', 'NCT04311177', 'Recruiting', 'Hospital Admission', 'April 2020', 'April 2021', 80, 'This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two  ... (588 characters truncated) ...  care alone\\nStandard of care plus hydroxychloroquine\\nStandard of care plus azithromycin\\nStandard of care plus hydroxychloroquine plus azithromycin', 'Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection', 'jason.stout@dm.duke.edu', 'Jason Stout, MD', '919-668-0826', '500', 'Duke Regional Hospital', 'Standard of care', 'Duke University', 'Durham', 'United States', 'North Carolina', '27704', 'NCT04335552', 'Not yet recruiting', 'World Health Organization (WHO) ordinal scale measured at 14 days after enrollment', 'April 2020', 'August 2020', 81, 'Novel Corona Virus (COVID-19) is known to cause Acute Respiratory Distress Syndrome, that results in death of approximately 50% of those who develop  ... (354 characters truncated) ... o + maximal intensive care. Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours.', 'Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress', 'rbesthof@neurorxpharma.com', 'Robert E Besthof, MIM', '+14842546134', '120', 'Miller School of Medicine / University of Miami Medical Center', 'Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.', 'NeuroRx, Inc.', 'Miami', 'United States', 'Florida', '33136', 'NCT04311697', 'Not yet recruiting', 'Mortality', 'April 2020', 'September 2020', 82, 'The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requir ... (224 characters truncated) ... s hypothesize that the addition of an ARB is beneficial in abating acute lung injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.', 'Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection', 'kathryn.miller@sharp.com', 'Katie Miller', '(858) 939-7162', '200', 'Sharp Grossmont Hospital', 'Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.', 'Sharp HealthCare', 'La Mesa', 'United States', 'California', '91942', 'NCT04340557', 'Recruiting', 'Mechanical ventilation', 'March 2020', 'December 2020', 83, 'A questionnaire containing some critical questions about practice inside GI endoscopy units in different countries will be distributed via emails. Re ... (40 characters truncated) ... latform and data will be analyzed to reveal the effect of SARS-CoV-2 pandemic on different aspects of GI endoscopy practice in the studied countries.', 'COVID-19 Endoscopy Survey', 'alboraie@azhar.edu.eg', 'Mohamed Alboraie, MD, MRCP(UK)', '00201155019700', '40', 'Kings County Hospital Center, Brooklyn, NY, USA', 'Physicians will report details of their endoscopy practice through answering the questions of the questionnaire', 'Al-Azhar University', 'Albertson', 'United States', 'New York', '11507', 'NCT04342637', 'Not yet recruiting', 'Effect of GI societies recommendations on prevention of SARS-CoV-2 infection', 'April 2020', 'December 2020', 84, 'SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmen ... (556 characters truncated) ... m COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.', 'BCG Vaccine for Health Care Workers as Defense Against SARS-COV2', 'Andrew.Dinardo@Bcm.Edu', 'Andrew DiNardo, MD', '832-822-1038', '700', 'Harvard T.H. Chan School of Public Health', 'BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.', 'Andrew Dinardo', 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04348370', 'Not yet recruiting', 'incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo', 'April 2020', 'November 2021', 85, 'Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to coronavirus disease 2019 (COVID-19).', 'A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019', 'arnaud.bastien@roivant.com', 'Arnaud Bastien, MD', '(609)-410-2691', '270', 'Mount Sinai', 'Gimsilumab is a fully human monoclonal antibody (mAb).', 'Kinevant Sciences GmbH', 'New York', 'United States', 'New York', '10029', 'NCT04351243', 'Recruiting', 'Primary endpoint', 'April 2020', 'October 2020', 86, 'The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19 pandemic.', 'Early Extubation for Patients With Acute Hypoxemic Respiratory Failure', 'bpatel@medicine.bsd.uchicago.edu', 'Bhakti Patel, MD', '773-702-6800', '108', 'University of Chicago Medical Center', 'After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressive ... (146 characters truncated) ...  0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04349332', 'Not yet recruiting', 'ventilator days', 'April 2020', 'June 2021', 87, 'Study Objective:\\n\\nTo test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the ... (65 characters truncated) ... roquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.', 'Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2', 'covid19@umn.edu', 'David Boulware (Please email), MD, MPH', '6126249996', '3000', 'Nationwide Enrollment via Internet, please email: covid19@umn.edu', '200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04308668', 'Recruiting', 'Incidence of COVID19 Disease among those who are asymptomatic at trial entry', 'March 2020', 'May 2020', 88, 'Phase 2:\\n\\nThe primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospit ... (98 characters truncated) ... udy is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 (severe and critical).', 'Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19', 'clinicaltrials@regeneron.com', 'Clinical Trials Administrator', '844-734-6643', '400', 'Regeneron Study Site', 'Single intravenous (IV) dose of sarilumab', 'Regeneron Pharmaceuticals', 'Los Angeles', 'United States', 'California', '90095', 'NCT04315298', 'Recruiting', 'Percent change in C-reactive protein (CRP) levels', 'March 2020', 'April 2021', 89, 'The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.', 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19)', 'GileadClinicalTrials@gilead.com', 'Gilead Clinical Study Information Center', '1-833-445-3230 (GILEAD-0)', '6000', 'Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue', 'Administered as an intravenous infusion', 'Gilead Sciences', 'Anaheim', 'United States', 'California', '92806', 'NCT04292899', 'Recruiting', 'The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14', 'March 2020', 'May 2020', 90, 'The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.', 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment', 'GileadClinicalTrials@gilead.com', 'Gilead Clinical Study Information Center', '1-833-445-3230 (GILEAD-0)', '1600', 'Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue', 'Administered as an intravenous infusion', 'Gilead Sciences', 'Anaheim', 'United States', 'California', '92806', 'NCT04292730', 'Recruiting', 'The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11', 'March 2020', 'May 2020', 91, 'This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.', 'A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia', 'global-roche-genentech-trials@gene.com', 'Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm', '888-662-6728', '330', 'University of California San Diego', 'Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.', 'Hoffmann-La Roche', 'La Jolla', 'United States', 'California', '92093', 'NCT04320615', 'Recruiting', 'Clinical Status Assessed Using a 7-Category Ordinal Scale', 'April 2020', 'September 2021', 92, 'ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.', 'Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease', 'coldmixon@mgh.harvard.edu', 'Katie Oldmixon, RN', '617 726-4777', '510', 'University of Arizona', 'Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.\\n\\nFor this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.', 'Massachusetts General Hospital', 'Tucson', 'United States', 'Arizona', '85721', 'NCT04332991', 'Recruiting', 'COVID Ordinal Outcomes Scale on Day 15', 'April 2020', 'July 2021', 93, 'This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.\\n\\nIt also contains a sub-study to enroll patients with severe COVID-19.', 'Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study', 'jho@ansunbiopharma.com', 'Jennifer Ho, M.D', '858-452-2631', '250', 'City of Hope cancer Center', 'DAS181 4.5mg nebulized qd x 7 OR 10 days', 'Ansun Biopharma, Inc.', 'Duarte', 'United States', 'California', '91010', 'NCT03808922', 'Recruiting', 'Percent of subjects who Return to Room Air (RTRA) (main study)', 'May 2019', 'December 2021', 94, 'This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hosp ... (1187 characters truncated) ... tudy is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19.', 'Adaptive COVID-19 Treatment Trial (ACTT)', 'DMIDClinicalTrials@niaid.nih.gov', '20-0006 Central Contact', '13017617948', '440', 'University of Alabama at Birmingham School of Medicine - Infectious Disease', 'The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Birmingham', 'United States', 'Alabama', '35233', 'NCT04280705', 'Recruiting', 'Percentage of subjects reporting each severity rating on an 8-point ordinal scale', 'February 2020', 'April 2023', 95, 'The specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease severity in ... (589 characters truncated) ...  Syndrome Coronavirus 2 (SARS-CoV-2) transmission and risk factors for Coronavirus Disease 19 (COVID-19) among health care workers and their families', 'Rutgers COVID-19 Cohort Study', 'jeffrey.carson@rutgers.edu', 'Jeffrey L Carson, MD', '732-235-7122', '750', 'Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -', 'This non-interventional study poses no additional risks to people with pre-existing conditions.', 'Rutgers, The State University of New Jersey', 'New Brunswick', 'United States', 'New Jersey', '08901', 'NCT04336215', 'Recruiting', 'Prevalence', 'April 2020', 'October 2021', 96, 'This project seeks to improve the effectiveness of a novel dissonance-based obesity prevention program that has reduced future BMI gain and overweigh ... (724 characters truncated) ... en the case with another dissonance-based prevention program, could markedly reduce the prevalence of obesity and associated morbidity and mortality.', 'Project Health: Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program', 'estice@ori.org', 'Eric M Stice, Ph.D.', '541-484-2123', '450', 'Oregon Research Institute', 'A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.', 'Oregon Research Institute', 'Eugene', 'United States', 'Oregon', '97403', 'NCT03710746', 'Recruiting', 'Body Fat', 'October 2018', 'July 2023', 97, \"This is a randomized intervention study to test and develop the national curriculum of a parent intervention training targeting parent's ability for  ... (772 characters truncated) ...  surveys. In-person visits to complete the psychological testing with the youth will be scheduled in the future when it is safe to meet face to face.\", 'Advocating for Supports to Improve Service Transitions', 'julie.l.taylor@vumc.org', 'Julie Lounds Taylor, PhD', '615-343-5659', '180', 'University of Illinois at Urbana-Champaign', 'The ASSIST program is a 12-week advocacy training to educate parents of youth with ASD about the adult service system. It is a group training, compri ... (434 characters truncated) ... l disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.', 'Vanderbilt University Medical Center', 'Chicago', 'United States', 'Illinois', '60007', 'NCT04173663', 'Recruiting', 'Change in Parental Knowledge about adult services questionnaire', 'December 2019', 'May 2024', 98, 'Healthcare workers are at the frontline of the fight against COVID-19, and as such they are at high risk for infection and possibly for serious infec ... (30 characters truncated) ... their exposure. The CROWN CORONATION trial prioritizes the protection of healthcare workers as a strategy to prevent collapse of healthcare services.', 'CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION', 'lindayun@wustl.edu', 'Linda Yun, BS', '314-273-2240', '55000', 'Washington University School of Medicine', 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate or 400mg hydroxychloroquine sulphate) weekly\\n\\nIn a ... (149 characters truncated) ... vided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.', 'Washington University School of Medicine', 'Saint Louis', 'United States', 'Missouri', '63110', 'NCT04333732', 'Not yet recruiting', 'Symptomatic COVID-19', 'April 2020', 'February 2021', 99, 'This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pr ... (227 characters truncated) ... laced on temporary administrative hold as of 3/17/2020. When such trial activities resume, the clinicaltrials.gov record will be updated accordingly.', 'Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes', 'Gregory.Schwartz@va.gov', 'Gregory G Schwartz, PhD MD', '(720) 723-6070', '7868', 'Phoenix VA Health Care System, Phoenix, AZ', 'For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a ... (157 characters truncated) ... cent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo.', 'VA Office of Research and Development', 'Phoenix', 'United States', 'Arizona', '85012', 'NCT02915198', 'Recruiting', 'Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization', 'February 2019', 'August 2024', 100, 'Most people with an eating disorder (ED) do not receive good treatment. The investigators have developed a new brief group treatment that is supposed ... (821 characters truncated) ... h an ED to either the new treatment or to a group treatment that represents what many college mental health clinics provide to their clients with ED.', 'Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders', 'estice@ori.org', 'Eric Stice, PhD', '541-484-2123', '180', 'Stanford University', '8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.', 'Oregon Research Institute', 'Stanford', 'United States', 'California', '94305', 'NCT03261050', 'Recruiting', 'Change in occurrences of binge eating episodes using Eating Disorder Diagnostic Interview', 'July 2017', 'June 2022')] (Background on this error at: http://sqlalche.me/e/e3q8)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mOperationalError\u001b[0m                          Traceback (most recent call last)",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36m_execute_context\u001b[1;34m(self, dialect, constructor, statement, parameters, *args)\u001b[0m\n\u001b[0;32m   1192\u001b[0m                         \u001b[0mparameters\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1193\u001b[1;33m                         context)\n\u001b[0m\u001b[0;32m   1194\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[0mBaseException\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\default.py\u001b[0m in \u001b[0;36mdo_execute\u001b[1;34m(self, cursor, statement, parameters, context)\u001b[0m\n\u001b[0;32m    506\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mdo_execute\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcursor\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparameters\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcontext\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 507\u001b[1;33m         \u001b[0mcursor\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mexecute\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparameters\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    508\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mOperationalError\u001b[0m: too many SQL variables",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[1;31mOperationalError\u001b[0m                          Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-20-3347b66e5864>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m()\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[0mmetadata\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mdb\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mMetaData\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 5\u001b[1;33m \u001b[0mcovid_df\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mto_sql\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m\"COVID_ClinicalTrials\"\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcon\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mengine\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mif_exists\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m\"replace\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\pandas\\core\\generic.py\u001b[0m in \u001b[0;36mto_sql\u001b[1;34m(self, name, con, schema, if_exists, index, index_label, chunksize, dtype)\u001b[0m\n\u001b[0;32m   2125\u001b[0m         sql.to_sql(self, name, con, schema=schema, if_exists=if_exists,\n\u001b[0;32m   2126\u001b[0m                    \u001b[0mindex\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mindex\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mindex_label\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mindex_label\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mchunksize\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mchunksize\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 2127\u001b[1;33m                    dtype=dtype)\n\u001b[0m\u001b[0;32m   2128\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2129\u001b[0m     def to_pickle(self, path, compression='infer',\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\pandas\\io\\sql.py\u001b[0m in \u001b[0;36mto_sql\u001b[1;34m(frame, name, con, schema, if_exists, index, index_label, chunksize, dtype)\u001b[0m\n\u001b[0;32m    448\u001b[0m     pandas_sql.to_sql(frame, name, if_exists=if_exists, index=index,\n\u001b[0;32m    449\u001b[0m                       \u001b[0mindex_label\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mindex_label\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mschema\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mschema\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 450\u001b[1;33m                       chunksize=chunksize, dtype=dtype)\n\u001b[0m\u001b[0;32m    451\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    452\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\pandas\\io\\sql.py\u001b[0m in \u001b[0;36mto_sql\u001b[1;34m(self, frame, name, if_exists, index, index_label, schema, chunksize, dtype)\u001b[0m\n\u001b[0;32m   1147\u001b[0m                          schema=schema, dtype=dtype)\n\u001b[0;32m   1148\u001b[0m         \u001b[0mtable\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mcreate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1149\u001b[1;33m         \u001b[0mtable\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0minsert\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mchunksize\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1150\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[1;33m(\u001b[0m\u001b[1;32mnot\u001b[0m \u001b[0mname\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0misdigit\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mand\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mname\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mislower\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1151\u001b[0m             \u001b[1;31m# check for potentially case sensitivity issues (GH7815)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\pandas\\io\\sql.py\u001b[0m in \u001b[0;36minsert\u001b[1;34m(self, chunksize)\u001b[0m\n\u001b[0;32m    661\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    662\u001b[0m                 \u001b[0mchunk_iter\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mzip\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0marr\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mstart_i\u001b[0m\u001b[1;33m:\u001b[0m\u001b[0mend_i\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0marr\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mdata_list\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 663\u001b[1;33m                 \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_execute_insert\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mconn\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mkeys\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mchunk_iter\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    664\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    665\u001b[0m     def _query_iterator(self, result, chunksize, columns, coerce_float=True,\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\pandas\\io\\sql.py\u001b[0m in \u001b[0;36m_execute_insert\u001b[1;34m(self, conn, keys, data_iter)\u001b[0m\n\u001b[0;32m    636\u001b[0m         \u001b[1;34m\"\"\"Insert data into this table with database connection\"\"\"\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    637\u001b[0m         \u001b[0mdata\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m[\u001b[0m\u001b[1;33m{\u001b[0m\u001b[0mk\u001b[0m\u001b[1;33m:\u001b[0m \u001b[0mv\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mk\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mv\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mzip\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mkeys\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mrow\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m}\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mrow\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mdata_iter\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 638\u001b[1;33m         \u001b[0mconn\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mexecute\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0minsert_statement\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mdata\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mconn\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    639\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    640\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0minsert\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mchunksize\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36mexecute\u001b[1;34m(self, object, *multiparams, **params)\u001b[0m\n\u001b[0;32m    946\u001b[0m             \u001b[1;32mraise\u001b[0m \u001b[0mexc\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mObjectNotExecutableError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mobject\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    947\u001b[0m         \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 948\u001b[1;33m             \u001b[1;32mreturn\u001b[0m \u001b[0mmeth\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmultiparams\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    949\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    950\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m_execute_function\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mfunc\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmultiparams\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\sql\\elements.py\u001b[0m in \u001b[0;36m_execute_on_connection\u001b[1;34m(self, connection, multiparams, params)\u001b[0m\n\u001b[0;32m    267\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m_execute_on_connection\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mconnection\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmultiparams\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    268\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msupports_execution\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 269\u001b[1;33m             \u001b[1;32mreturn\u001b[0m \u001b[0mconnection\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_execute_clauseelement\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmultiparams\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    270\u001b[0m         \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    271\u001b[0m             \u001b[1;32mraise\u001b[0m \u001b[0mexc\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mObjectNotExecutableError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36m_execute_clauseelement\u001b[1;34m(self, elem, multiparams, params)\u001b[0m\n\u001b[0;32m   1058\u001b[0m             \u001b[0mcompiled_sql\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1059\u001b[0m             \u001b[0mdistilled_params\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1060\u001b[1;33m             \u001b[0mcompiled_sql\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mdistilled_params\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1061\u001b[0m         )\n\u001b[0;32m   1062\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_has_events\u001b[0m \u001b[1;32mor\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mengine\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_has_events\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36m_execute_context\u001b[1;34m(self, dialect, constructor, statement, parameters, *args)\u001b[0m\n\u001b[0;32m   1198\u001b[0m                 \u001b[0mparameters\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1199\u001b[0m                 \u001b[0mcursor\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1200\u001b[1;33m                 context)\n\u001b[0m\u001b[0;32m   1201\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1202\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_has_events\u001b[0m \u001b[1;32mor\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mengine\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_has_events\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36m_handle_dbapi_exception\u001b[1;34m(self, e, statement, parameters, cursor, context)\u001b[0m\n\u001b[0;32m   1411\u001b[0m                 util.raise_from_cause(\n\u001b[0;32m   1412\u001b[0m                     \u001b[0msqlalchemy_exception\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1413\u001b[1;33m                     \u001b[0mexc_info\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1414\u001b[0m                 )\n\u001b[0;32m   1415\u001b[0m             \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\util\\compat.py\u001b[0m in \u001b[0;36mraise_from_cause\u001b[1;34m(exception, exc_info)\u001b[0m\n\u001b[0;32m    201\u001b[0m     \u001b[0mexc_type\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mexc_value\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mexc_tb\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mexc_info\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    202\u001b[0m     \u001b[0mcause\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mexc_value\u001b[0m \u001b[1;32mif\u001b[0m \u001b[0mexc_value\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mexception\u001b[0m \u001b[1;32melse\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 203\u001b[1;33m     \u001b[0mreraise\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtype\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mexception\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mexception\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtb\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mexc_tb\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcause\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mcause\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    204\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    205\u001b[0m \u001b[1;32mif\u001b[0m \u001b[0mpy3k\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\util\\compat.py\u001b[0m in \u001b[0;36mreraise\u001b[1;34m(tp, value, tb, cause)\u001b[0m\n\u001b[0;32m    184\u001b[0m             \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m__cause__\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mcause\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    185\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m__traceback__\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mtb\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 186\u001b[1;33m             \u001b[1;32mraise\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mwith_traceback\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtb\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    187\u001b[0m         \u001b[1;32mraise\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    188\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\base.py\u001b[0m in \u001b[0;36m_execute_context\u001b[1;34m(self, dialect, constructor, statement, parameters, *args)\u001b[0m\n\u001b[0;32m   1191\u001b[0m                         \u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1192\u001b[0m                         \u001b[0mparameters\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1193\u001b[1;33m                         context)\n\u001b[0m\u001b[0;32m   1194\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[0mBaseException\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1195\u001b[0m             self._handle_dbapi_exception(\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sqlalchemy\\engine\\default.py\u001b[0m in \u001b[0;36mdo_execute\u001b[1;34m(self, cursor, statement, parameters, context)\u001b[0m\n\u001b[0;32m    505\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    506\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mdo_execute\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcursor\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparameters\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcontext\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 507\u001b[1;33m         \u001b[0mcursor\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mexecute\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparameters\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    508\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    509\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mdo_execute_no_params\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcursor\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstatement\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcontext\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mOperationalError\u001b[0m: (sqlite3.OperationalError) too many SQL variables [SQL: 'INSERT INTO \"COVID_ClinicalTrials\" (\"index\", briefsummary, brieftitle, contactemail, contactname, contactphone, enrollmentcount, facility, interventiondesc, leadsponsor, locationcity, locationcountry, locationstate, locationzip, nctid, overallstatus, primaryoutcomedesc, starting_date, completion_date) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?), (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)'] [parameters: (0, \"The purpose of this study is to determine how peoples' bodies respond to exposure to COVID-19. Employees of Beaumont Health in Michigan who are older ... (1068 characters truncated) ... on.The results of the serology test are used for research only and will not affect clinical decisions regarding participants' treatment or quarantine\", 'Beaumont Health Large-scale Automated Serologic Testing for COVID-19', 'Maureen.Cooney@beaumont.org', 'Maureen Cooney, RN, BSN', '248-551-0099', '50000', 'Beaumont Health System', 'Serology testing to detect SARS-CoV-2 antibodies', 'William Beaumont Hospitals', 'Royal Oak', 'United States', 'Michigan', '48073', 'NCT04349202', 'Recruiting', 'Prevalence COVID antibodies in employees of Beaumont Health', 'April 2020', 'June 2021', 1, 'This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.', 'Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19', 'Valerie.Aston@imail.org', 'Valerie T Aston, MBA', '8015074606', '300', 'Intermountain Medical Center', 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).', 'Intermountain Health Care, Inc.', 'Murray', 'United States', 'Utah', '84107', 'NCT04329832', 'Recruiting', 'COVID Ordinal Outcomes Scale at 14 days', 'March 2020', 'December 2021', 2, 'This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.', 'Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19', 'Valerie.Aston@imail.org', 'Valerie T Aston, MBA', '8015074606', '1550', 'Intermountain Medical Center', 'Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < ... (141 characters truncated) ...  in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.', 'Intermountain Health Care, Inc.', 'Murray', 'United States', 'Utah', '84107', 'NCT04334382', 'Recruiting', 'Hospitalization within 14 days of enrollment', 'April 2020', 'December 2021', 3, 'The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.', 'Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19', 'jeffrey.miller@emory.edu', 'Jeffrey Miller, MD', '404-778-7200', '5', 'Emory University Hospital', 'The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use und ... (146 characters truncated) ... and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.', 'Emory University', 'Atlanta', 'United States', 'Georgia', '30322', 'NCT04331366', 'Recruiting', 'Change in Oxygen Saturation by Pulse Oximetry', 'April 2020', 'May 2020', 4, 'Specific Aims:\\n\\nThe investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisiti ... (226 characters truncated) ... certain whether changes on ultrasound could improve care through earlier diagnosis or identification of patients at high risk of disease progression.', 'Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)', 'yocum007@umn.edu', 'Matthew Yocum, MD', '612-626-8015', '500', 'University of Minnesota Medical Center (UMMC)', 'The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS ... (578 characters truncated) ...  mm), abnormal (>10 mm)\\nLeft ventricular (LV) mass approximation by septal thickness\\nLeft Ventricular Chamber Size by internal diameter at diastole', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04339998', 'Not yet recruiting', 'POCUS Score - Lungs', 'April 2020', 'October 2020', 5, \"The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent  ... (397 characters truncated) ... -face contact; study materials including study drug will be shipped to participants' houses. Only residents of Missouri and Illinois may participate.\", 'A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection', 'stevens.a@wustl.edu', 'Angela Stevens', '(314)362-6291', '152', 'BJC', 'Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.', 'Washington University School of Medicine', 'Belleville', 'United States', 'Illinois', '62220', 'NCT04342663', 'Recruiting', 'Time to clinical worsening', 'April 2020', 'July 2020', 6, 'This current proposal evaluates the Longitudinal Energy Expenditure and Metabolic Effects in Patients with COVID-19 (LEEP-COVID) to understand, guide ... (326 characters truncated) ... ter with 2 of the FDA-approved devices in existence currently capable of collecting this vital data to guide the care of COVID-19 patients worldwide.', 'Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)', 'paul.wischmeyer@duke.edu', 'Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM', '919-681-6437', '120', 'Duke University Medial Center', 'COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04350073', 'Not yet recruiting', 'Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device', 'April 2020', 'December 2020', 7, 'Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, cli ... (420 characters truncated) ... atients in Arizona.\\n\\nThis study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2', 'Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19', 'nhank@prcresearcheducation.com', 'Nicole C Hank, PhD,MCR,MHSM', '4804716132', '80', 'Perseverance Research Center', '200 mg PO BID 5 days', 'Perseverance Research Center, LLC', 'Scottsdale', 'United States', 'Arizona', '85254', 'NCT04344457', 'Recruiting', 'Improvement of clinical status', 'April 2020', 'September 2020', 8, 'This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.\\nSubjects will be  ... (158 characters truncated) ... bed in the statistical section 8.\\nThe final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.', 'Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection', 'Mariefel.Vendivil@HackensackMeridian.org', 'Mariefel Vendivil', '551-996-5828', '55', 'Hackensack University Medical Center', 'Fresh plasma will be infused one time to hospitalized patients with COVID-19 infection', 'Hackensack Meridian Health', 'Hackensack', 'United States', 'New Jersey', '07601', 'NCT04343755', 'Recruiting', 'For patients hospitalized for COVID-19 but not intubated', 'April 2020', 'April 2021', 9, 'This study is a randomized, open label clinical trial to evaluate the safety and efficacy of hydroxychloroquine (HCQ) plus usual care compared to usu ... (121 characters truncated) ... ison between open label hydroxychloroquine and usual care. The course of treatment (HCQ) is five days. Participants will be followed to study day 28.', 'A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients', 'tseto@queens.org', 'Todd Seto, MD', '808 354-3533', '350', \"Queen's Medical Center\", 'oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet', \"Queen's Medical Centre\", 'Honolulu', 'United States', 'Hawaii', '96813', 'NCT04345692', 'Recruiting', 'i. Clinical status', 'March 2020', 'December 2021', 10, 'Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized  ... (1262 characters truncated) ... ollow-up, or death. As a patient-centric registry, patients themselves may propose, suggest, and/or submit evidence or ideas for relevant collection.', 'Behavior, Environment And Treatments for Covid-19', 'info@beat19.org', 'BEAT19.org', '(415) 754-9290', '100000', 'BEAT19.org', 'Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.', 'xCures', 'San Francisco', 'United States', 'California', '94022', 'NCT04321811', 'Recruiting', 'Define Natural Symptom Course', 'March 2020', 'March 2022', 11, 'This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent infection with COVID-19', 'A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection', 'sabinehazan@aim.com', 'Sabine Hazan, MD', '805-200-7426', '600', 'ProgenaBiome', 'Prophylaxis treatment for COVID-19', 'ProgenaBiome', 'Ventura', 'United States', 'California', '93003', 'NCT04335084', 'Not yet recruiting', 'Prevention of COVID-19 measured by negative testing with RT-PCR', 'April 2020', 'July 2021', 12, 'Patients who are severely ill with COVID-19 may benefit from receiving plasma infusions from donors who have recovered from the disease and are prove ... (733 characters truncated) ... ts are processed in this special population. This protocol does not involve the administration of blood products to patients with COVID-19 infection.', 'COVID-19 Plasma Collection', 'CovidPlasma@jefferson.edu', 'Julie Karp, MD', '215-503-4838', '2000', 'Thomas Jefferson University Hospital', 'Previously infected COVID-19 patients will be recruited to donate convalescent plasma.', 'Thomas Jefferson University', 'Philadelphia', 'United States', 'Pennsylvania', '19107', 'NCT04344015', 'Recruiting', 'Number of patients who screen eligible for donation', 'April 2020', 'April 2021', 13, 'Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. ... (150 characters truncated) ... sitioning combined with HFNC can avoid the need for intubation in COVID-19 induced moderate to severe ARDS patients needs to be further investigated.', 'Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS', 'Jie_Li@rush.edu', 'Jie Li, PhD', '312-947-0065', '346', 'Rush University Medical Center', \"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Na ... (67 characters truncated) ... â‰¤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.\", 'Rush University Medical Center', 'Chicago', 'United States', 'Illinois', '60612', 'NCT04325906', 'Not yet recruiting', 'Treatment failure', 'April 2020', 'June 2020', 14, 'The purpose of this study is 1) to understand effects of COVID-19 crisis on wellness of pulmonary and critical care faculty and trainees who are at f ... (75 characters truncated) ... ekly web based crisis management coaching from world renowned experts in coaching and 3) identify future areas of opportunities in physician wellness', 'COPING With COVID-19( CWC-19)', 'erika.ratcliffe@duke.edu', 'Erika Ratcliffe', '919-681-5006', '100', 'Duke University', 'Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04343690', 'Not yet recruiting', 'Change in stress level as measured by survey', 'April 2020', 'June 2020', 15, 'This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19.\\n\\nBriefly, 50 patients with ... (517 characters truncated) ... e decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group.', 'Study of Open Label Losartan in COVID-19', 'msalathe@kumc.edu', 'Matthias Salathe, MD', '9135886000', '50', 'University of Kansas Medical Center', '25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion', 'University of Kansas Medical Center', 'Kansas City', 'United States', 'Kansas', '66160', 'NCT04335123', 'Recruiting', 'Number of participants with treatment-related adverse events as assessed by protocol definition of AE', 'March 2020', 'October 2020', 16, 'The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life ... (626 characters truncated) ... easibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.', 'COVID-19 Convalescent Plasma', 'mlmadariaga@bsd.uchicago.edu', 'Maria Lucia Madariaga, MD', '773-270-2004', '10', 'University of Chicago Medicine', 'Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04340050', 'Recruiting', 'Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients', 'April 2020', 'December 2021', 17, 'The goal of the research is to assess candidate rapid (5-15 min) antibody tests in order to judge their clinical accuracy compared to Centers for Dis ... (476 characters truncated) ... the safety, ease-of-use and validity of finger-stick capillary blood self-testing assisted by mobile device imaging and telemedicine remote support..', 'COVID-19 Antibody Self-testing Using Virtual Point-of-care', 'drdon@neuroganicslabs.com', 'Donald Cooper, Ph.D.', '7204313495', '100', 'Neuroganics', 'An immunodiagnostic rapid (10-20 minute) test detects circulating antibodies (IgM and IgG) in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 in the past.', 'Neuroganics LLC', 'Northglenn', 'United States', 'Colorado', '80260', 'NCT04348864', 'Recruiting', 'Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result', 'April 2020', 'April 2021', 18, 'There is significant interest throughout the United States in performing a well-designed study to evaluate whether there is value in using Hydroxychl ... (450 characters truncated) ... 450 patients treated with 400mg Hydroxychloroquine daily\\nA post-exposure arm of 100 patients treated with 400mg Hydroxychloroquine daily for 7 days.', 'Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study', 'usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil', 'Scott A Wallace, MD', '703-697-3255', '1450', 'Pentagon', 'Daily dosing of hydroxychloroquine as PrEP or PEP', 'United States Department of Defense', 'Arlington', 'United States', 'Virginia', '20301', 'NCT04343677', 'Not yet recruiting', 'Incidence', 'April 2020', 'August 2020', 19, 'This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the m ... (387 characters truncated) ... the lungs and possibly other organs.\\n\\nThe study will recruit patients who have been diagnosed with COVID-19.\\n\\nThe goal is to recruit 80 patients.', 'Safety and Efficacy of Baricitinib for COVID-19', 'bari-covid19@cuanschutz.edu', 'Angela Rachubinski, PhD', '(720) 507-9107', '80', 'University of Colorado, Denver', 'Subjects will receive a 2 mg oral dose of baricitinib.', 'University of Colorado, Denver', 'Aurora', 'United States', 'Colorado', '80045', 'NCT04340232', 'Not yet recruiting', 'Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)', 'April 2020', 'October 2020', 20, 'The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.', 'Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)', 'eco7@cumc.columbia.edu', 'Elizabeth Oelsner, MD, MPH', '212-305-9056', '1600', 'Columbia University Irving Medical Center', 'Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04318444', 'Not yet recruiting', 'Number of participants with symptomatic, lab-confirmed COVID-19.', 'March 2020', 'March 2022', 21, 'Coronavirus disease-2019 (COVID-19) has a quoted inpatient mortality as high as 25%. This high mortality may be driven by hyperinflammation resemblin ... (1882 characters truncated) ... n of fever and the biochemical outcome measures of time to CRP normalization for the individual patient and the rate of patients whose CRP normalize.', 'Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis', 'pankti.reid@uchospitals.edu', 'Pankti Reid, MD, MPH', '7737021220', '50', 'University of Chicago Medicine', 'Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinica ... (8 characters truncated) ... ochemical responses performed every 24 hours.\\n\\nSecond dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04331795', 'Recruiting', 'Clinical response', 'April 2020', 'December 2020', 22, 'The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in ... (314 characters truncated) ... an subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the \"common cold.\"', 'PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)', 'hwangph@stanford.edu', 'Peter H Hwang, MD', '650-725-6500', '45', 'Stanford Health Care', 'Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day', 'Stanford University', 'Stanford', 'United States', 'California', '94305', 'NCT04347954', 'Not yet recruiting', 'Mean change in viral titers of SARS-CoV-2', 'May 2020', 'August 2020', 23, 'The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort ... (172 characters truncated) ... of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.', 'The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)', 'amelia.anderson@pennmedicine.upenn.edu', 'Amelia Anderson', '215-509-5690', '400', 'University of Pennsylvania', 'Antimalarial compound', 'Ravi Amaravadi, MD', 'Philadelphia', 'United States', 'Pennsylvania', '19104', 'NCT04329923', 'Recruiting', 'Median release from quarantine time', 'April 2020', 'December 2021', 24, 'The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.', 'COVID-19 Remote Monitoring', 'sam.cammack@mountsinai.org', 'Sam Cammack', '212-824-8931', '1000', 'Icahn School of Medicine at Mount Sinai', 'This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring  ... (45 characters truncated) ... pplied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).', 'Vivek Reddy', 'New York', 'United States', 'New York', '10029', 'NCT04350476', 'Not yet recruiting', 'Number of different arrhythmias', 'April 2020', 'April 2021', 25, 'This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.', 'High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19', 'rjan@medicine.bsd.uchicago.edu', 'Reem Jan, MBBS BSc', '734-972-7953', '20', 'University of Chicago', 'Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04351620', 'Recruiting', 'Tolerability of high dose HCQ as measured by HCQ dose modification', 'April 2020', 'June 2020', 26, 'This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with COVID- ... (151 characters truncated) ...  daily for 30 days in addition to background local standard of care therapy, in reducing disease progression, complications, and all-cause mortality.', 'Dapagliflozin in Respiratory Failure in Patients With COVID-19', 'swindsor@saint-lukes.org', 'Sheryl Windsor', '816-932-9858', '900', \"Saint Luke's Mid America Heart Institute\", 'Active Comparator: Dapagliflozin 10mg', \"Saint Luke's Health System\", 'Kansas City', 'United States', 'Missouri', '64111', 'NCT04350593', 'Recruiting', 'Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:', 'April 2020', 'December 2020', 27, 'This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).', 'A Study of Quintuple Therapy to Treat COVID-19 Infection', 'sabinehazan@aim.com', 'Sabine Hazan, MD', '805-200-7436', '600', 'ProgenaBiome', 'treatment with hydroxychloroquine', 'ProgenaBiome', 'Ventura', 'United States', 'California', '93003', 'NCT04334512', 'Not yet recruiting', 'Successful treatment as determined by Negative Test and resolution of symptoms', 'April 2020', 'July 2021', 28, 'The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in h ... (275 characters truncated) ... andomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 15 days.', 'CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment', 'pzheng@oncoimmune.com', 'Pan Zheng, MD, PhD', '(202) 7516823', '230', 'Institute of Human Virology, University of Maryland Baltimore', 'CD24Fc is given on Day 1.', 'OncoImmune, Inc.', 'Baltimore', 'United States', 'Maryland', '21201', 'NCT04317040', 'Recruiting', 'Improvement of COVID-19 disease status', 'April 2020', 'May 2022', 29, 'PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a prospective cohort study of pregnant and recently pregnant women who are: either patients und ... (83 characters truncated) ... ill be used to evaluate the impact of COVID-19 on the clinical course and pregnancy outcomes of pregnant women and women within 6 weeks of pregnancy.', 'COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)', 'PRIORITYCOVID19@ucsf.edu', 'Ruth Gebrezghi', '(415) 754-3749', '1000', 'University of California, San Francisco', 'This is an observational study with no intervention', 'University of California, San Francisco', 'San Francisco', 'United States', 'California', '94143', 'NCT04323839', 'Recruiting', 'Clinical presentation', 'March 2020', 'March 2024', 30, 'The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in ... (274 characters truncated) ... his two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.', 'Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19', 'lberra@mgh.harvard.edu', 'Lorenzo Berra', '+16176437733', '240', 'Massachusetts General Hospital', 'Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from tim ... (177 characters truncated) ... re between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.', 'Massachusetts General Hospital', 'Boston', 'United States', 'Massachusetts', '02114-2621', 'NCT04305457', 'Recruiting', 'Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation', 'March 2020', 'April 2022', 31, 'Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper res ... (995 characters truncated) ... ral shedding/viral load and viral transmission, secondary bacterial load, nasopharyngeal inflammation in patients infected with the novel SARS-CoV-2.', 'Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19', 'kate.vonwahlde@vumc.org', 'Kate Von Wahlde, MJ, CCRP', '615-322-0333', '90', 'Vanderblt University Medical Center', 'Saline nasal irrigation BID', 'Vanderbilt University Medical Center', 'Nashville', 'United States', 'Tennessee', '37232', 'NCT04347538', 'Not yet recruiting', 'Change in SARS-CoV-2 mucosal immune response in the nasopharynx', 'May 2020', 'June 2022', 32, 'Patients who meet inclusion criteria will be randomized into treatment vs control group. Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control group.', 'Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection', 'englemd94@gmail.com', 'John F Engle, MD', '985-768-8918', '48', 'Ochsner Medical Center', 'Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.', 'Ochsner Health System', 'New Orleans', 'United States', 'Louisiana', '70121', 'NCT04343183', 'Not yet recruiting', 'Decrease incidence of intubation by 30% or greater', 'April 2020', 'June 2020', 33, 'This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.', 'Azithromycin for COVID-19 Treatment in Outpatients Nationwide', 'ACTIONTrial@ucsf.edu', 'Jessica M Brogdon, MPH', '(415) 514-1582', '2271', 'University of California San Francisco', 'Participants will be shipped a single 1 g dose of oral azithromycin', 'University of California, San Francisco', 'San Francisco', 'United States', 'California', '94143', 'NCT04332107', 'Not yet recruiting', 'Hospitalization', 'April 2020', 'July 2021', 34, 'Prospective randomized, two-stage trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs. standard of care in up to 40 subjects (20 inpatient and 20 outpatient) with COVID-19 infection.', 'Pegylated Interferon Lambda Treatment for COVID-19', 'JLGustafson@mgh.harvard.edu', 'Jenna Gustafson, MSc', '6177243836', '40', 'Massachusetts General Hospital', '180 mcg subcutaneous injection of pegylated interferon lambda', 'Raymond Chung', 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04343976', 'Not yet recruiting', 'Undetectable COVID PCR at day 7', 'May 2020', 'December 2021', 35, 'For this study, 48 patients who have been diagnosed with COVID-19 will be randomly assigned to four study groups: control, saline, chlorhexidine gluc ... (200 characters truncated) ... tion in their nose four times daily. Patients will then be tested for COVID-19 once daily in the evening for 7 days and viral loads will be measured.', 'Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19', 'scott.rickert@nyulangone.org', 'Scott Rickert, MD', '646-501-7890', '48', 'NYU Langone Health', '5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.', 'NYU Langone Health', 'New York', 'United States', 'New York', '10016', 'NCT04344236', 'Recruiting', 'Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx', 'April 2020', 'May 2020', 36, 'The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.', 'Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)', 'kushd@amarexcro.com', 'Kush Dhody, MBBS, MS, CCRA', '301-956-2536', '390', 'Montefiore Medical Center', 'Placebos', 'CytoDyn, Inc.', 'Bronx', 'United States', 'New York', '10467', 'NCT04347239', 'Recruiting', 'All-cause mortality at Day 28', 'April 2020', 'April 2021', 37, 'The objective of this study is to provide remote mindfulness session(s) to help during the COVID-19 pandemic.', 'Mindfulness During COVID-19', 'rewells@wakehealth.edu', 'Rebecca E Wells, MD, MPH', '336-716-2357', '200', 'Wake Forest Health Sciences', 'The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).', 'Wake Forest University Health Sciences', 'Winston-Salem', 'United States', 'North Carolina', '27157', 'NCT04319445', 'Recruiting', 'Helpfulness of the session', 'March 2020', 'December 2020', 38, 'This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the ... (14 characters truncated) ... randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.', 'Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease', 'jeannine.ascani@lcmchealth.org', 'Jeannine Ascani, MS', '5047023141', '600', 'University Medical Center New Orleans', 'tablets provided as described in Arm B', 'LCMC Health', 'New Orleans', 'United States', 'Louisiana', '70112', 'NCT04344444', 'Recruiting', 'Most severe outcome', 'April 2020', 'December 2021', 39, 'The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. We  ... (400 characters truncated) ... nical status, concomitant medications and laboratory parameters. Study specific biomarkers will be measured at baseline and then at days 3, 7 and 14.', 'Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia', 'guptans@ucmail.uc.edu', 'Nishant Gupta, MD', '5135584831', '30', 'University of Cincinnati', 'Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.', 'University of Cincinnati', 'Cincinnati', 'United States', 'Ohio', '45267', 'NCT04341675', 'Recruiting', 'Progression to advanced respiratory support', 'April 2020', 'September 2020', 40, 'Minimal risk research study:\\n\\nComparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus;\\nQuantifying the development and trajectory of the disease through clinic visits and blood values.', 'A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research', 'ethan.berke@uhg.com', 'Ethan Berke', '603/286-0376', '120', 'Everett Clinic', 'The nostril used and order of testing will be different in each arm.', 'Dr. Deneen Vojta', 'Seattle', 'United States', 'Washington', '98133', 'NCT04327804', 'Recruiting', 'Detection of SARS-CoV-2 virus', 'March 2020', 'April 2020', 41, 'This open-label randomized controlled study will evaluate safety, efficacy, and the pharmacokinetic profile of CM4620-IE in patients with severe COVI ... (233 characters truncated) ...  receive local standard of care only. The infusion of CM4620-IE will start within 8 hours from the time the patient or LAR provides informed consent.', 'A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia', 'sudarshan@calcimedica.com', 'Sudarshan Hebbar, MD', '816-838-7105', '120', 'Henry Ford Hospital', 'CM4620-IE 2.0 mg/kg on Day 1 and then 1.6 mg/kg on Days 2 and 3. All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.', 'CalciMedica, Inc.', 'Detroit', 'United States', 'Michigan', '48202', 'NCT04345614', 'Recruiting', 'Improvement on a 7-point Ordinal Scale', 'April 2020', 'September 2020', 42, 'The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respir ... (477 characters truncated) ... atus, prevents future hospitalization, and improves the clinical course in patients diagnosed with COVID-19 specifically in the emergency department.', 'Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED', 'nsharris@mgh.harvard.edu', 'N. Stuart Harris, MD, MFA', '617-724-3290', '260', 'Massachusetts General Hospital', 'Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes', 'Massachusetts General Hospital', 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04338828', 'Not yet recruiting', 'Rates of return visits to the ED', 'April 2020', 'April 2022', 43, 'Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patient ... (203 characters truncated) ... rtion of this study, a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.', 'Hyperbaric Oxygen for COVID-19 Patients', 'Scott.Gorenstein@nyulangone.org', 'Scott Gorenstein', '516-663-8498', '40', 'NYU Winthrop Hospital', 'The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the tr ... (82 characters truncated) ... of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.', 'NYU Langone Health', 'Mineola', 'United States', 'New York', '11501', 'NCT04332081', 'Recruiting', 'Mortality', 'April 2020', 'July 2020', 44, 'In this study clazakizumab will be administered to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical pic ... (140 characters truncated) ... nts will be enrolled and randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo', 'A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection', 'bonnie.lonze@nyulangone.org', 'Bonnie Lonze, MD', '212-263-8365', '30', 'New York University School of Medicine', 'The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of  ... (210 characters truncated) ... If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.', 'NYU Langone Health', 'New York', 'United States', 'New York', '10016', 'NCT04343989', 'Recruiting', 'Incidence of serious adverse events associated with clazakizumab or placebo', 'March 2020', 'July 2020', 45, 'A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.', 'TXA and Corona Virus 2019 (COVID19) in Outpatients', 'tness@uabmc.edu', 'Timothy J Ness, MD PhD', '2059079743', '100', 'University of Alabama at Birmingham', 'Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos', 'University of Alabama at Birmingham', 'Birmingham', 'United States', 'Alabama', '35222', 'NCT04338074', 'Not yet recruiting', 'Hospitalization', 'April 2020', 'October 2020', 46, 'Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.', 'Pre-exposure Prophylaxis for SARS-Coronavirus-2', 'covid19prep@umn.edu', 'Radha Rajasingham (Please Email), MD', '612-626-8171', '3500', 'Nationwide Enrollment via Internet, please email: covid19@umn.edu', 'Hydroxychloroquine; 200mg tablet; oral', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04328467', 'Recruiting', 'COVID-19-free survival', 'April 2020', 'August 2020', 47, 'This study is for cancer patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutrali ... (389 characters truncated) ... l treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.', 'Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19', 'cancerclinicaltrials@cumc.columbia.edu', 'Lisa Olmos, RN', '212.342.5162', '138', 'Columbia University Irving Medical Center', 'BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).', 'Matthew Dallos', 'New York', 'United States', 'New York', '10032', 'NCT04347226', 'Not yet recruiting', 'Time to Improvement in the 7-point ordinal scale', 'April 2020', 'September 2022', 48, 'This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus  ... (210 characters truncated) ... luate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.', 'Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection', 'ssneddo2@jhmi.edu', 'Stephanie Katz, BSN', '443-997-1900', '164', 'Johns Hopkins Hospital', 'Peginterferon lambda-1a 180 micrograms by subcutaneous injection', 'Johns Hopkins University', 'Baltimore', 'United States', 'Maryland', '21287', 'NCT04344600', 'Not yet recruiting', 'Proportion of participants with no evidence of SARS-CoV-2 infection', 'April 2020', 'June 2021', 49, 'The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.', 'Convalescent Plasma in the Treatment of COVID 19', 'Latha.Dulipsingh@trinityhealthofne.org', 'Latha Dulipsingh, MD', '860-714-4402', '15', 'Trinity Health Of New England', 'treatment with 2 Units of convalescent plasma', 'Saint Francis Care', 'Hartford', 'United States', 'Connecticut', '06105', 'NCT04343261', 'Not yet recruiting', 'Mortality', 'April 2020', 'April 2021', 50, 'Although a number of therapeutics are being utilized by clinicians to treat patients with COVID-19, none have been systematically evaluated in clinic ... (574 characters truncated) ... RBs. This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo.', 'COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2', 'jennifer.victory@bassett.org', 'Jennifer Victory, RN', '6075476965', '4000', 'Bassett Medical Center', 'administered for minimum of 5 days, up to 14 days if supply available', 'Bassett Healthcare', 'Cooperstown', 'United States', 'New York', '13326', 'NCT04328012', 'Recruiting', 'National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)', 'April 2020', 'April 2021', 51, 'Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify anti ... (105 characters truncated) ... ffective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.', 'Acquiring Convalescent Specimens for COVID-19 Antibodies', 'yl4459@cumc.columbia.edu', 'Yang Luo, PhD', '2123046205', '12', 'Columbia University Irving Medical Center/NYP', 'Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04342195', 'Recruiting', 'Number of antibodies against coronaviruses isolated and identified from patient samples', 'March 2020', 'March 2021', 52, 'This study will test to see if a 72-hour intravenous vitamin C infusion protocol (100 mg/kg every 8 hours) in patients with hypoxemia and suspected COVID-19 will reduce the lung injury caused by the SARS-Cov-2.', 'Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)', 'mkashiouris@vcu.edu', 'Markos G Kashiouris, MD MPH', '804-305-7187', '200', 'Hunter Holmes McGuire VA Medical Center', '100 mg/kg intravenous vitamin C infusion every 8 hours for up to 72 hours', 'Virginia Commonwealth University', 'Richmond', 'United States', 'Virginia', '23249', 'NCT04344184', 'Not yet recruiting', 'Number of ventilator-free days', 'April 2020', 'May 2021', 53, 'This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.', 'Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19', 'kushd@amarexcro.com', 'Kush Dhody, MBBS, MS, CCRA', '301-956-2536', '75', 'Montefiore Medical Center', 'Placebo', 'CytoDyn, Inc.', 'Bronx', 'United States', 'New York', '10467', 'NCT04343651', 'Recruiting', 'Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)', 'April 2020', 'April 2021', 54, 'The current COVID-19 pandemic is providing healthcare organizations with considerable challenges and opportunities for rapid cycle improvement effort ... (1376 characters truncated) ... or these patients, while further directing the necessary protective measures for additional team members involved in the care of the injured patient.', 'The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation', 'jose.diaz-miron@childrenscolorado.org', 'Jose L Diaz-Miron, MD', '720-777-6571', '20', \"Children's Hospital Colorado\", 'FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey th ... (639 characters truncated) ... ubpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings.', 'University of Colorado, Denver', 'Aurora', 'United States', 'Colorado', '80045', 'NCT04340479', 'Not yet recruiting', 'Correlation of FAST+ pulmonary findings with active COVID infection', 'May 2020', 'May 2021', 55, 'A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals a ... (722 characters truncated) ...  trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.', 'University of Utah COVID-19 Hydrochloroquine Trial', 'christina.pacchia@hsc.utah.edu', 'Christina Pacchia, PhD', '8012138735', '400', 'University of Utah', 'HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days', 'University of Utah', 'Salt Lake City', 'United States', 'Utah', '84108', 'NCT04342169', 'Recruiting', 'Duration of viral shedding', 'April 2020', 'April 2023', 56, \"Participants scheduled for for an echocardiogram (echo) and being evaluated for, or is positive for COVID-19 will be asked if they would be willing t ... (288 characters truncated) ... being used clinically and is FDA approved. The main reason for using the updated version is that it's faster and better in terms of guiding the user.\", 'CAPTION AI to Minimize Risk of COVID Exposure', 'kristine.arges@duke.edu', 'Kristine Arges, BSN', '919-668-0927', '500', 'Duke University Medical Center', 'Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.', 'Duke University', 'Durham', 'United States', 'North Carolina', '27710', 'NCT04336774', 'Not yet recruiting', 'Percent of patient echos that are not interpretable', 'April 2020', 'November 2020', 57, 'The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection', 'Effects of DPP4 Inhibition on COVID-19', 'giacobellis@med.miami.edu', 'Gianluca Iacobellis, MD PhD', '3052433636', '20', 'University of Miami', '5 mg Linagliptin administered by mouth once daily', 'University of Miami', 'Miami', 'United States', 'Florida', '33136', 'NCT04341935', 'Not yet recruiting', 'Changes in Glucose Llevels', 'April 2020', 'September 2020', 58, 'This is a study for patients who have respiratory infection caused by SARS-CoV-2 that have not gotten better. Because there is no standard treatment  ... (399 characters truncated) ...  cells, such as blood and muscle cells.\\n\\nThe purpose of this study is to see if MSCs can help to treat respiratory infections caused by SARS-CoV-2.', 'Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)', 'LaQuisa.Hill@bcm.edu', 'LaQuisa Hill, MD', '(713) 441-1450', '30', 'Houston Methodist Hospital', 'Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.', 'Baylor College of Medicine', 'Houston', 'United States', 'Texas', '77030', 'NCT04345601', 'Not yet recruiting', 'Incidence of unexpected adverse events', 'May 2020', 'February 2022', 59, 'A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.', 'Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients', 'tness@uabmc.edu', 'Timothy J Ness, MD PhD', '2059079743', '60', 'University of Alabama at Birmingham', 'previously described', 'University of Alabama at Birmingham', 'Birmingham', 'United States', 'Alabama', '35233', 'NCT04338126', 'Not yet recruiting', 'Admission to Intensive Care Unit', 'April 2020', 'December 2020', 60, 'The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory ... (340 characters truncated) ... mation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.', 'A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure', 'craig.selzman@hsc.utah.edu', 'Craig Selzman, MD', '(801) 581-5311', '10', 'University of Utah Health', 'Administration of amniotic fluid in SARS-CoV-2 positive patients', 'University of Utah', 'Salt Lake City', 'United States', 'Utah', '84132', 'NCT04319731', 'Recruiting', 'Ventilator Free Days', 'March 2020', 'March 2021', 61, 'This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic me ... (205 characters truncated) ... to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).', 'Hydroxychloroquine for COVID-19 PEP', 'meigs@uw.edu', 'Meighan Krows', '206-520-3833', '2000', 'NYU Langone Health', 'Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy', 'University of Washington', 'New York', 'United States', 'New York', '10016', 'NCT04328961', 'Not yet recruiting', 'Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection', 'March 2020', 'October 2020', 62, 'Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Mo ... (2 characters truncated) ... efiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness.', 'Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore', 'pnori@montefiore.org', 'Priya Nori, MD', '(718) 920-4622', '100', 'Montefiore Medical Center', '400 mg tablet', 'Montefiore Medical Center', 'Bronx', 'United States', 'New York', '10467', 'NCT04350450', 'Not yet recruiting', 'Time to resolution of symptoms', 'April 2020', 'August 2020', 63, 'The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SAR ... (283 characters truncated) ... scanning session. After the CT scan, patients are followed for 30 days by reviewing their medical records and by phone after discharge from hospital.', 'Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2', 'joanne.gondert@beaumont.org', 'Joanne Gondert, RN, BSN', '248-898-0343', '25', 'Beaumont Health', 'CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan', 'William Beaumont Hospitals', 'Royal Oak', 'United States', 'Michigan', '48073', 'NCT04320511', 'Not yet recruiting', 'Predictive association between CT-V, PBM score and disease progression', 'April 2020', 'March 2022', 64, 'Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.', 'Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19', 'deleaf@bwh.harvard.edu', 'David E Leaf, MD, MMSc', '617-525-7612', '2000', \"Brigham and Women's Hospital\", 'Observational', \"Brigham and Women's Hospital\", 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04343898', 'Recruiting', '14-Day Mortality', 'April 2020', 'June 2022', 65, 'This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromy ... (110 characters truncated) ... e control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.', 'Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19', 'hussaisa@rwjms.rutgers.edu', 'Sabiha Hussain, MD', '732-235-7840', '160', 'Robert Wood Johnson University Hopsital', 'Given PO', 'Rutgers, The State University of New Jersey', 'New Brunswick', 'United States', 'New Jersey', '08901', 'NCT04336332', 'Recruiting', 'Changes in patients viral load', 'April 2020', 'April 2021', 66, 'The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVI ... (51 characters truncated) ...  Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.', 'Saved From COVID-19', 'ada20@cumc.columbia.edu', 'Anca D. Askanase, MD, MPH', '212-305-0856', '350', 'Columbia University Irving Medical Center/NYP', 'Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months ... (12 characters truncated) ... with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.', 'Columbia University', 'New York', 'United States', 'New York', '10032', 'NCT04349371', 'Recruiting', 'Number of symptomatic illness in at risk healthcare workers', 'April 2020', 'April 2021', 67, 'This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRAÂ® 2000 device in healthy adult volunteers.', 'Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers', 'clinical.trials@inovio.com', 'Inovio Call Center', '(267) 440-4237', '40', 'Center for Pharmaceutical Research', 'INO-4800 will be administered ID on Day 0 and Week 4.', 'Inovio Pharmaceuticals', 'Kansas City', 'United States', 'Missouri', '64114', 'NCT04336410', 'Recruiting', 'Percentage of Participants with Adverse Events (AEs)', 'April 2020', 'November 2020', 68, 'This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.', 'Losartan for Patients With COVID-19 Requiring Hospitalization', 'Covid19trial@umn.edu', 'Christopher Tignanelli, MD', '612-624-4373', '200', 'Hennepin County Medical Center', 'Losartan; 50 mg daily; oral administration', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55415', 'NCT04312009', 'Recruiting', 'Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days', 'April 2020', 'April 2021', 69, 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first ... (1515 characters truncated) ... e treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.', 'Cardiovascular Manifestations of COVID-19', 'Efstratios.Koutroumpakis@uth.tmc.edu', 'Efstratios Koutroumpakis, MD', '4123203161', '500', 'Memorial Hermann Hospital-Texas Medical Center', 'Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.', 'Memorial Hermann Health System', 'Houston', 'United States', 'Texas', '77030', 'NCT04335630', 'Recruiting', 'Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.', 'March 2020', 'March 2022', 70, 'This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in  ... (98 characters truncated) ... imately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.', 'Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)', 'jean-claude.tardif@icm-mhi.org', 'Jean-Claude Tardif, MD', '514-376-3330', '6000', 'New York University School of Medecine', 'Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.', 'Montreal Heart Institute', 'New York', 'United States', 'New York', '10010', 'NCT04322682', 'Recruiting', 'Number of participants who die or require hospitalization due to COVID-19 infection', 'March 2020', 'September 2020', 71, \"The viral Covid-19 outbreak is now considered a pandemic according to the World Health Organisation (WHO). A free monitoring app 'COVID-19 Symptom Tr ... (409 characters truncated) ... ss of COVID-19 infection in different people, and why some go on to develop more severe or fatal disease while others have only mild symptoms do not.\", 'COVID-19 Symptom Tracker', 'victoria.vazquez@kcl.ac.uk', 'Victoria Vazquez', '02071886765', '10000000', 'Massachusetts General Hospital', 'No Intervention', \"King's College London\", 'Boston', 'United States', 'Massachusetts', '02114', 'NCT04331509', 'Recruiting', 'Physical health symptoms', 'March 2020', 'March 2022', 72, 'The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.', 'Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases', 'brannock.robert@mayo.edu', 'Robert Brannock', '904-953-2000', '120', 'Mayo Clinic Florida', 'Analysis of volatile organic compounds in breath', 'Mayo Clinic', 'Jacksonville', 'United States', 'Florida', '32224', 'NCT04341012', 'Recruiting', 'Breath volatile organic compound profiles', 'September 2019', 'December 2021', 73, 'Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilatio ... (486 characters truncated) ... roves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter single-blinded randomized controlled trial with 1:1 individual allocation', 'Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19', 'lberra@mgh.harvard.edu', 'Lorenzo Berra, MD', '+16176437733', '200', 'University of Alabama', '80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\\n\\nWeaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.', 'Massachusetts General Hospital', 'Birmingham', 'United States', 'Alabama', '35294', 'NCT04306393', 'Recruiting', 'Change of arterial oxygenation at 48 hours from enrollment', 'March 2020', 'March 2022', 74, 'This is a phase I, open-label, dose ranging clinical trial in males and non-pregnant females, 18 to 55 years of age, inclusive, who are in good healt ... (643 characters truncated) ...  is to evaluate the safety and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart, across 3 dosages in healthy adults.', 'Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)', 'KPWA.vaccine@kp.org', '20-0003 Central Contact', '12062872061', '45', 'Emory Vaccine Center - The Hope Clinic', 'Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mR ... (25 characters truncated) ...  manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Decatur', 'United States', 'Georgia', '30030-1705', 'NCT04283461', 'Recruiting', 'Frequency of solicited local reactogenicity adverse events (AEs)', 'March 2020', 'June 2021', 75, 'Primary Objective:\\n\\nTo assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COV ... (131 characters truncated) ... ression of disease in outpatient adults with COVID-19\\nTo assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19', 'Hydroxychloroquine in Outpatient Adults With COVID-19', 'Contact-US@sanofi.com', 'Trial Transparency email recommended (Toll free number for US & Canada)', '800-633-1610', '210', 'Investigational Site Number 8400001', 'Pharmaceutical form:Tablet Route of administration: Oral', 'Sanofi', 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04333654', 'Recruiting', 'Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)', 'March 2020', 'May 2020', 76, 'The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2  ... (612 characters truncated) ... e of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.', 'Will Hydroxychloroquine Impede or Prevent COVID-19', 'whipcovid19@hfhs.org', 'Dee Dee Wang, MD', '313-574-2651', '3000', 'Henry Ford Hospital', 'The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents app ... (114 characters truncated) ... ess likely to produce side effects than standard of care.\\n\\nAll treatment groups will receive placebo pills to have the patients take 2 pills a day.', 'Henry Ford Health System', 'Detroit', 'United States', 'Michigan', '48202', 'NCT04341441', 'Recruiting', 'Reduction in the number of COVID-19 infections in healthcare workers.', 'April 2020', 'April 2021', 77, 'This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.', 'Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection', 'mklebert@wustl.edu', 'Michael Klebert, RN PhD', '314 747 1098', '500', 'Washington University School of Medicine Infectious Disease Clinical Research Unit', 'anti-rheumatic drug (DMARD)', 'Washington University School of Medicine', 'Saint Louis', 'United States', 'Missouri', '63110', 'NCT04341727', 'Recruiting', 'Hours to recovery', 'April 2020', 'August 2021', 78, 'This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.', 'Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)', 'US.Info@I-MabBiopharma.com', 'US Site Head', '240-767-6981', '144', 'OSF Healthcare Saint Francis Medical Center', 'patients receive a single infusion', 'I-Mab Biopharma Co. Ltd.', 'Peoria', 'United States', 'Illinois', '61637', 'NCT04341116', 'Recruiting', 'Proportion (%) of subjects experiencing deterioration in clinical status', 'April 2020', 'September 2020', 79, 'This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).', 'Losartan for Patients With COVID-19 Not Requiring Hospitalization', 'Covid19trial@umn.edu', 'Christopher Tignanelli, MD', '612-624-4373', '580', 'Hennepin County Medical Center', 'Losartan; 25 mg daily; oral administration', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55415', 'NCT04311177', 'Recruiting', 'Hospital Admission', 'April 2020', 'April 2021', 80, 'This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two  ... (588 characters truncated) ...  care alone\\nStandard of care plus hydroxychloroquine\\nStandard of care plus azithromycin\\nStandard of care plus hydroxychloroquine plus azithromycin', 'Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection', 'jason.stout@dm.duke.edu', 'Jason Stout, MD', '919-668-0826', '500', 'Duke Regional Hospital', 'Standard of care', 'Duke University', 'Durham', 'United States', 'North Carolina', '27704', 'NCT04335552', 'Not yet recruiting', 'World Health Organization (WHO) ordinal scale measured at 14 days after enrollment', 'April 2020', 'August 2020', 81, 'Novel Corona Virus (COVID-19) is known to cause Acute Respiratory Distress Syndrome, that results in death of approximately 50% of those who develop  ... (354 characters truncated) ... o + maximal intensive care. Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours.', 'Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress', 'rbesthof@neurorxpharma.com', 'Robert E Besthof, MIM', '+14842546134', '120', 'Miller School of Medicine / University of Miami Medical Center', 'Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.', 'NeuroRx, Inc.', 'Miami', 'United States', 'Florida', '33136', 'NCT04311697', 'Not yet recruiting', 'Mortality', 'April 2020', 'September 2020', 82, 'The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requir ... (224 characters truncated) ... s hypothesize that the addition of an ARB is beneficial in abating acute lung injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.', 'Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection', 'kathryn.miller@sharp.com', 'Katie Miller', '(858) 939-7162', '200', 'Sharp Grossmont Hospital', 'Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.', 'Sharp HealthCare', 'La Mesa', 'United States', 'California', '91942', 'NCT04340557', 'Recruiting', 'Mechanical ventilation', 'March 2020', 'December 2020', 83, 'A questionnaire containing some critical questions about practice inside GI endoscopy units in different countries will be distributed via emails. Re ... (40 characters truncated) ... latform and data will be analyzed to reveal the effect of SARS-CoV-2 pandemic on different aspects of GI endoscopy practice in the studied countries.', 'COVID-19 Endoscopy Survey', 'alboraie@azhar.edu.eg', 'Mohamed Alboraie, MD, MRCP(UK)', '00201155019700', '40', 'Kings County Hospital Center, Brooklyn, NY, USA', 'Physicians will report details of their endoscopy practice through answering the questions of the questionnaire', 'Al-Azhar University', 'Albertson', 'United States', 'New York', '11507', 'NCT04342637', 'Not yet recruiting', 'Effect of GI societies recommendations on prevention of SARS-CoV-2 infection', 'April 2020', 'December 2020', 84, 'SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmen ... (556 characters truncated) ... m COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.', 'BCG Vaccine for Health Care Workers as Defense Against SARS-COV2', 'Andrew.Dinardo@Bcm.Edu', 'Andrew DiNardo, MD', '832-822-1038', '700', 'Harvard T.H. Chan School of Public Health', 'BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.', 'Andrew Dinardo', 'Boston', 'United States', 'Massachusetts', '02115', 'NCT04348370', 'Not yet recruiting', 'incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo', 'April 2020', 'November 2021', 85, 'Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to coronavirus disease 2019 (COVID-19).', 'A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019', 'arnaud.bastien@roivant.com', 'Arnaud Bastien, MD', '(609)-410-2691', '270', 'Mount Sinai', 'Gimsilumab is a fully human monoclonal antibody (mAb).', 'Kinevant Sciences GmbH', 'New York', 'United States', 'New York', '10029', 'NCT04351243', 'Recruiting', 'Primary endpoint', 'April 2020', 'October 2020', 86, 'The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19 pandemic.', 'Early Extubation for Patients With Acute Hypoxemic Respiratory Failure', 'bpatel@medicine.bsd.uchicago.edu', 'Bhakti Patel, MD', '773-702-6800', '108', 'University of Chicago Medical Center', 'After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressive ... (146 characters truncated) ...  0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.', 'University of Chicago', 'Chicago', 'United States', 'Illinois', '60637', 'NCT04349332', 'Not yet recruiting', 'ventilator days', 'April 2020', 'June 2021', 87, 'Study Objective:\\n\\nTo test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the ... (65 characters truncated) ... roquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.', 'Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2', 'covid19@umn.edu', 'David Boulware (Please email), MD, MPH', '6126249996', '3000', 'Nationwide Enrollment via Internet, please email: covid19@umn.edu', '200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days', 'University of Minnesota', 'Minneapolis', 'United States', 'Minnesota', '55455', 'NCT04308668', 'Recruiting', 'Incidence of COVID19 Disease among those who are asymptomatic at trial entry', 'March 2020', 'May 2020', 88, 'Phase 2:\\n\\nThe primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospit ... (98 characters truncated) ... udy is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 (severe and critical).', 'Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19', 'clinicaltrials@regeneron.com', 'Clinical Trials Administrator', '844-734-6643', '400', 'Regeneron Study Site', 'Single intravenous (IV) dose of sarilumab', 'Regeneron Pharmaceuticals', 'Los Angeles', 'United States', 'California', '90095', 'NCT04315298', 'Recruiting', 'Percent change in C-reactive protein (CRP) levels', 'March 2020', 'April 2021', 89, 'The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.', 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19)', 'GileadClinicalTrials@gilead.com', 'Gilead Clinical Study Information Center', '1-833-445-3230 (GILEAD-0)', '6000', 'Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue', 'Administered as an intravenous infusion', 'Gilead Sciences', 'Anaheim', 'United States', 'California', '92806', 'NCT04292899', 'Recruiting', 'The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14', 'March 2020', 'May 2020', 90, 'The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.', 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment', 'GileadClinicalTrials@gilead.com', 'Gilead Clinical Study Information Center', '1-833-445-3230 (GILEAD-0)', '1600', 'Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue', 'Administered as an intravenous infusion', 'Gilead Sciences', 'Anaheim', 'United States', 'California', '92806', 'NCT04292730', 'Recruiting', 'The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11', 'March 2020', 'May 2020', 91, 'This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.', 'A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia', 'global-roche-genentech-trials@gene.com', 'Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm', '888-662-6728', '330', 'University of California San Diego', 'Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.', 'Hoffmann-La Roche', 'La Jolla', 'United States', 'California', '92093', 'NCT04320615', 'Recruiting', 'Clinical Status Assessed Using a 7-Category Ordinal Scale', 'April 2020', 'September 2021', 92, 'ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.', 'Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease', 'coldmixon@mgh.harvard.edu', 'Katie Oldmixon, RN', '617 726-4777', '510', 'University of Arizona', 'Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.\\n\\nFor this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.', 'Massachusetts General Hospital', 'Tucson', 'United States', 'Arizona', '85721', 'NCT04332991', 'Recruiting', 'COVID Ordinal Outcomes Scale on Day 15', 'April 2020', 'July 2021', 93, 'This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.\\n\\nIt also contains a sub-study to enroll patients with severe COVID-19.', 'Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study', 'jho@ansunbiopharma.com', 'Jennifer Ho, M.D', '858-452-2631', '250', 'City of Hope cancer Center', 'DAS181 4.5mg nebulized qd x 7 OR 10 days', 'Ansun Biopharma, Inc.', 'Duarte', 'United States', 'California', '91010', 'NCT03808922', 'Recruiting', 'Percent of subjects who Return to Room Air (RTRA) (main study)', 'May 2019', 'December 2021', 94, 'This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hosp ... (1187 characters truncated) ... tudy is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19.', 'Adaptive COVID-19 Treatment Trial (ACTT)', 'DMIDClinicalTrials@niaid.nih.gov', '20-0006 Central Contact', '13017617948', '440', 'University of Alabama at Birmingham School of Medicine - Infectious Disease', 'The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Birmingham', 'United States', 'Alabama', '35233', 'NCT04280705', 'Recruiting', 'Percentage of subjects reporting each severity rating on an 8-point ordinal scale', 'February 2020', 'April 2023', 95, 'The specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease severity in ... (589 characters truncated) ...  Syndrome Coronavirus 2 (SARS-CoV-2) transmission and risk factors for Coronavirus Disease 19 (COVID-19) among health care workers and their families', 'Rutgers COVID-19 Cohort Study', 'jeffrey.carson@rutgers.edu', 'Jeffrey L Carson, MD', '732-235-7122', '750', 'Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -', 'This non-interventional study poses no additional risks to people with pre-existing conditions.', 'Rutgers, The State University of New Jersey', 'New Brunswick', 'United States', 'New Jersey', '08901', 'NCT04336215', 'Recruiting', 'Prevalence', 'April 2020', 'October 2021', 96, 'This project seeks to improve the effectiveness of a novel dissonance-based obesity prevention program that has reduced future BMI gain and overweigh ... (724 characters truncated) ... en the case with another dissonance-based prevention program, could markedly reduce the prevalence of obesity and associated morbidity and mortality.', 'Project Health: Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program', 'estice@ori.org', 'Eric M Stice, Ph.D.', '541-484-2123', '450', 'Oregon Research Institute', 'A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.', 'Oregon Research Institute', 'Eugene', 'United States', 'Oregon', '97403', 'NCT03710746', 'Recruiting', 'Body Fat', 'October 2018', 'July 2023', 97, \"This is a randomized intervention study to test and develop the national curriculum of a parent intervention training targeting parent's ability for  ... (772 characters truncated) ...  surveys. In-person visits to complete the psychological testing with the youth will be scheduled in the future when it is safe to meet face to face.\", 'Advocating for Supports to Improve Service Transitions', 'julie.l.taylor@vumc.org', 'Julie Lounds Taylor, PhD', '615-343-5659', '180', 'University of Illinois at Urbana-Champaign', 'The ASSIST program is a 12-week advocacy training to educate parents of youth with ASD about the adult service system. It is a group training, compri ... (434 characters truncated) ... l disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.', 'Vanderbilt University Medical Center', 'Chicago', 'United States', 'Illinois', '60007', 'NCT04173663', 'Recruiting', 'Change in Parental Knowledge about adult services questionnaire', 'December 2019', 'May 2024', 98, 'Healthcare workers are at the frontline of the fight against COVID-19, and as such they are at high risk for infection and possibly for serious infec ... (30 characters truncated) ... their exposure. The CROWN CORONATION trial prioritizes the protection of healthcare workers as a strategy to prevent collapse of healthcare services.', 'CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION', 'lindayun@wustl.edu', 'Linda Yun, BS', '314-273-2240', '55000', 'Washington University School of Medicine', 'chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate or 400mg hydroxychloroquine sulphate) weekly\\n\\nIn a ... (149 characters truncated) ... vided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.', 'Washington University School of Medicine', 'Saint Louis', 'United States', 'Missouri', '63110', 'NCT04333732', 'Not yet recruiting', 'Symptomatic COVID-19', 'April 2020', 'February 2021', 99, 'This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pr ... (227 characters truncated) ... laced on temporary administrative hold as of 3/17/2020. When such trial activities resume, the clinicaltrials.gov record will be updated accordingly.', 'Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes', 'Gregory.Schwartz@va.gov', 'Gregory G Schwartz, PhD MD', '(720) 723-6070', '7868', 'Phoenix VA Health Care System, Phoenix, AZ', 'For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a ... (157 characters truncated) ... cent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo.', 'VA Office of Research and Development', 'Phoenix', 'United States', 'Arizona', '85012', 'NCT02915198', 'Recruiting', 'Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization', 'February 2019', 'August 2024', 100, 'Most people with an eating disorder (ED) do not receive good treatment. The investigators have developed a new brief group treatment that is supposed ... (821 characters truncated) ... h an ED to either the new treatment or to a group treatment that represents what many college mental health clinics provide to their clients with ED.', 'Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders', 'estice@ori.org', 'Eric Stice, PhD', '541-484-2123', '180', 'Stanford University', '8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.', 'Oregon Research Institute', 'Stanford', 'United States', 'California', '94305', 'NCT03261050', 'Recruiting', 'Change in occurrences of binge eating episodes using Eating Disorder Diagnostic Interview', 'July 2017', 'June 2022')] (Background on this error at: http://sqlalche.me/e/e3q8)"
     ]
    }
   ],
   "source": [
    "engine = db.create_engine('sqlite:///COVID-Clinical-Trials')\n",
    "# connection = engine.connect()\n",
    "metadata = db.MetaData()\n",
    "\n",
    "covid_df.to_sql(\"COVID_ClinicalTrials\", con=engine, if_exists=\"replace\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
